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Summary 
Nuclear receptors are ligand dependent transcription factors and have defined expression patterns in 
classical tissues for example the Vitamin D receptor is expressed in small bowel, kidney and skin, as 
related to its function in maintaining serum calcium levels. However, nuclear receptor expression has 
also been demonstrated in non classical tissues for example VDR expression in the prostate and breast. 
Differential expression of a panel of nuclear receptors in bladder cancer cell lines (RT-4, RT-112, 
HT1376 and EJ-28 cells) at mRNA level and VDR and FXR expression at protein level has ben 
demonstrated. These cell lines demonstrate a range of anti-proliferative responses upon treatment with 
ligands to the panel of nuclear receptors (1α,25(OH)2D3, 9 cis RA, EPA, ETYA, CDA, LCA, 22HC, 
GW3965 and DHA). EJ-28 cells are the least sensitive to the anti-proliferative effects of 5 of these 
ligands (1α,25(OH)2D3, LCA, EPA, ETYA, CDA). EJ-28 cells also have the highest expression of the 
co-repressor NCoR1; this may be partly responsible for the reduced sensitivity displayed by EJ-28 
cells by maintaining a closed chromatin structure around the nuclear receptor response elements. To 
test this, NCoR1 has been stably over-expressed in RT-4 cells which have the lowest relative 
expression of this co-repressor. This led to a statistically significant reduction in anti-proliferative 
response to CDA, LCA and the histone deacetylase inhibitor SAHA.  
To further test the hypothesis that raised NCoR1 expression and hence a predominance of the co-
repressor complex in EJ-28 cells was affecting the sensitivity to NR ligands, the four bladder cancer 
cell lines were co-treated with the NR ligands and the HDAC inhibitor SAHA. This demonstrated a 
strongly additive anti-proliferative response in RT-112 and E-28 cells which have raised NCoR1 
expression. This may be due increased HDAC association with NRs at their respective response 
elements which may make these particular cells more susceptible to co-treatment with ligand and 
SAHA. The possible mechanism of the anti-proliferative response within EJ-28 cells is demonstrated 
to be a G1/S phase cell cycle arrest upon treatment with LCA +/- SAHA. 
The expression of putative target genes was investigated using Q-RT-PCR, Q-RT-PCRm  and 
Affymetrix human U133 genechip arrays upon treatment with LCA +/- SAHA. RT-4 and EJ-28 cells 
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express CDKN1A upon combined treatment with LCA + SAHA. LCA treatment leads to expression of 
the cytochrome P450 enzyme CYP3A4 mRNA in RT-4, RT-112 and HT1376 cells. However, the 
combined treatment with LCA + SAHA leads to CYP3A4 expression in EJ-28 cells.  
RT-4 cells stably transfected to over-express NCoR1, were treated with LCA and the target 
transcriptome investigated using Q-RT-PCRm. Three predominant groups of genes were induced; 
ABC transporter family of trans-membrane efflux pumps, detoxifying enzymes and cell cycle arrest 
proteins. EJ-28 cells were treated with LCA +/- SAHA and the target transcriptome investigated by 
hybridisation of cRNA to U133 Affymetrix genechip arrays. This yielded 3 predominant groups of 
targets; genes which drive cell proliferation and cell cycle progression, genes involved in transcription 
and post translational mRNA processing and genes involved in repair of damaged cellular 
components. Taken together, these two target transcriptomes suggest the presence of a xenobiotic 
protective response within the bladder urothelium which upon exposure to toxic compounds such as 
LCA inhibits cell division, expresses trans-membrane transporters and detoxifying enzymes to rid the 
cell of the toxin and finally initiates cellular repair. These findings may be harnessed for 
chemoprevention of bladder cancer by enhancing resistance to xenobiotics such as those derived from 
cigarette smoke.     
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 Abbreviations:- 
ABC  ATP-binding cassette 
AIF   apoptosis inducing factor 
AMV   avian myeloblastosis virus 
AR Androgen receptor 
ATP Adenosine triphosphate 
ATRA All-trans retinoic acid 
9 cRA   9 cis retinoic acid 
22-HC    22-hydroxycholesterol  
cAMP   cyclic adenosine monophosphate  
CAR Constitutive androsterone receptor 
CBP cAMP response element binding protein binding protein 
CDA   chenodeoxycholic acid  
CDC25 cell division cycle 25 
CDK cyclin dependent kinase 
CDKI cyclin dependent kinase inhibitor 
cDNA complimentary deoxyribonucleic acid 
ChIP chromatin immunoprecipitation 
CHO Chinese hamster ovary 
CIS Carcinoma in situ 
CoA co-activator 
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CoR co-repressor 
cRNA complimentary ribonucleic acid 
CYP cytochrome p450 enzyme 
CYP3A4 cytochrome p450 enzyme, family 3, subfamily A, polypeptide 4 
CYP24 cytochrome p450 enzyme, 24-hydroxylase 
DBD DNA binding domain 
DEX dexamethasone 
DHA Cis 4,7,10,13,16,19 Docosahexaenoic acid 
DMEM Dulbecco‟s modified Eagle‟s medium 
DNA  deoxyribonucleic acid 
DRIP vitamin D receptor interacting protein 
DTT Dithiothreitol 
ED25   Dose required to inhibit cell proliferation by 25% 
ED50   Dose required to inhibit cell proliferation by 50% 
EDTA   ethylenediaminetetraacetic acid 
EGFR   epidermal growth factor receptor 
ER   estrogen receptor 
EPA   Eicosapentaenoic acid  
ETYA  5,8,11,14-eicosatetraenoic acid 
FACS  fluorescence activated cell sorter 
FXR   Farnesoid X-activated receptor 
GAG  Glycosaminoglycans 
GR  glucocorticoid receptor 
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GSTM1  Glutathione-S-transferase M1 
HAT  histone acetyltransferase 
HDAC  histone deacetylase 
HDACi  histone deacetylase inhibitor 
HIV  human immunodeficiency virus 
HNF4α  hepatocyte nuclear factor 4α 
HRP  horseradish peroxidase 
Kb  kilo base 
KD kilo Dalton 
LCA  Lithocholic acid 
LCOR  Ligand-dependent nuclear receptor corepressor 
LBD  ligand binding domain 
LXR  Liver X receptor 
MMLV  Moloney murine leukemia virus 
MNAR  modulator of non-genomic action of estrogen receptor 
MR  mineralocorticoid receptor 
mRNA  messenger ribonucleic acid 
NAT2  N-acetyltransferase 2 
Na Cl  Sodium chloride 
NCOR1  Nuclear receptor co-repressor 1  
NCOR2/SMRT Silencing mediator of retinoid and thyroid hormone receptors/Nuclear 
receptor co-repressor 2  
NR  nuclear receptor 
OD  optical density 
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PAGE  polyacrylamide gel electrophoresis 
PBS  phosphate buffered saline 
PCN  pregnenalone-16α-carbonitrile 
PCR  polymerase chin reaction 
PI  Propidium iodide 
PPAR   Peroxisome proliferator activated receptor 
PR  progesterone receptor 
PVDF  polyvinylidene difluoride 
PXR  pregnane X receptor 
Q-RT-PCR  quantitative real time, reverse transcription polymerase chain reaction 
Q-RT-PCRM  micro-fluidic quantitative real time, RT polymerase chain reaction 
RAR  retinoic acid receptor 
Rb  retinoblastoma protein 
RE  response element 
RT  reverse transcription 
RXR  retinoid X receptor 
SAHA  suberoylanilide hydroxamic acid or vorinostat 
SDS  sodium dodecyl-sulphate 
SEM  standard error of the mean 
SLIRP  SRA stem loop-interacting rna-binding protein 
TCC  Transitional cell carcinoma 
TRIP15/Alien  Co-repressor Thyroid hormone receptor interactor 15/Alien 
TSA  Trichostatin A 
UV  ultra-violet 
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VDR  vitamin D receptor 
1 25(OH)2D3   1 25dihydroxyvitaminD3 
XREM  xenobiotic response enhancer module 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 10 
Table of Contents 
 
Summary ................................................................................................................................... 2 
Acknowledgements ................................................................................................................... 4 
Abbreviations:- ......................................................................................................................... 5 
Chapter 1 INTRODUCTION ................................................................................................... 20 
1.1 Opening Statement ......................................................................................................... 20 
1.2 Development and function of the urinary bladder ..................................................... 21 
1.2.1 Human urinary bladder embryology................................................................... 21 
1.2.2 Transitional epithelium (Urothelium) and Barrier Function ................................... 21 
1.3 Histopathology of Bladder Cancers ................................................................................ 23 
1.4 Histopathology, grades and staging of TCC .............................................................. 24 
1.5 Epidemiology of Bladder Cancer .............................................................................. 25 
1.5.1 Incidence and Mortality ...................................................................................... 25 
1.6 Pathology of bladder cancer ...................................................................................... 26 
1.6.1 Bladder Cancer Risk Factors .............................................................................. 26 
1.6.2 Molecular Pathology of Bladder Cancer ................................................................. 29 
1.7 Nuclear Receptor Superfamily ....................................................................................... 35 
1.7.1 Structure of Nuclear Receptors................................................................................ 35 
1.7.2  Nuclear Receptor Signal Transduction ................................................................... 37 
1.7.3  Nuclear Receptors and Bladder Cancer Cells......................................................... 41 
1.7.4 Histone Deacetylase Inhibitors (HDACi) ................................................................ 42 
1.8 AIMS .............................................................................................................................. 49 
Chapter 2 General Methods ...................................................................................................... 50 
2.1 NR ligands and HDAC inhibitors ................................................................................... 50 
 11 
2.2 Tissue culture techniques................................................................................................ 50 
2.3 ATP bioluminescent proliferation assay......................................................................... 51 
2.3.1 Assay Principle ........................................................................................................ 51 
2.3.2 Assay method .......................................................................................................... 52 
2.4 Cell cycle analysis .......................................................................................................... 53 
2.4.1 Principle of assay ..................................................................................................... 53 
2.4.2 Method ..................................................................................................................... 54 
2.5 RNA extraction protocols ............................................................................................... 55 
2.5.1 Principle ................................................................................................................... 55 
2.5.2 Method ..................................................................................................................... 56 
2.6 Reverse transcription polymerase chain reaction (RT-PCR) ......................................... 57 
2.6.1 Reverse transcription (RT) : Principle ..................................................................... 57 
2.6.2 Method ..................................................................................................................... 58 
2.6.3 Polymerase chain reaction (PCR) ............................................................................ 59 
2.6.4 Quantitative RT-PCR (Q-RT-PCR) ................................................................... 62 
2.6.5  Microfluidic Q-RT-PCRM ................................................................................. 68 
2.7 Protein extraction ............................................................................................................ 69 
2.7.1 Protease inhibitor cocktail ....................................................................................... 69 
2.7.2 Extraction of cell protein ......................................................................................... 69 
2.7.3 Nuclear/Cytosolic Protein Fractionation ................................................................. 70 
2.7.4 Assay to determine protein concentration: Modified Lowry Assay ........................ 71 
2.8 Western Blotting-Resolution of proteins by SDS-PAGE ............................................... 71 
2.8.1  Principle .................................................................................................................. 71 
2.8.2 Western blotting: Method ........................................................................................ 73 
 12 
2.9 Stable transfection of NCoR1 over-expressing plasmid................................................. 74 
2.9.1 Transformation and maxi-prep: Principle................................................................ 74 
2.9.2 Transformation and maxi-prep: Method.................................................................. 75 
2.9.3 Plasmid DNA purification: Method ........................................................................ 77 
2.9.4 Stable transfection of plasmid ................................................................................. 77 
2.10 Affymetrix® gene expression arrays ............................................................................ 79 
2.10.1 Reverse transcription ............................................................................................. 80 
2.10.2  Microarray Statistical Analysis ............................................................................ 83 
Chapter 3 : Expression profiling of nuclear receptors and co-repressors in bladder cancer cell 
lines. .......................................................................................................................................... 85 
3.1 Introduction: ................................................................................................................... 85 
3.2 Materials and Methods ................................................................................................... 86 
3.3  Results ........................................................................................................................... 86 
3.3.1 Bladder Cancer Cell lines have a spectrum of anti-proliferative responses to nuclear 
receptor ligands................................................................................................................. 86 
3.3.2 Bladder Cancer cell lines display a spectrum of nuclear receptor and co-repressor 
expression. ........................................................................................................................ 91 
3.3.3 VDR and FXR are expressed in bladder cancer cells at the protein level. .............. 93 
3.3.4 Cell Sensitivity is Partly Correlated with Nuclear Receptor to Co-repressor Ratio 95 
3.3.5 NCoR1 stable over-expression. ............................................................................... 98 
3.3.6 Co-treatment of NR ligands with histone deacetylase inhibitor SAHA. .......... 102 
3.3.7 Co-treatment of NCoR1 over-expressing clones with SAHA ............................... 106 
3.4  Discussion .................................................................................................................... 108 
Chapter 4 : Gene regulation in response to NR ligands. ........................................................ 113 
 13 
4.1 Introduction .................................................................................................................. 113 
4.2 Methods ........................................................................................................................ 114 
4.3 Results .......................................................................................................................... 114 
4.3.1 Cell cycle effects of lithocholic acid +/- SAHA .................................................... 114 
4.3.2 Induction of CDKN1A (p21
(Waf1/Cip1)
) post treatment with LCA+/- SAHA .......... 117 
4.3.3 Induction of CYP3A4 after treatment with LCA +/- SAHA ................................. 118 
4.3.4 Target gene expression in NCoR1 transfectants ................................................... 121 
4.3.5  Target gene expression of EJ-28 cells when treated with Lithocholic acid and a 
histone deacetylase inhibitor SAHA and assessed with Affymetrix™ U133 array. ...... 136 
4.4 Discussion ..................................................................................................................... 142 
4.4.1   LCA and the Cell Cycle....................................................................................... 142 
4.4.2 LCA and Expression of Metabolic Enzymes ........................................................ 144 
4.4.3 LCA and Expression of ABC Transporters ........................................................... 146 
4.4.4    A Coordinated Xenobiotic Protective Response in the Bladder ........................ 147 
4.4.5  The Hepatocellular Protective Response to Xenobiotics ..................................... 148 
Chapter 5 : Discussion ............................................................................................................ 150 
5.1 Summary ....................................................................................................................... 150 
5.1.1  Expression of nuclear receptors in non-classical tissue sites ............................... 150 
5.1.2  Bladder cancer cell lines display a spectrum of anti-proliferative responses towards 
a panel of nuclear receptor ligands ................................................................................. 150 
5.1.3  Forced over-expression of NCoR1 leads to reduced sensitivity towards CDA, LCA 
and SAHA ...................................................................................................................... 151 
5.1.4  Co-treatment with HDAC inhibitor SAHA leads to a cooperative anti-proliferative 
response in cells which over-express NCoR1 ................................................................ 151 
 14 
5.1.5  LCA induces a G1/S phase cell cycle arrest in EJ-28 cells .................................. 152 
5.1.6 Induction of CDKN1A (p21
(Waf1/Cip1)
) and CYP3A4 upon treatment with LCA +/- 
SAHA ............................................................................................................................. 152 
5.1.7 LCA induces a xenobiotic protective response in RT-4 cells .......................... 153 
5.2 Future Studies ............................................................................................................... 155 
5.2.1  Measurement of VDR, FXR and NCoR1 expression in human samples ............. 155 
5.2.2  Chromatin Immunoprecipitation .......................................................................... 155 
Journal publications related to this thesis ............................................................................... 158 
Published Abstracts ................................................................................................................ 158 
Conference Proceedings ......................................................................................................... 159 
Appendix 1 ............................................................................................................................. 160 
List of genes on Q-RT-PCRm genecard ............................................................................. 160 
Appendix 2 ............................................................................................................................. 167 
List of genes uniquely regulated by LCA + SAHA on Affymetrix U133 genechip array 
after 6 hours treatment. ....................................................................................................... 167 
 
 
 
 
 
 
 
 
 15 
Table of Figures 
FIGURE 1.1: DIAGRAM OF THE STRUCTURE OF THE NORMAL UROTHELIUM.. .............................. 22 
FIGURE 1.2: THE INCIDENCE OF BLADDER CANCER PER COUNTRY. ............................................ 26 
FIGURE 1.3: CELL CYCLE CONTROL. .......................................................................................... 32 
FIGURE 1.4: CANONICAL STRUCTURE OF NR DOMAINS. DBD – DNA BINDING DOMAIN, LBD – 
LIGAND BINDING DOMAIN. ................................................................................................. 37 
FIGURE 1.5: DIAGRAM OF THE CONVENTIONAL MODEL OF NR SIGNAL TRANSDUCTION.. .......... 39 
FIGURE 1.6: A:THE STRUCTURE OF TSA. .................................................................................. 45 
FIGURE 2.1: REPRESENTATIVE COPY OF FACS HISTOGRAM . .................................................... 54 
FIGURE 2.2: THE KEY STEPS IN REVERSE TRANSCRIPTION. ......................................................... 58 
FIGURE 2.3: CONVENTIONAL PCR GEL IMAGE OF 18 S RIBOSOMAL RNA. ................................ 61 
FIGURE 2.4: THE PRINCIPLE OF TAQMAN QRT-PCR.. ................................................................ 64 
FIGURE 2.5: STRUCTURE OF THE PCDNA3 PLASMID.. ................................................................ 78 
FIGURE 3.1: CELLS WERE PLATED AT THE FOLLOWING DENSITIES INTO 96 WELL PLATES; RT-4 
2X10
3
 CELLS PER WELL, HT-1376 4X10
3 
PER WELL, RT112 AND EJ28 3X10
3 
CELLS PER 
WELL. THESE CELL DENSITIES WERE PRE-OPTIMISED TO RESULT IN CELLS IN THE 
EXPONENTIAL PHASE OF GROWTH. THE ATP LEVELS WERE DETERMINED AS PER SECTION 
2.3 AT 96 HOURS POST TREATMENT WITH AN ADDITIONAL DOSE AT 48 HOURS. THE 
LUMINESCENCE FOR THE TREATMENT WELLS WAS DIVIDED BY THAT FOR THE NEGATIVE 
CONTROL TO GIVE A SURVIVAL FRACTION. THEREFORE, SURVIVAL >100 % DENOTES A PRO-
PROLIFERATIVE RESPONSE AND <100 % DENOTES AN ANTI-PROLIFERATIVE RESPONSE. THE 
EXPERIMENTS WERE CONDUCTED IN TRIPLICATE AND WERE REPEATED THREE TIMES. 
ERROR BARS DENOTE STANDARD ERROR OF THE MEAN. .................................................... 88 
 16 
FIGURE 3.2: CELLS WERE PLATED AT THE FOLLOWING DENSITIES INTO 96 WELL PLATES; RT-4 
2X10
3
 CELLS PER WELL, HT-1376 4X10
3 
PER WELL, RT112 AND EJ28 3X10
3 
CELLS PER 
WELL. THE ATP LEVELS WERE DETERMINED AS PER SECTION 2.3 AT 96 HOURS POST 
TREATMENT WITH AN ADDITIONAL DOSE AT 48 HOURS. THE LUMINESCENCE FOR THE 
TREATMENT WELLS WAS DIVIDED BY THAT FOR THE NEGATIVE CONTROL TO GIVE A 
SURVIVAL FRACTION. THEREFORE, SURVIVAL >100 % DENOTES A PRO-PROLIFERATIVE 
RESPONSE AND <100 % DENOTES AN ANTI-PROLIFERATIVE RESPONSE. THE EXPERIMENTS 
WERE CONDUCTED IN TRIPLICATE AND WERE REPEATED THREE TIMES. ERROR BARS 
DENOTE STANDARD ERROR OF THE MEAN. ......................................................................... 89 
FIGURE 3.3: RELATIVE EXPRESSION OF A PANEL OF NUCLEAR RECEPTORS AND CO-REPRESSORS
 .......................................................................................................................................... 92 
FIGURE 3.4: WESTERN IMMUNOBLOT OF NUCLEAR AND CYTOPLASMIC PROTEINS ..................... 93 
FIGURE 3.5: WESTERN IMMUNOBLOT FOR FXR. ........................................................................ 95 
FIGURE 3.6: RNA WAS EXTRACTED FROM TRANSFECTED CELLS IN MID-EXPONENTIAL PHASE, 
REVERSE TRANSCRIBED AND Q-RT-PCR PERFORMED FOR NCOR1 (18S AS INTERNAL 
CONTROL). THE FOLD CHANGES ARE EXPRESSED AS RELATIVE TO THE MEAN ΔCT OF ALL OF 
THE MOCK TRANSFECTED CLONES (PCDNA3 CLONES #1,5,6,7). THE STAR SIGNIFIES 
SIGNIFICANT OVER-EXPRESSION AS TESTED BY A ONE-TAILED STUDENT‟S T-TEST. ............ 98 
FIGURE 3.7: WESTERN BLOT FOR NCOR1 IN TRANSFECTED CLONES. ........................................ 99 
FIGURE 3.8: SENSITIVITY TO INHIBITION OF PROLIFERATION BY TREATMENT WITH  NR 
LIGANDS.. ........................................................................................................................ 101 
FIGURE 3.9 (A)-(D): PROLIFERATION ASSAYS OF CELL LINES TREATED BY EITHER ED25 
CONCENTRATIONS OF NR LIGAND, SAHA OR IN COMBINATION . .................................... 105 
 17 
FIGURE 3.10 (A)-(B): PROLIFERATION ASSAYS OF NCOR1 OVER-EXPRESSING RT-4 CLONE 
(NCOR#7) AND MOCK TRANSFECTED CLONES (PCDNA#7) TREATED BY ED25 
CONCENTRATIONS OF EITHER NR LIGAND, SAHA OR IN COMBINATION. ......................... 107 
FIGURE 4.1: CELL CYCLE ANALYSIS USING FACS ................................................................... 115 
FIGURE 4.2: INDUCTION OF CDKN1A(P21
WAF1/CIP1
) AFTER LCA+/- SAHA AT 6 HOURS.. ........ 118 
FIGURE 4.3: CYP3A4 INDUCTION AFTER LCA +/- SAHA TREATMENT AT 6 HOURS. ............... 120 
FIGURE 4.4: TIME COURSE EXPERIMENT OF EXPRESSION OF CDKN1A AS MEASURED BY TAQMAN 
Q-RT-PCR. ..................................................................................................................... 122 
FIGURE 4.5: TIME COURSE EXPERIMENT OF CYP3A4 EXPRESSION AS MEASURED BY TAQMAN 
QRT-PCR. ....................................................................................................................... 123 
FIGURE 4.6: NETWORK DIAGRAM OF BASAL GENE CHANGES IN PNCOR OVEREXPRESSING CLONE 
#7 AS COMPARED TO CONTROL MOCK TRANSFECTED PCDNA CLONE #6. ........................ 132 
FIGURE 4.7: NETWORK DIAGRAM OF GENE CHANGES IN CONTROL MOCK TRANSFECTED PCDNA 
CLONE #6 ON TREATMENT WITH LITHOCHOLIC ACID. ...................................................... 133 
FIGURE 4.8: NETWORK DIAGRAM OF GENE CHANGES ON TREATING PNCOR OVEREXPRESSING 
CLONE #7 WITH LITHOCHOLIC ACID. ................................................................................ 134 
FIGURE 4.9: HEAT MAP OF THE RAW DATA FROM AFFYMETRIX® U133 EXPRESSION CHIP 
ANALYSIS......................................................................................................................... 140 
FIGURE 4.10: NETWORK DIAGRAM OF GENES UNIQUELY REGULATED BY TREATMENT WITH LCA 
+ SAHA.. ........................................................................................................................ 141 
 
 
 
 
 18 
Table of Tables 
TABLE 1.1: SUMMARY OF HDAC CLASSES, CELLULAR LOCATION AND FUNCTION (PAN ET AL., 
2007A). ______________________________________________________________ 43 
TABLE 1.2: SUMMARY TABLE OF CURRENT HDAC INHIBITORS IN CLINICAL DEVELOPMENT. NA-
NOT AVAILABLE. ADAPTED FROM (XU ET AL., 2007B). __________________________ 47 
TABLE 2.2: DETAILS OF VARIOUS ANTIBODIES USED FOR WESTERN BLOTTING. 21
 O
C DENOTES 
ROOM TEMPERATURE. ___________________________________________________ 74 
TABLE 2.3: THE FOLLOWING B SUBTILIS GENES ARE PRESENT IN THE POLY-A CONTROL 
CONCENTRATE: ________________________________________________________ 80 
TABLE 3.1: NUCLEAR RECEPTOR LIGANDS AND THEIR RESPECTIVE RECEPTORS. ___________ 87 
TABLE 3.2: THE ED50 VALUES OF THE FOUR BLADDER CANCER CELL LINES WHEN TREATED 
WITH NR LIGANDS ______________________________________________________ 90 
TABLE 3.3: THE FOUR BLADDER CANCER CELL LINES ARE ARRANGED IN THEIR ORDER OF 
REDUCING DIFFERENTIATION. TOTAL MRNA FROM RT-4, RT-112, HT1376 AND EJ-28 
WAS EXTRACTED, IN TRIPLICATE, FROM MID-EXPONENTIALLY PROLIFERATING CELLS, AND 
THE LEVELS OF NCOR1 AND THE INDICATED RECEPTORS WAS MEASURED BY Q-RT-PCR. 
FROM THESE VALUES THE FOLD CHANGES OF EACH TARGET, IN EACH CELL TYPE, WAS 
DETERMINED IN COMPARISON TO RT-4 CELLS. FROM THESE TWO VALUES A RATIO OF THE 
FOLD CHANGES IN LEVELS OF NCOR1 TO RECEPTOR MRNA IS GIVEN (NCOR1:RECEPT), 
FOR EACH RECEPTOR AND EACH CELL TYPE. PARALLEL CULTURES WERE EXPOSED TO DOSE 
TITRATION STUDIES OF THE COGNATE LIGANDS TO GENERATE SIGMOIDAL DOSE-RESPONSE 
CURVES FROM WHICH THE ESTIMATED DOSE REQUIRED TO INHIBIT PROLIFERATION BY 50% 
(ED50) WAS CALCULATED. THE CORRELATION BETWEEN THE NCOR1:RECEPTOR RATIO 
 19 
AND THE ED50 WAS MEASURED AND R2 AND P VALUES ARE INDICATED. T DENOTES THOSE 
RELATIONSHIPS THAT FOLLOW THE SAME TREND. ______________________________ 97 
TABLE 4.1: FOLD CHANGES IN EXPRESSION OF GENES, AS MEASURED BY TAQMAN GENECARD.
 ___________________________________________________________________ 124 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 20 
Chapter 1 INTRODUCTION 
1.1 Opening Statement 
Bladder cancer is a common condition with 10,278 new cases diagnosed every year in the 
United Kingdom and is the fourth most common cancer in men (Office of National Statistics). 
This cancer has two broad forms of presentation; approximately 55-60% of tumours present 
as superficial bladder tumours which have excellent long term survival but are characterised 
by frequent recurrences (Messing et al., 1995; Prout, Jr. et al., 1992). Approximately 30 % 
present as muscle invasive disease which is lethal if untreated with the overwhelming 
majority of patients dying within two years (PROUT and MARSHALL, 1956). Due to the 
long survival and repeated recurrences in patients with superficial bladder cancer, repeated 
long term surveillance is necessary with cystoscopic examinations of the bladder. These 
morbidity and mortality figures are similar in much of Europe and North America. This 
results in bladder cancer being one of the most costly of all tumours for example with an 
estimated per patient cost from diagnosis to death at $ 96,000 to $ 187,000 amounting to a 
direct cost within the USA in 2001 of $ 3.7 billion (Stenzl et al., 2008). Therefore there is an 
acute need for research led efforts that can firstly distinguish accurately and early between 
superficial and invasive tumours and secondly generate treatments that can reduce the 
recurrence rate of these tumours. 
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1.2 Development and function of the urinary bladder 
1.2.1 Human urinary bladder embryology 
Development of the human urinary bladder originates from the embryonal hindgut. The 
terminal part of this structure is an expanded cavity called the cloaca and is lined by 
endoderm. The anterior aspect of the cloaca is continuous with the allantois, which is a 
fingerlike diverticulum of the yolk sac. The cloaca is partitioned into an anterior and posterior 
portion by a wedge of mesenchyme called the urogenital septum. This partitioning is 
complete by the seventh week of development. The anterior portion is called the urogenital 
sinus and is divided into a cranial vesical part which is continuous with the allantois, a middle 
pelvic part and a caudal phallic part. The vesical part gives rise to the urinary bladder. The 
pelvic part of the urogenital sinus gives rise to the prostatic glandular cells in males.   
1.2.2 Transitional epithelium (Urothelium) and Barrier Function 
The lining the bladder is described as transitional cell epithelium. This extends from the 
collecting system of the kidneys, along the ureters, through the bladder and extends to the 
prostatic urethra in men. This urothelium consists of three layers of cells; the superficial layer 
of large and flat umbrella shaped cells; an intermediate layer of upto four cells thick which 
have their long axis perpendicular to the basement membrane and finally a basal layer of 
cuboidal cells.  
 22 
 
Figure 1.1: Diagram of the structure of the normal urothelium. (adapted from Campbell’s Urology 2008, 
chapter 56). There are three layers of cells; the superficial layer of large and flat umbrella shaped cells; an 
intermediate layer of upto four cells thick which have their long axis perpendicular to the basement 
membrane and finally a basal layer of cuboidal cells.  
 
 
 On the luminal surface of the urothelium, there is a layer of glycosaminoglycans (GAGs). 
These consist of large polysaccharides which are normally found in the ground substance of 
connective tissue (Poggi et al., 2000). This GAG layer was proposed to be responsible for the 
“blood-urine barrier” (Parsons et al., 1975) however, this has been discredited due to a 
number of experimental findings. The GAG layer allows small molecules such as the drug 
amiloride to pass through it (Niku et al., 1994) and  use of microelectrodes has revealed the 
first electrical resistive barrier to be upon entry into the umbrella cells rather than across the 
GAG layer. 
The umbrella cells form the true blood-urine barrier in the urothelium. They have a uniquely 
asymmetric cell membrane structure composed of an outer leaflet of large protein plaques and 
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hinge like regions in between these proteins. The protein plaques are composed of four types 
of uroplakin proteins (type Ia, Ib, II and III). These proteins are thought to provide the barrier 
function of the bladder epithelium (Walz et al., 1995). This barrier is further strengthened by 
tight junctions between umbrella cells (Peter, 1978), these in combination with the protein 
plaques form the waterproof barrier in the urinary bladder. 
The urinary bladder forms a classical epithelium that has significant barrier function as it is 
exposed to potentially harmful chemical and xenobiotics in the urine on the luminal side and 
which need to be contained and not allowed to leach into the blood. This is of key importance 
as much of our current understanding of bladder carcinogenesis is based on exposure of 
carcinogens carried in the urine, from industrial sources and from cigarette smoke.   
1.3 Histopathology of Bladder Cancers 
Transitional cell carcinoma (TCC) accounts for > 90% of bladder cancer. This is further 
divided by pathology into three main patterns. The majority are papillary TCCs, which appear 
as exophytic, frondlike structures. Second, are sessile TCCs , which are less frondular and 
have a more solid looking lesion with a broad base. A third form is the carcinoma in situ 
(CIS). This is characterised by flat, erythematous lesions, which may be multifocal and of a 
high grade. By definition, CIS is a pre-invasive form however, its presence indicates a higher 
degree of biological aggressiveness and hence a higher chance of progression to an invasive 
tumour.  
Squamous cell carcinoma account for 7-8% of bladder cancer and is associated with chronic 
irritation of the bladder epithelium. Worldwide, the majority of these cases are linked with 
chronic Schistosomiasis infection. In the developed world, other causes include bladder 
calculi and long term urinary catheters.  
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Adenocarcinoma of the bladder accounts for 1-2 % of cases and is associated with either 
chronic infection, bladder extrophy or may develop in urachal remnants in the dome of the 
bladder. The urachus is a thick, fibrous cord which develops from the allantois (see 
embryology). 
Rare types of bladder tumours consist of sarcoma, small cell carcinoma, melanoma and 
carcinoid tumour. 
1.4 Histopathology, grades and staging of TCC 
Transitional cell carcinoma is graded into well (G1), moderately (G2) and poorly 
differentiated (G3) tumours. Grade 1 tumours show increased number of urothelial layers 
with loss of orientation and hyperchromasia (dark staining nuclei indicative of an increased 
amount of chromatin). Grade 2 tumours show an increased degree of cell proliferation and 
loss of polarity within the epithelial layer. Grade 3 lesions are the least differentiated; in some 
cases it may be difficult to recognise the transitional nature of the epithelium (as described in 
section 1.2.2).  
Bladder cancer is staged according to the 2002 TNM (tumour, lymph nodes and metastases) 
system. Tumours that have not invaded and breached the basement membrane are denoted 
pTa. Tumours that have breached through to the lamina propria are denoted pT1; pT2 
tumours have invaded the muscularis mucosa; pT3 tumours have invaded the perivesical 
tissue and pT4 tumours have invaded neighbouring organs (prostate, uterus, vagina, pelvic 
and abdominal wall). 
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1.5 Epidemiology of Bladder Cancer 
1.5.1 Incidence and Mortality  
Bladder cancer is the fourth most common male malignancy and the tenth most common 
cancer in women in the western world. In Western Europe and the United States, bladder 
cancer account for 5-10 % of all malignancies in men. The risk of developing bladder cancer 
is quoted at 2-4 % for men and 0.5-1 % for women under the age of 75 years. The median age 
at diagnosis is between 65 and 70 years. Age standardised mortality rates globally, vary from 
2-10 per 100,000 per year for men and 0.5-4 per 100,000 per year for women.  
Bladder cancer has a clear preponderance for men; it is 3-4 times more common in men than 
women. This excess is not fully explained by the differences in smoking and occupational 
exposure, which are the two leading risk factors. Evidence from surveys of cancer incidence 
and mortality suggest that parous women have a lower risk of developing bladder cancer as 
compared to nulliaparous women. Furthermore, it appears the risk may reduce with increasing 
parity (Kirkali et al., 2005). Animal experiments suggest a role for androgenic exposure to 
increasing the risk of developing bladder cancer. Rats treated with androgens had a higher 
incidence of bladder tumours as compared to animals treated with estrogens. Certainly the 
reduced incidence in women and further in parous women, suggests a protective role for 
estrogens in humans too. 
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Figure 1.2: The incidence of bladder cancer per country. This illustrates the approximately 3:1 male : 
female ratio of bladder cancer. The UK has the 10
th
 highest bladder cancer incidence amongst developed 
countries. (Cancer Research UK, http://info.cancerresearchuk.org/cancerstats/types/bladder/incidence/)  
 
 
1.6 Pathology of bladder cancer 
1.6.1 Bladder Cancer Risk Factors 
The two largest groups of risk factors for the development of bladder cancer are 
industrial/occupational chemicals and smoking. These external carcinogens are likely to exert 
their effects via exposure of the urothelium to urine containing these carcinogens. Indeed, 
there is epidemiological evidence that passing urine at night is protective against bladder 
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cancer even in smokers (Silverman et al., 2008), suggesting that the urothelium‟s contact time 
with urine containing carcinogens is important in the pathogenesis of bladder cancer. 
1.6.1.1 Occupational / Industrial and Recreational Carcinogens 
Industrial bladder carcinogens are most often aromatic amines. As early as 1895, aniline dyes 
used in the textile industry were identified as bladder carcinogens (Rehn L, Ueber 
blasentrumoren bei fuchsinarbeitern. Arch Kind Chir 1895;50:588). Other chemicals, mainly 
used in the rubber and textile industries, also known to be bladder carcinogens are 2-
naphthylamine, 4-aminobiphenyl and benzidine (Morrison and Cole, 1976). This occupational 
exposure is estimated to be responsible for 20 % of bladder cancers in the USA (Cole et al., 
1972). 
Cigarette smoking is also associated with a four fold increase in the risk of developing 
bladder cancer (Morrison, 1984; Burch et al., 1989). This risk decreases down to that of non-
smokers after 20 years of cessation (Augustine et al., 1988). The exact identity of the bladder 
specific carcinogenic compounds in cigarette smoke is unknown; however, 4-aminobiphenyl, 
2-naphthylamine and nitrosamine, all known carcinogens, are known to be present. The risk 
of the individual developing bladder cancer is not only dependent on exposure to carcinogens 
but also depends on genetic variation in xenobiotic metabolising enzymes, for example 
smokers (with > 30 year smoking history) homozygous for the NAT1*10 allele of the N-
acetyltransferase, NAT1 gene have an 8.5 fold odds ratio of developing bladder cancer as 
compared to wild-type carriers (Taylor et al., 1998). 
1.6.1.2 Xenobiotic metabolising enzymes and Bladder Cancer Risk 
As an epithelial lining, the bladder urothelium is constantly exposed to a wide ranging milieu 
of chemicals in the urine. As noted above, chronic exposure to geno- and cellulo-toxic 
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compounds is likely to be a causative factor in bladder cancer initiation and progression. 
However, the epithelial lining has protective mechanisms against this potentially toxic milieu; 
genetic and epigenetic variation within the cells of this protective armamentarium most likely 
leads to variation in bladder cancer risk i.e. individuals who have a more effective protective 
response have a lower risk of developing bladder cancer that others.  
4-aminobiphenyl, a bladder carcinogen in industrial chemicals and cigarette smoke, is 
detoxified via N-acetylation. N-acetyltransferase 2 (NAT2) is a major acetylating enzyme 
which exists predominantly in 6 different allelic forms in Caucasians. One particular allele 
leads to more rapid acetylation activity, hence, people who are homozygous for this allele 
may have the fastest acetylation activity. Risch et al (Risch et al., 1995) demonstrated that in a 
group of 189 bladder cancer patients in Birmingham, UK, slow acetylator genotypes 
predominated amongst bladder cancer patients in groups with industrial chemical and 
cigarette smoke exposure and without any carcinogenic exposure history at all.  Okkels et al 
(Okkels et al., 1997) have similarly shown that smokers who carry the slow acetylator 
genotype have a higher risk of developing bladder cancer. 
A second enzyme, CYP1A2, a member of the cytochrome P450 group is also implicated with 
bladder cancer risk. This enzyme de-methylates aromatic amines thereby activating potential 
carcinogens in urine. Brockmuller et al (Brockmoller et al., 1998) have demonstrated 
increased risk of bladder cancer in subjects with the highly inducible allele of CYP1A2 who 
were smokers or had the slow acetylator allels of the NAT-2 enzyme. 
Glutathione-S-transferase M1 (GSTM1) is a key carcinogen detoxifying enzyme which 
conjugates polycyclic aromatic hydrocarbons in cigarette smoke to glutathione. The incidence 
of homozygous deletion of the gene for this enzyme in Caucasians is approximately 50 % 
(Bell et al., 1993b). Subjects who are homozygous for the absence of this gene are x1.8 more 
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likely to develop bladder cancer if they are smokers (Bell et al., 1993). Interestingly, the risk 
of bladder cancer is identical for non-smokers who are homozygous for GSTM1 absence as 
for non-smokers who have the allele. Therefore, this gene only seems to provide protection if 
the individual is exposed to cigarette smoke.   
 
The above provides a second layer to the model of the bladder epithelium being bathed in a 
milieu of carcinogens in urine. The epithelium has different strategies to effect protection of 
urothelial integrity and the efficacy of these strategies combine to determine overall risk of 
malignant change. Expression of detoxifying enzymes is a key epithelial protective 
strategy. 
1.6.2 Molecular Pathology of Bladder Cancer 
Malignant transformation of a cell is modelled as a stepwise process of increasing genotypic 
and epigenetic accumulation of abnormalities which lead to the acquisition of a common set 
of phenotypic characteristics. Hanahan and Weinberg (Hanahan and Weinberg, 2000) 
elucidated this model in terms of six key phenotypic traits which could be acquired in any 
sequence but would allow the cell to behave in a transformed malignant manner. These traits 
are as follows: 
1. Self sufficiency in growth signals. 
2. Insensitivity to growth inhibitory signals. 
3. Evasion of programmed cell death. 
4. Limitless replicative potential. 
5. Sustained angiogenesis. 
6. Tissue invasion and metastasis. 
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Self sufficiency in growth signals is most commonly manifest by activating, dominant 
mutations in oncogenes.  
1.6.2.1 Oncogenes in bladder cancer 
The best characterised oncogene to be mutated in bladder cancer is H-RAS. This encodes a 
GTP-ase that is a key signal transduction molecule, allowing signals from activated cell 
membrane based receptors, such as epidermal growth factor receptor (EGFR), to be 
transmitted to the cell nucleus. H-RAS mutations have been detected in upto 45 % of bladder 
tumours and the frequency appears to be greater in higher grade tumours; upto 65 % in poorly 
differentiated bladder transitional cell cancers (Czerniak et al., 1992). 
EGFR (ERBB1) is one of the family of growth factor receptors found to be overexpressed in 
bladder cancer patients. Neal et al (Neal et al., 1990) have demonstrated EGFR (ERBB1) 
positivity in 48 % of their series of bladder cancer patients and have shown a significant 
independent association of EGFR positivity with poor outcome i.e. risk of death from bladder 
cancer, risk of recurrence and shorter time to recurrence.  
These are examples of self-sufficency in growth signals. Activating mutations of H-RAS 
allow a growth stimulatory signalling pathway to be constitutively switched on driving cell 
proliferation. This pathway would normally be turned on in response to ligand binding of a 
growth factor to its relevant receptor, however, mutations bypass this requirement and allow 
inappropriate signal transduction. Increased expression of growth factor receptors, such as 
EGFR (ERBB1) and ERBB2, a similar growth factor receptor (Sauter et al., 1993; Moch et 
al., 1993), allows the cancer cell to firstly be more sensitive to growth signals and in the case 
of constitutively active mutations, allow downstream growth signalling in the absence of 
appropriate growth factor binding.  
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1.6.2.2 Tumour Suppressor Gene defects in Bladder Cancer 
Tumour suppressor genes encode for proteins which have a growth restricting role. The 
retinoblastoma gene was first described (Knudson, Jr., 1971) as requiring two hits or 
mutations for retinoblastoma to develop. Hence, tumour suppressor genes are recessive.  
P53 is a key tumour suppressor gene which functions in three important ways to inhibit 
carcinogenesis. In the presence of DNA damage, it causes a G1/S cell cycle arrest which can 
progress into cellular senescence, it upregulates DNA repair enzymes and may also lead the 
cell down an apoptosis or programmed cell death pathway. 
1.6.2.2.1 p53 and bladder cancer 
P53 has long been associated with bladder cancer. Wild type p53 has a very short half life of 
15 to 30 minutes (Oren et al., 1981). Mutations in the p53 gene lead to dysfunctional nuclear 
accumulation of the protein (Finlay et al., 1988) which is the basis of detection via immuno-
histochemistry. Cote and co-workers have assessed the relative effects of gene mutations and 
altered p53 protein accumulation and outcomes in bladder cancer (George et al., 2007). Their 
sample population consisted of 150 radical cystectomy specimens from patients with muscle 
invasive or recurrent high grade, non-invasive bladder cancer. P53 gene mutations were 
detected using the Affymetrix® p53 gene chip; protein mutations were assessed by immuno-
histochemistry. The authors divided samples in two groups; tumours with less than 10 % of 
tumour nuclei staining for p53 were designated wild type and tumours with 10% or greater 
nuclei staining were designated altered p53 protein status. 37 % of tumours were found to 
have p53 gene mutations and 36 % of tumours had nuclear accumulation of p53 protein. 
Mutations were associated with clinical stage of the tumours. Therefore, 26%, 42 % and 50 % 
of organ confined, locally advanced and lymph node positive tumours respectively had p53 
gene mutations and 19%, 40% and 63% of organ confined, locally advanced and lymph node 
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positive tumours had p53 altered protein status. Interestingly, the p53 gene mutations were 
concentrated in exons 5-8 which represent the DNA binding domains.  
Confirming the close relationship between abnormal p53 status and bladder cancer, both 
protein status and gene mutations have a correlation with clinical outcome. Tumours with 
wild type p53 protein have a 5 year recurrence free survival of 70 % as compared to 32 % for 
altered p53 protein. Similarly, patients with wild type p53 genes had a 5 year recurrence free 
survival of 66 % as compared to 44 % for patients with tumours with p53 gene mutations.  
1.6.2.2.2 Retinoblastoma protein (Rb) and Bladder Cancer 
Rb is the prototypical tumour suppressor gene. Its role is central in regulating the cell cycle.  
 
 
Figure 1.3: Cell cycle control as exerted by cyclins, cyclin dependent kinases and Rb protein and E2F 
family of transcription factors (Kolch et al., 2002). 
 
Regulation of the cell cycle is concentrated within the G1 phase. This phase is divided by the 
presence of a restriction point which behaves as a point of no return and is present after 
approximately 80-90 % of G1 has passed. The period of G1 preceding the restriction point is 
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characterised by the cell‟s dependence on constant extracellular mitogenic signals, usually via 
growth factors binding to cell membrane based receptors. Withdrawal of these mitogenic 
signals during this part of phase G1 would cease further passage of the cell through the 
remaining phases of the cell cycle. Once a cell passes the restriction point, it ceases to require 
any further extracellular growth signals to complete cell division and proceeds through the 
remaining phases of the cell cycle generally independent of the surrounding cell signalling 
milieu, whether pro- or anti-proliferative. Therefore, the restriction point is of fundamental 
importance to cell cycle regulation; Rb protein provides the molecular explanation of this 
aspect of the cell cycle. At a molecular level, the degree of phosphorylation of Rb protein 
molecules is key to its regulation. At the beginning of G1, D-type cyclins together with their 
partners, CDK4/6 (cyclin dependent kinase 4/6) initiate Rb phosphorylation. In this 
hypophosphorylated state, Rb continues to remain bound to the E2F family of transcription 
factors and inhibits their function as transcriptional activators of S-phase. As the cell 
approaches the restriction point, cyclin E levels rise and, together with its partner CDK2, 
further phosphorylate Rb to a hyper-phosphorylated state. In this state, Rb binding to E2F 
family members is inhibited and the unbound E2F transcription factors are free to initiate 
transcription of target genes which in turn act to drive the cell through the remaining phases 
of the cell cycle. 
Rb gene mutations have been reported in all grades of urothelial cancer. Miyamoto  
investigated 30 primary bladder tumour samples using PCR based restriction fragment length 
polymorphism analysis (Miyamoto et al., 1995). Eight samples (27 %) were found to have Rb 
gene mutations which were spread across grades between superficial as well as muscle 
invasive bladder tumours. Therefore, 10 % of grade 1, 50 % of grade 2 and 25 % of poorly 
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differentiated grade 3 tumours had Rb mutations. 21 % of superficial tumours and 36 % of 
muscle invasive tumours had mutations.  
Cote et al have correlated the expression of Rb with recurrence rate and survival in bladder 
cancer patients (Cote et al., 1998). They have analysed 185 radical cystectomy specimens in 
patients who have muscle invasive bladder cancer using immunohistochemistry to delineate 
nuclear expression of Rb protein. They divided the samples into 3 groups; patients with no 
expression, patients with moderate expression defined as 1%-50% of tumour cells showing 
Rb expression and finally patients with high levels of expression defined as >50 % of cells 
positive for nuclear Rb expression. Interestingly, both patients with no expression and those 
with high expression of Rb had similar rates of tumour recurrence (60% and 61 % 
respectively) and 5 year survival (33 % both groups). A possible explanation is provided by a 
later study of levels of Rb phosphorylation in bladder cancer (Chatterjee et al., 2004) by the 
same group. They studied 28 muscle invasive bladder cancer specimens and measured Rb and 
phosphorylated-Rb levels using Western blotting from frozen tumour specimens as well as 
using immunohistochemistry, using antibodies specific for the native as well as the 
phosphorylated forms of Rb protein. The authors demonstrated 71 % hyperphosphorylation of 
Rb in tumours with a high expression of total Rb as compared to 36 % hyperphosphorylation 
in tumours with moderate expression suggesting that constitutive hyperphosphorylation of the 
Rb protein may be a mechanism of Rb inactivation despite high overall expression. This is an 
interesting example of corruption of the normal cellular regulation mechanisms in cancer cells 
which afford a selective growth advantage to the cell. Therefore, as previously described, Rb 
hyperphosphorylation is involved in reversibly inactivating Rb at the restriction point of the 
cell cycle which leads to its detachment from members of the E2F family of transcription 
factors. The degree of hyperphosphorylation increases throughout S, G2 and M phases. At the 
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junction between mitosis and the onset of G1, Rb is dephosphorylated. It is the corruption of 
this process which may lead to constitutively hyperhosphorylated Rb in a subset of bladder 
cancer. 
 
1.7 Nuclear Receptor Superfamily 
1.7.1 Structure of Nuclear Receptors 
Nuclear receptors (NR) constitute a family of transcription factors which mostly bind 
lipophilic molecules; thus becoming activated and binding particular response elements 
within the promoters of target genes and thereby regulating target gene transcription. 
Sequence homology studies have revealed 21 NR genes in Drosophila melanogaster, 48 in 
humans, 49 in mice and 270 in Caenorhabditis elegans. NRs have a common canonical 
structure; consisting of an N-terminal AF1 domain which behaves as a constitutively active 
transactivation domain. The DNA binding domain (DBD) is the most conserved region within 
NR structure. This contains a short motif called the P-box which is responsible for DNA 
binding specificity on sequences containing a hexameric nucleotide motif. A highly conserved 
feature of the DBD are two zinc fingers each containing four cystine amino acids which each 
chelate a zinc ion. This region is also involved in dimerisation of NRs.   
After the DBD, NRs contain a D-domain which acts as a hinge region between the DBD and 
the ligand binding domain (LBD). The latter is the largest domain and contains a secondary 
protein structure of 12 α helices. As expected, the LBD is also responsible for trans-activation 
function of NRs following biding of ligand.  
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The nuclear receptor superfamily is divided into 7 subfamilies; within each subfamily NRs 
are classified into separate groups and individual genes within each group. The subfamilies 
are summarised below: 
 
Subfamily 1: Thyroid Hormone Receptor-like 
Group A: Thyroid hormone receptor (Thyroid hormone) 
     Group B: Retinoic acid receptor (Vitamin A and related compounds) 
     Group C: Peroxisome proliferator-activated receptor (fatty acids, prostaglandins) 
     Group D: Rev-ErbA (heme) 
      Group F: RAR-related orphan receptor (cholesterol, ATRA) 
     Group H: Liver X receptor-like (oxysterol) 
     Group I: Vitamin D receptor-like 
           
Subfamily 2: Retinoid X Receptor-like 
Group A: Hepatocyte nuclear factor-4 (HNF4) (fatty acids) 
     Group B: Retinoid X receptor (RXRα) (retinoids) 
     Group C: Testicular receptor 
     Group E: TLX/PNR 
     Group F: COUP/EAR 
 
Subfamily 3: Estrogen Receptor-like 
Group A: Estrogen receptor (Sex hormones: Estrogen) 
     Group B: Estrogen related receptor 
     Group C: 3-Ketosteroid receptors 
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Subfamily 4: Nerve Growth Factor IB-like 
Group A: NGFIB/NURR1/NOR1 
 
Subfamily 5: Steroidogenic Factor-like 
Group A: SF1/LRH1 
  
Subfamily 6: Germ Cell Nuclear Factor-like 
Group A: GCNF 
  
Subfamily 0: Miscellaneous 
Group B: DAX/SHP 
    Group C: Nuclear receptors with two DNA binding domains (2DBD-NR)  
(A novel subfamily) 
 
 AF1  DBD       D   LBD   AF2 
 
 
Figure 1.4: Canonical structure of NR domains. DBD – DNA binding domain, LBD – ligand binding 
domain. 
 
1.7.2  Nuclear Receptor Signal Transduction 
1.7.2.1 Classical signalling pathways 
Nuclear receptors may be present in the cell cytoplasm, bound to chaperone heat shock 
proteins or alternatively may be present within the cell nucleus bound to a multimeric mega-
NH2 COOH 
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dalton co-repressor protein complex (see below). The dynamics of receptor distribution and 
re-distribution upon ligand activation are becoming increasingly apparent. NR ligands are 
lipid soluble small molecules which diffuse freely across the cell membrane and bind to the 
LBD of the relevant NR. This initiates a conformational change within the NR structure and 
leads to dissociation of either chaperone proteins or the co-repressor protein complex. 
Cytoplasmic NRs translocate to the nucleus and both types bind hormone response elements 
which are short DNA sequences within promoters of target genes. This binding is co-incident 
with the recruitment of a multimeric mega-dalton co-activator complex of proteins which 
associate with the ligand bound NR dimer. This complex contains co-activator proteins which 
have histone acetyltransferase activity; histone acetylation results in local uncoiling of DNA 
around structural histone proteins. The co-activator complex also recruits RNA polymerase II 
and the basal transcriptional machinery; chromatin uncoiling allows RNA pol II access to the 
transcriptional start site resulting in target gene transcription.   
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Figure 1.5: Diagram of the conventional model of NR signal transduction for a cytoplasmic located 
receptor such as AR. Most NR ligands are lipophilic, hence freely diffuse across the lipid bilayer cell 
membrane. The ligands bind NR either in the cytoplasm or the nucleus. This NR-ligand complex binds at 
relevant response elements in target gene promoters along with a multimeric mega-dalton co-activator 
complex which recruits the basal transcription machinery and hence target gene transcription is initiated. 
 
Co-regulator complexes contain three broad groups of proteins. Firstly, there are proteins that 
covalently modify histones such as acetylases/deacetylases, methylases/demethylases, 
phosphorylases/dephosphorylases and ubiquitylases/deubiquitylases. The co-activators are 
associated with histone acetylases and the co-repressors with histone deacetylases. The 
second group of proteins in the co-regulatory complexes are involved with ATP dependent 
chromatin re-modelling. Thirdly, there are proteins which are involved in the recruitment and 
disassembly of co-regulator complexes (Perissi and Rosenfeld, 2005). Activation of receptor 
and gene transactivation involves highly choreographed and cyclical actions of components of 
all of these complexes. 
Image downloaded from Wikipedia.org under open-access status 
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1.7.2.2 Membrane bound rapid NR signalling 
There is emerging evidence that nuclear receptors are involved in alternative signalling 
pathways other than that described in the previous section. These pathways involve NRs to be 
located at the cell membrane and involve cross-talk between NRs and other membrane 
localised receptors such as growth factor receptors and G-protein linked receptors.  
The estrogen receptors ERα and β, progesterone receptors PRα and β and the androgen 
receptor (AR) have been demonstrated to be present at the plasma membrane in CHO 
(Chinese hamster ovary) and breast cancer cells (Pedram et al., 2007; Levin, 2008). These 
receptors require palmitoylation as a post translational modification onto a conserved motif on 
the E-domain of the nuclear receptors (Pedram et al., 2007); this leads to association with 
caveolin 1 proteins and transport to the cell membrane (Razandi et al., 2003). There is also 
evidence that ERα homodimerises upon exposure to 17β-estradiol at the plasma membrane to 
allow rapid signal transduction (Razandi et al., 2004).  
 
Membrane localised nuclear receptors appear to cross-talk with well established membrane 
based signal transduction pathways, when exposed to ligand.  Therefore, when ERα is 
exposed to 17β estradiol at the plasma membrane, it activates Gα proteins which leads onto a 
rise in calcium and cAMP levels in keeping with second messenger activation (Razandi et al., 
1999). ERα also recruits and activates Gβγ proteins and stimulates downstream signal 
transduction (Kumar et al., 2007); an example being the stimulation of endothelial nitric oxide 
synthase and production of nitric oxide from endothelial cells which leads to vasodilation 
(Pedram et al., 2006). 
ERα activates a number of kinase based signal transduction pathways via interactions 
involving different scaffold proteins. The MNAR protein (modulator of non-genomic action 
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of estrogen receptor) mediates the interaction between the E-domain of ERα and src tyrosine 
kinase which in turn leads to PI3 kinase pathway activation (Cheskis et al., 2008; Wong et al., 
2002). ER, mineralocorticoid receptor (MR) and progesterone receptors (PR) also bind to and 
activate receptor tyrosine kinases such as epidermal growth factor receptor (EGFR) 
(Grossmann et al., 2008; Filardo et al., 2000; Razandi et al., 2003; Faivre and Lange, 2007). 
In response to ligand, membrane bound ERα again activates SRC kinases by activating G-
proteins. In response, SRC activates cellular matrix metalloproteinases which lead to the 
release of heparin-binding EGF like growth factor (HB-EGF) which is an EGFR ligand 
(Filardo et al., 2000; Razandi et al., 2003).  
Hence, there is mounting evidence of the presence of nuclear receptors, particularly the 
estrogen receptors, at the cell membrane and their responsiveness to ligand which stimulates 
downstream signalling events via cross-talk with established membrane based cellular 
signalling pathways. 
1.7.3  Nuclear Receptors and Bladder Cancer Cells 
There is evidence of expression of a number of NRs in bladder cancer cells. Hermann et al 
investigated the expression of VDR in normal and malignant bladder tissue from 26 patients 
by immunohistochemistry and demonstrated an increased expression with more advanced 
bladder tumours (Hermann and Andersen, 1997). Similarly, Sahin et al demonstrated VDR 
expression by immunohistochemistry, in 85.7 % of superficial TCC as compared to 66.6 % of 
control, normal bladder tissue. Patients with the highest VDR expression had the highest risk 
of tumour progression, the lowest disease free survival and the largest tumour size (Sahin et 
al., 2005). There is no identifiable published evidence of FXR expression in the urinary 
bladder.   
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1.7.4 Histone Deacetylase Inhibitors (HDACi) 
1.7.4.1 Histone deacetylase enzymes 
DNA is packaged in nucleosomes each of which is a repeating unit of DNA wound around an 
octamer of four pairs of core histone proteins. This compact structure places a barrier to the 
interaction of the multimeric basal transcription machinery with gene promoters. This barrier 
is overcome by local unwinding of the nucleosome which is enacted by covalent binding of 
moieties such as acetyl groups to the positively charged histone tails. This is catalysed by 
histone acetyltransferase (HAT) enzymes. The histone acetylation neutralises the positive 
charge on specific histone lysines which loosens their interaction with the negatively charged 
DNA and leads to a localised loosening of the nucleosome structure to allow gene 
transcription to occur (Pan et al., 2007). The converse process, histone deacetylation is 
catalysed by histone deacetylase enzymes (HDAC) which remove acetyl groups from histones 
which leads to transcriptional silencing of target enzymes.  
HDACs are divided into four classes depending on their homology to yeast HDACs. Classes 
I, II and IV contain a Zinc ion and this is key to the mechanism of action of many HDAC 
inhibitors.  
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Classification   Location Function 
Zn
2+
 dependent Class I HDAC 1 Nucleus Participate in Sin3, NuRD (nucleosome 
  HDAC 2 Nucleus remodelling and deacetylation) and Co-
REST complex 
  HDAC 3 Nucleus, 
rarely cyto 
Participate in co-repressor SMRT and 
NCoR complexes 
  HDAC 8 Nucleus - 
 Class IIa HDAC 4 Nucleus, 
Cyto 
Interaction with co-repressors SMRT, 
NCoR, BcoR and CtBP. 
  HDAC 5 Nucleus, 
Cyto 
 
  HDAC 7 Nucleus, 
Cyto 
 
  HDAC 9 Nucleus, 
Cyto 
Muscle differentiation 
 Class IIb HDAC 6 Cyto Tubulin deacetylase 
  HDAC 10 Nucleus, 
Cyto 
Recruitment of other HDACs 
 Class IV HDAC 11 Nucleus, 
Cyto 
- 
Zn
2+
 
independent 
Class III SIRT 1-7   
 
Table 1.1: Summary of HDAC classes, cellular location and function (Pan et al., 2007). 
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1.7.4.2 HDAC Inhibitors (HDACi) 
HDACi can be classified into four groups according to their chemical class, as illustrated in 
the table below. The chemical interaction of TSA and the bacterial HDAC homologue HDLP 
(histone deacetylase-like protein) has been elucidated via x-ray crystallographic analysis 
(Finnin et al., 1999). The structure of the HDAC catalytic domain consists of a long tube 
equivalent of 4-6 straight carbon chain in length. The key part of the structure is a Zinc ion at 
the bottom of this catalytic tube. HDACi such as TSA and SAHA are divided into zinc 
chelating motif, an aliphatic linker and a polar cap group (Lin et al., 2006).  The hydroxamate 
group has two functions; it acts to chelate the zinc ion and also forms a salt bridge, thereby 
forming a strong interaction between the HDACi and the catalytic domain of the HDAC. The 
NH-OH group in the hydroxamate motif transfers a proton to Histidine 131 thereby 
developing a negative charge. This allows the formation of a strong salt bridge between the 
positively charged Zinc ion and the negatively charged NH-OH group. This may be the 
reason for the high potency of hydroxamate based HDACi as compared to the other classes of 
HDACi, as they are able to form this strong interaction with the important zinc ion. 
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Figure 1.6: A:The structure of TSA demonstrating three functional motifs. B: The interaction between the 
Zinc ion (purple sphere) and the TSA hydroxamate motif. C: The proton transfer between the 
hydroxamate NH-OH group and Histidine 131 allows a salt bridge to form between the positively charged 
Zn
2+
 ion and the now negatively charged NH-O
- 
. 
 
HDAC inhibitors cause both gene expression and repression in a panel of leukemia, multiple 
myeloma and solid tumour cell lines including bladder cancer cells (Chambers et al., 2003; 
Glaser et al., 2003; Mitsiades et al., 2004; Peart et al., 2005). Interestingly, HDACi are 
estimated to only alter expression of 7-10 % of genes as assessed by gene micro-arrays (Xu et 
al., 2007; Chambers et al., 2003; Glaser et al., 2003; Mitsiades et al., 2004; Peart et al., 2005; 
Sasakawa et al., 2005; Sasakawa et al., 2005). This pattern of gene regulation also reflects the 
multitude of anti-tumour responses elicited by HDACi treatment; cell may undergo growth 
arrest, terminal differentiation, apoptosis via intrinsic, extrinsic pathways, autophagic cell 
death and reactive oxygen species facilitated cell death (Xu et al., 2007).  
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Tumour cells treated with HDACi may undergo G1/S phase cell cycle arrest and this is 
frequently associated with a rise in p21
(waf1/cip1)
 expression (Richon et al., 2000). 
Concomitantly, deletion of p21
(waf1/cip1) 
abolishes the ability of the sodium butyrate to induce 
G1/S phase cell cycle arrest (Archer et al., 1998). However, these effects are cell and HDACi 
context dependent. Therefore, in the p21
waf1/cip1 
deleted colon cancer cell line HCT116, TSA 
induces a G1/S cell cycle arrest by upregulating the expression of p15 (INK4b), which is an 
inhibitor of cyclin D dependent kinases (Hitomi et al., 2003). In other cell contexts, SAHA as 
well as TSA upregulate expression of p27, also a CDK inhibitor, in leukemia cell lines K562 
and LAMA-84 (Nimmanapalli et al., 2003) and in breast cancer cell lines MCF-7 and MDA-
MB-231 (Huang and Pardee, 2000; Xu et al., 2007).  
Apoptosis may occur via extrinsic and intrinsic pathways. The extrinsic pathway occurs when 
death receptors such as FAS, TNFR1 and the TRAIL receptors DR4 and DR5 bind their 
respective ligands, FAS ligand, TNF and TRAIL. This leads to caspase activation and 
apoptosis. Nakata et al have demonstrated that both TSA and sodium butyrate increase the 
expression of the TRAIL death receptor DR5 (Nakata et al., 2004) in Jurkat acute 
lymphoblastic leukemia cells. They also demonstrate modest levels of apoptosis when Jurkat 
cells were treated with a minimal concentration TSA (0.5 µM) or 50 ng/ml of recombinant 
TRAIL. However, when both TSA and TRAIL were added together, there was a synergistic 
rise in apoptosis to 58 % of cells from 17 % and 12 % respectively; suggesting that TSA 
sensitises Jurkat cells to the apoptotic effects of recombinant TRAIL. 
The intrinsic pathway of apoptosis is mediated by release of mitochondrial proteins such as 
cytochrome c, apoptosis inducing factor (AIF) and SMAC into the cytoplasm which leads to 
caspase activation and apoptosis. This process is regulated by the relative expression and 
function of pro- and anti-apoptotic members of the BCL-2 family of proteins. HDACi lead to 
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release of cytochrome c and activation of caspase 9 by unknown mechanisms (Xu et al., 
2007). The HDACi suberic bishydroxamate, has also been shown to upregulate expression of 
pro-apoptotic members of the bcl-2 family, Bim, Bax and Bak and down-regulated expression 
of anti-apoptotic members Bcl-xL and Mcl-1 in melanoma cell lines (Zhang et al., 2004).  
 
Class Compound HDAC target Potency (cells) Stage of 
development 
Hydroxamate SAHA Classes I,II µM FDA approved 
 Trichostatin A NA nM - 
 LBH589 Classes I,II nM Phase I 
 PXD101 Classes I,II µM Phase II 
 ITF2357 Classes I,II nM Phase I 
 PCI-24781 Classes I,II NA Phase I 
Cyclic peptide FK228 HDAC 1,2 nM Phase II 
Benzamide MS-275 HDAC 1,2,3 µM Phase II 
 MGCD0103 Class I NA Phase II 
Aliphatic acid Phenylbutyrate Classes I, IIa mM Phase II 
 Valproic acid Classes I, IIa mM Phase II 
 AN-9 NA µM Phase II 
 Baceca Class I NA Phase II 
 Savicol NA NA Phase II 
 
Table 1.2: Summary table of current HDAC inhibitors in clinical development. NA-not available. Adapted 
from (Xu et al., 2007).  
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The urinary bladder is constantly exposed  to toxins and xenobiotics within the urine and is 
likely to have protective mechanisms to ensure continued epithelial integrity. Nuclear 
receptors are involved in the execution of such a xenobiotic protective response in other organ 
systems, namely the liver and bowel. The liver is exposed to the toxic secondary bile acid, 
LCA; the levels of primary bile acids are sensed by the nuclear receptor FXR which in turn 
regulates the enzymes involved bile acid synthesis. Levels of LCA are further sensed by the 
nuclear receptor PXR which in turn switches on the expression of the xenobiotic metabolising 
enzymes CYP3A4 and SULT2A1 as well as the active cell membrane transporters MRP2 and 
MDR1 which actively excrete LCA out of hepatocytes (Elias and Mills, 2007). The urinary 
bladder may well require a similar xenobiotic protective response to maintain epithelial 
integrity in the face of constant exposure to xenobiotics. The bladder is known to express NRs 
such as VDR, which is a known inducer of both CYP3A4 (Matsubara et al., 2008; Jurutka et 
al., 2005) and SULT2A1 enzymes (Echchgadda et al., 2004); nuclear receptors may well act 
as the urinary bladder‟s xenobiotic sensors.  
NRs, in particular VDR have been implicated in cancer (Thorne and Campbell, 2008) and 
hence, may be targeted with their respective ligands. However, despite the presence of 
functional NR, a cancer cell may exhibit resistance to the effects of NR ligands. Previously, 
our research group has demonstrated this resistance may be due to over-expression of the co-
repressors NCoR2/SMRT in prostate cancer (Khanim et al., 2004) and NCoR1 in breast 
cancer (Banwell et al., 2006). With the above in mind, the aims of this thesis are follows:  
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1.8 AIMS 
 To establish the expression pattern of a panel of nuclear receptors that bind dietary 
derived ligands and corresponding co-repressors in a panel of bladder cancer cell line 
models.  
 To establish the sensitivity to the anti-proliferating effects of the nuclear receptor 
ligands in a panel of cell lines. To investigate the correlation between cell sensitivity 
with relative nuclear receptor and co-repressor expression and to what extent these 
effects can be enhanced by HDACi. 
 To modulate co-repressors in relevant cell lines to investigate the effect of co-
repressor expression on cell proliferation and sensitivity to NR ligands.  
 To investigate target gene expression on treatment with NR ligands in wild type cells 
with either forced co-repressor overexpression or HDACi co-treatment.   
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Chapter 2 General Methods 
This chapter describes the basic laboratory techniques used. Any modifications to these 
general methods have been specified in the relevant chapters. 
2.1 NR ligands and HDAC inhibitors 
1 ,25(OH)2D3, 9 cis RA and EPA (generous gift of Dr. Milan R. Uskokovic, Hoffman La 
Roche, Nutley, NJ 07110, U.S.A.) were stored as stock solutions of 1mM in ethanol at -20
o
C. 
All trans retinoic acid (ATRA), Lithocholic acid (LCA), Chenodeoxycholic acid (CDA), 
Arachidonic acid (ETYA) were all stored as 1 mM stock solutions in ethanol at –20oC. 
Suberoylanilide hydroxamic acid (SAHA) was provided by Dr Victoria Richon (Merck 
Research Laboratories, Boston, MA, United States) via a materials transfer agreement with Dr 
M.J. Campbell. This was stored in –20oC as a 1 mM stock solution. 22 (R) 
hydroxycholesterol (22HC) and GW3965 (both from Sigma-Aldrich) were stored as stock 
solutions in DMSO at 1mM at -20
 o
C. Cis 4,7,10,13,16,19 Docosahexaenoic acid (DHA) 
(Sigma- Aldrich) was stored as a 1 mM stock solution in chloroform at -20
 o
C. 
2.2 Tissue culture techniques 
All culture techniques were undertaken in a laminar flow cabinet to maintain a sterile 
environment. RT-4, HT-1376, RT-112 and EJ-28 bladder cancer cell lines were used in vitro 
to represent 3 different grades of bladder cancer; RT-4 is derived from G1 well differentiated 
bladder transitional cell papilloma, RT-112 is derived from a G2 moderately differentiated 
TCC and HT-1376 and EJ-28 are both derived from G3 poorly differentiated TCC. RT-4 and 
HT-1376 were obtained from the ATCC. RT-112 and EJ-28 were a kind gift from Professor 
David Neal‟s laboratory from the Department of Oncology at the University of Cambridge. 
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RT-4 was cultured in tissue culture flasks in McCoys 5a modified medium (Cambrex), HT-
1376 was cultured with modified Eagle‟s medium, RT-112 and EJ-28 were cultured in 
Dulbecco‟s modified Eagle‟s medium; all with 10% FCS, 1% Penicillin and streptomycin 
(SIGMA), 1% L-glutamine (SIGMA) and incubated at 37
o
C with 5% CO2. 
Each cell line was washed with sterile PBS and split with 0.25% trypsin EDTA/PBS solution. 
Cells required for investigation were counted using a haemocytometer.  
2.3 ATP bioluminescent proliferation assay 
2.3.1 Assay Principle 
All living cells require free energy in order to perform essential cellular functions; this free 
energy is carried in the form of Adenosine triphosphate (ATP). This molecule contains two 
energy rich phosphoanhydride bonds; free energy is released when ATP is broken down to 
adenosine di-phosphate which in turn regenerates further ATP as a result of cellular 
metabolism. Therefore, the levels of ATP within a cell are a close marker for cellular numbers 
and proliferation. 
The ViaLight HS™ (Cambrex) kit was used to estimate relative cellular ATP levels. This 
utilises the following chemical reaction: 
 
ATP + luciferin + O2     Oxyluciferin + AMP + CO2  
+ LIGHT (at 565 nm) 
The emitted light intensity has a linear relationship to ATP concentration and is measured 
using a luminometer at 18-22
o
C (Crouch et al., 1993). 
 
Luciferase, Mg
2+
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2.3.2 Assay method 
This assay was developed to look at the proliferation of bladder cancer cell lines in vitro over 
a 96 hour time period. Each experiment was dosed at set up and re-dosed at 48hrs before 
results were obtained.  
Cells were trypsinized and resuspended in culture media to yield a single cell suspension. 
They were then counted using a haematocrit slide, diluted in media and added to sterile white 
walled flat bottom 96-well plates to yield 2-4 x10
3
 cells per well (depending on cell line – see 
figure legend below). Nuclear receptor ligands and/or SAHA were added to each well to 
make up a total volume of 100 µl per well. Each plate was then incubated at 37
o
C with 5% 
CO2 for 96hrs, redosing with agent +/- SAHA at 48 hours. After the 96hrs incubation the 
plates were processed. This involved the addition of 100μl of nucleotide releasing reagent 
(Vialight HS, Cambrex) to the wells and incubation at room temperature for 15mins.  During 
this time ATP monitoring reagent (Vialight HS, Cambrex), containing luciferin, luciferase 
and magnesium, was reconstituted with TRIS Acetate buffer (Vialight HS, Cambrex) and 
vortexed to equilibrate. Using the Orion Microplate Luminometer (Bethhold detection 
systems) 20μl of ATP monitoring reagent was added to each well and the luminescence 
measured with a 10 second exposure and recorded. ATP levels were recorded in relative light 
units and expressed as a percentage of untreated controls. 
The sum of the individual mean effects for each compound acting alone was the predicted 
combined inhibition.  The mean observed combined inhibition was then compared with this 
value using the Student‟s t-test.  The inhibitory effects were designated as follows: strongly-
additive effects were those with an observed value significantly greater than the predicted 
value, additive effects were those in which the observed value did not significantly differ 
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from the predicted value and sub-additive effects were those in which the observed value was 
significantly less than the predicted value (Khanim et al., 2004; Banwell et al., 2006). 
 
2.4 Cell cycle analysis 
2.4.1 Principle of assay 
Cell cycle analysis measures DNA content of individual cells and conveniently reveals cell 
distribution against DNA content, which indicates the locations of cells in the cell cycle. G2 
and M phase occur after DNA synthesis (S-phase), therefore cells in these phases contain 
twice as many chromosomes (and twice as much DNA) as cells in G1 and G0 phases. FACS 
analysis uses this feature to estimate the numbers of cells in a suspension that are within 
G2/M phases as compared to G1/G0 phases. Cells are treated with a fluorescent dye, 
propidium iodide which intercalates within the major groove of DNA. The cell suspension is 
passed through a FACS machine (fluorescence activated cell sorter) and is excited by light at 
a wavelength of 488 nm. The fluorochrome, propidium iodide, fluoresces and the intensity is 
measured by detectors. Cells in G2 and M phases will have twice as much fluorescence 
intensity as cells in G1/G0 phases. Cells in S phase are synthesising DNA, hence their DNA 
content and therefore fluorescence intensity will be intermediate between the two previous 
groups of cells. 
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Figure 2.1: Representative copy of FACS histogram obtained. The x-axis represents intensity of 
fluorescence and the y-axis represents cell count. The peak labelled by R2 represents cell in G1 and G0. 
The much smaller peak labelled R3 represents cells in G2 and M phases. The area of the curve in between 
the peaks represents cells in S-phase.   
 
 
2.4.2 Method 
Cells (1.5 x 10
6
) were plated in T75 flasks and incubated for 24 hrs to ensure mid-
exponential proliferation and were dosed at 24 and 48 hrs with single or combination agents.    
Cells were harvested by trypsinisation at 72 hours, transferred into labelled tubes and 
centrifuged for 5 minutes at 1200 rpm to gather all of the cellular material into a pellet. 
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Detached cells were also included. The cells were resuspended in 1ml of PBS and transferred 
to a fluorescent activated cell sorter (FACS) tube (Becton Dickinson Labware).  Cells were 
once again spun down before resuspension in 0.5ml of cell cycle buffer (5g sodium citrate, 
0.5mls Triton X-100, 0.1mM sodium chloride, made up to 500mls with distilled water) 
containing fresh propidium iodide (2mg/ml). This buffer contains salt and detergent which 
disrupts the cell membrane and leaves nuclei intact. Cell membrane disruption is important to 
allow the propidium iodide access to DNA within the nuclei. Each sample was vortexed 
thoroughly, covered in foil (as propidium iodide is light sensitive) and incubated on ice (to 
minimum for 30mins) before being analysed in a Becton-Dickinson FACS machine using 
Cell-Cycle Analysis software. The effect on cell cycle distribution of each treatment was 
examined in triplicate. 
 
2.5 RNA extraction protocols 
2.5.1 Principle 
RNA from cell lines was extracted using Tri-reagent (Sigma) which is an organic solution 
containing guanidine isocyanate and phenol. The guanidine isocyanate is a strong denaturant 
and the phenol acts to denature cellular RNAses and improve RNA yield. This method is a 
refinement on the single step method described by Chomczynski, P. and Sacchi, N 
(Chomczynski and Sacchi, 1987). 
Cells are lysed by adding Tri-reagent. 1-Bromo-3-Chloropropane is added to this solution; 
this allows two layers form, an upper aqueous layer which is acidic and under these 
conditions dissolves RNA. The lower organic pink layer contains DNA and proteins. This 
step is called phase separation. This mixture is then centrifuged which leads to separation into 
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a lower organic phase containing proteins, the upper aqueous phase containing RNA and a 
cloudy interphase containing DNA. Chloroform may be used in place of 1-Bromo-3-
Chloropropane however, is more toxic and is associated with a higher level of DNA 
contamination (Chomczynski and Mackey, 1995). The upper aqueous layer is separated 
carefully and isopropanol is added which causes RNA precipitation. Contaminants such as 
DNA are removed from the RNA pellet by washing with ice cold 70 % ethanol.   
2.5.2 Method 
Cells were prepared for total RNA extraction, by seeding 2x10
6
 cells per T25 flask. At 
indicated time points, 1 ml of Tri reagent (Sigma) was added and the plates swirled to mix for 
5 minutes. This was transferred to labelled eppendorf tubes. Subsequently, 100 l 1-bromo-3-
chloro propane (BCP) was added, mixed and left for 15 minutes at room temperature. The 
eppendorfs were then centrifuged at 12,000 x g for 15 minutes at 4
o
C and the upper phase 
transferred to a clean eppendorf. 500 l of isopropanol was then added, the tubes inverted to 
mix and then left for 15 minutes at room temperature. The eppendorfs were again centrifuged 
at 12,000 x g for 10 minutes at 4
o
C. The supernatant was aspirated with care to avoid 
disturbing the pellet, and 1ml of 75% ethanol added and centrifuged at 12,000 x g for 5 
minutes at 4
o
C. The ethanol was then aspirated off and the pellet of purified RNA was 
resuspended in 30 l of nuclease-free H2O. 
The RNA was then quantified by diluting 4µl of purified RNA solution into 996µl dH2O and 
the optical density (OD) measured at 260nm using the equation: 
 
O.D. reading x ((40 µg/ 1000 µl)/ 1 O.D. unit) x dilution factor = concentration in µg/µl 
(Gallagher and Desjardins, 2008) 
RNA samples are stored at -80 
o
C to prevent degradation. 
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2.6 Reverse transcription polymerase chain reaction (RT-PCR)  
2.6.1 Reverse transcription (RT) : Principle 
Reverse transcription refers to the chemical reaction which results in single stranded RNA 
converted into complimentary DNA (cDNA). This process originates in RNA viruses or 
retroviruses which carry their genetic information as RNA, examples include the human 
immunodeficiency virus (HIV), Moloney murine leukemia virus (MMLV) and avian 
myeloblastosis virus (AMV). The key enzyme, reverse transcriptase catalyses this reaction 
and contains three enzymatic activities: 
1. RNA dependent DNA polymerase. 
2. Hybrid dependent exonuclease (RNase H) 
3. DNA dependent DNA polymerase. 
In vitro, only the first two functions are utilised to produce single stranded DNA. This is then 
used in downstream applications such as quantitative real-time PCR. The reaction has three 
phases. The RNA is heated at 70 
o
C to denature the secondary structure. It is then incubated at 
42 
o
C for reverse transcription to occur, i.e. cyclical rounds of primer binding, elongation of 
the cDNA strand and degradation of the RNA template by the RNase H activity. Finally the 
sample is heated to 95 
o
C to inactivate the reaction; this temperature degrades the reverse 
transcriptase enzyme and any remaining RNA fragments. Primers for this reaction may be a 
poly-T primer which will bind to the poly-A tails of the mRNA molecules, may be random 
hexamers which will bind to corresponding random complimentary sequences on RNA 
molecules, or lastly, may be a specific primer for a particular RNA species corresponding to 
expression of a particular gene.   
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Figure 2.2: The key steps in reverse transcription. 1
st
 step is primer annealing, then extension of the cDNA 
molecule and lastly degradation of the template RNA molecule. Downloaded from Google images 
(http://8e.devbio.com/images/ch04/0405fig2.jpg). 
 
 
2.6.2 Method   
Samples and reagents were allowed to thaw on ice. 1µg of RNA was prepared in 10µl of 
nuclease free water and incubated at 70
o
C for 5mins to allow degradation of the RNA 
secondary structure. 10µl of RT mastermix (2µ 10x reaction buffer (stratascript), 2µl 10mM 
dNTP‟s (Promega), 1µl RNAsin (40iu/µl, promega), random primers (250ng/µl, Promega), 
1µl MLV-RT (10,000iu/µl, stratascript) and 4µl nuclease free water (promega) was prepared, 
RNase H 
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vortexed and spun down before being added to the reaction. Each reaction was vortexed, spun 
down and incubated at 42
o
C for 1hr to enable reverse transcription elongation to occur, 95
o
C 
for 5 mins to inactivate the reaction.  
 
2.6.3 Polymerase chain reaction (PCR) 
2.6.3.1 Conventional PCR: Principles 
Conventional PCR is a chemical process employed to replicate a particular DNA sequence 
multiple fold. It is credited to Kay Mullis (Saiki et al., 1985) who used heat stable DNA 
polymerase enzyme from the Thermus aquaticus bacterium. Most enzymes would denature 
over a temperature of 50 
o
C however, this DNA polymerase has an optimum working 
temperature of 72 
o
C.  
Conventional PCR has three basic steps; denaturation, annealing and elongation. Denaturation 
describes the separation of double stranded DNA into single strands by heating to 94 
o
C; at 
this temperature the hydrogen bonds between complimentary DNA bases is disrupted. 
Annealing describes the binding of primers to the sequence of DNA which is to be amplified. 
Primers are short sequences of oligonucleotides which are complimentary to the 5‟ ends of the 
DNA sequence to be amplified and are required to allow DNA Taq polymerase to start the 
polymerisation reaction. Primers need to bind at the 5‟ ends of the DNA template as DNA 
polymerase only polymerises the new DNA strand in the 5‟ to 3‟ direction. The annealing 
temperature is usually 3-5 
o
C below the melting temperature of the primers. The melting 
temperature refers to the temperature at which the primers dissociate from the DNA template. 
Clearly the annealing temperature needs to be below the melting temperature, however, as the 
annealing temperature is reduced the chances of non-specific primer binding increases. 
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Therefore, as a compromise, an annealing temperature 3-5 
o
C below the melting temperature 
is used. Elongation refers to the synthesis of the new DNA strand complementary to the 
template. The optimal temperature for Taq polymerase is 72 
o
C    
 
2.6.3.2 Conventional PCR: Method 
All samples and reagents were allowed thawed on ice. A 20µl PCR mastermix was prepared 
using the following reagents: 
 
 10x Reaction Buffer (Promega)  2µl 
 25mM MgCl2 (Promega)   3.2µl 
 10mM dNTP‟s (Promega)   2µl 
 Forward Primer (30µM)   0.4µl 
 Reverse Primer (30µM)   0.4µl 
 5iu/µl Taq polymerase (Promega)  0.4µl 
 Nuclease free water (Promega)  9.6µl 
 Total      18µl 
 
50ng of cDNA in 2µl of nuclease free water was added to the mastermix and vortexed. Using 
the Gene Amp PCR system 9700 thermal cycler, a sequence of denaturing (94
o
C) for 30 
seconds, annealing at 60 
o
C for 30 seconds, and elongation (72
o
C)  for 30 seconds cycled for 
35 cycles prior to a 7 minute 72
o
C period of elongation at the end of the reaction. The product 
was then loaded onto a 1% agarose gel with 4x loading buffer alongside the 1Kb DNA ladder 
plus (Bioline) before development under UV light and annotation.  
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Figure 2.3: Conventional PCR gel image of 18 S ribosomal RNA reverse transcribed and amplified from 
RNA from bladder cancer cell lines.  
 
2.6.3.3 Agarose gel electrophoresis of PCR products 
1% agarose gels are used to resolve DNA PCR products by size using electrophoresis. 1g 
electrophoresis grade agarose (Sigma) was dissolved in 100 ml 1x Tris/Borate/EDTA (TBE) 
buffer (108g tris, 55g boric acid, 40ml 0.5M EDTA pH 8.0 in 10L H2O) with 5 l of 10mg/ml 
ethidium bromide (final concentration 1 g/ml) to visualise cDNA. 1µl of the 1Kb plus DNA 
ladder (Bioline) was diluted in 9µl H2O and 2µl 6x loading buffer (0.25% Bromophenol Blue, 
0.25% xylene FF and 30% glycerol in H20). Samples in 6x loading buffer were prepared and 
loaded onto polymerised 1% agarose gels. Following electrophoresis at 55V for 20mins 
images were developed under UV light and annotated. 
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2.6.4 Quantitative RT-PCR (Q-RT-PCR) 
2.6.4.1 Q-RT-PCR: Principles 
Quantitative real time PCR is a technique which allows precise quantification of gene 
expression by performing a PCR reaction on cDNA, allowing measurement of changes in 
mRNA of a particular gene of interest from different samples. This is a highly sensitive 
technique which allows a high throughput of samples.  
Taqman Q-RT-PCR involves a PCR reaction with two pairs of primers for a particular gene 
of interest, along with a probe. The probe is an oligonucleotide which is complementary to a 
sequence which is 3‟ downstream of the primer binding site. The probe should ideally bind a 
sequence which is at an exon-exon boundary. This will ensure that the probe only binds 
cDNA which does not contain introns as compared to contaminating genomic DNA. The 
probe contains a fluorophore reporter at its 5‟ end and a quencher molecule at its 3‟ end. The 
fluorophore is a chemical molecule such as 6-carboxyfluorescein (shortened to FAM) which 
fluoresces, however its proximity to the quencher results in inhibition of fluorescence. During 
a PCR cycle, DNA Taq polymerase causes polymerisation of the PCR product and when it 
arrives at the 5‟ end of the probe, its 5‟ to 3‟ exonuclease activity cleaves off the fluorophore 
which loses its proximity to the quencher and therefore can fluoresce which is detected and 
recorded by the real-time thermocyclers. Therefore, the amount of fluorescence recorded is 
directly proportional to the amount of PCR product. 
The above PCR reaction allows quantification of the process unlike Northern or Southern 
blots. A Northern blot allows RNA to be electrophoresed on a gel, transferred onto a 
membrane and detected by hybridisation with a labelled oligoncleotide probe. This is a semi-
quantitative method at best and is cumbersome and time consuming. A Southern blot in this 
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setting describes electrophorescing cDNA on a gel; it is also at best a semi-quantitative 
technique. 
Q-RT-PCR is quantified by plotting the fluorescence or ∆Rn (fluorescence detected – 
background) against cycle number on a logarithmic scale. The exponential phase of the PCR 
reaction is a straight line (as the plot is on a logarithmic scale); this is when the PCR reaction 
rate is the highest and there are no limiting factors such as primer availability. Hence, a 
sample which contains a higher concentration of a particular cDNA should achieve the 
exponential phase of reaction at an earlier cycle number as compared to a sample with a lower 
concentration of the cDNA species being investigated. This cycle number is denoted Ct and is 
normalised by subtracting it from the Ct of a housekeeping gene which should be abundantly 
expressed and this should not vary between different samples. This difference in Ct gives rise 
to the ∆Ct. As the PCR product doubles per cycle, the fold difference in expression between 
samples is calculated as 2
-(∆Ct1-∆Ct2) 
where ∆Ct1-∆Ct2 is the difference between the ∆Ct of the 
two samples. 
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Figure 2.4: The principle of Taqman qRT-PCR. The probe binds its complementary sequence. As the Taq 
DNA polymerase forms the PCR product, it cleaves off the fluorochrome (blue) which releases 
fluorescence as it is detached from the quencher (green). This is detected by the real-time PCR thermal 
cycler. Diagram downloaded from Google Images. 
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2.6.4.2 Q-RT-PCR: Method 
The sequences of the primers and probes used are shown below:  
Sequences or primers and probes for Q-RT-PCR. 
Primer Sequence 
TRIP15/Alien Forward primer 
TRIP15/Alien Reverse primer 
TRIP15/Alien Probe 
CCTCATCCACTGATTATGGGAGT 
CATCATAATTCTTGAAGGCTTCA 
CCCTCAAGTGCATTTTACCACCACATTCTCT 
NCoR1Forward primer 
NCoR1Reverse primer 
NCoR1Probe 
TGAAGGTCTTGGCCCAAAAG 
TTTGTCTTGATGTTCTCATGGTA 
CTGCCACTGTATAACCAGCCATCAGATACCA 
NCoR2/SMRT Forward primer 
NCoR2/SMRT Reverse primer 
NCoR2/SMRT Probe 
CACCCGGCAGTATCATGAGA 
CGAGCGTGATTCCTCCTCTT 
CTTCCGCATCGCCTGGTTTATT 
VDR Forward Primer 
VDR Reverse Primer 
VDR Probe 
CTTCAGGCGAAGCATGAAGC 
CCTTCATCATGCCGATGTCC  
AAGGCACTATTCACCTGCCCCTTCAA 
P21 Forward Primer 
P21 Reverse Primer 
P21 Probe 
GCAGACCAGCATGACAGATTTC 
GGATTAGGGCTTCCTCTTGGA 
CCACTCCAAACGCCGGCTGATCTTT 
 (Khanim et al. Oncogene 2004,23;40:6712) 
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Primers and probes for a further panel of nuclear receptors were ordered via the Applied 
Biosystems Assays on Demand service. The catalogue numbers are listed below as the primer 
and probe sequences are commercially restricted. 
 
FXR Hs00231968_m1 
LXR α Hs00172885_m1 
LXR β Hs00173195_m1 
PPAR δ Hs00602622_m1 
RAR α Hs00230907_m1 
RAR β Hs00233407_m1 
RXR α Hs00172565_m1 
Cyp3A4 Hs00430021_m1 
18S internal control 4308329 
  
All samples and reagents were allowed to thaw on ice. A mastermix was prepared for each 
gene, depending on whether the reaction was singleplex (one gene per well, requiring an 
additional control well per sample for 18S VIC dye labelled probe) or duplex (18S VIC dye 
labelled probe and gene of interest, 6-FAM dye labelled probe in same well with different 
reporter dyes).  
Each 20µl mastermix was prepared using the following reagents: 
Singleplex 18S mastermix (housekeeping gene): 
2x Q-RT-PCR Mastermix (Applied Biosystems)   10µl 
18S ribosomal RNA control probe (Applied Biosystems)  0.1µl 
 18S ribosomal RNA control forward primer (Applied Biosystems) 0.1µl 
 18S ribosomal RNA control reverse primer (Applied Biosystems) 0.1µl 
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}  44 cycles 
 cDNA         1µl 
 Nuclease Free Water (Promega)     8.7µl 
 Total         20µl 
Singleplex assays-on-demand mastermix: 
 2x Q-RT-PCR Mastermix (Applied Biosystems)   10µl 
 20x Assays-on-demand mastermix (Applied Biosystems)  1µl 
 cDNA         1µl 
 Nuclease Free Water (Promega)     8µl 
 Total         20µl 
 
 
Duplex mastermix: 
 2x Q-RT-PCR Mastermix (Applied Biosystems)   10µl 
 Gene specific probe 1.25µM (Oswell)    2µl 
 Gene specific forward primer 9µM (Alta bioscience)  2µl 
 Gene specific reverse primer 9 µM (Alta bioscience)  2µl 
18S ribosomal RNA control probe (Applied Biosystems)  0.1µl 
 18S ribosomal RNA control forward primer (Applied Biosystems) 0.1µl 
 18S ribosomal RNA control reverse primer (Applied Biosystems) 0.1µl 
 cDNA         1µl 
 Nuclease Free Water (Promega)     8.7µl 
 Total         20µl 
 
19µl of mastermix is then loaded in 96 well plate format into each well and 200µg cDNA 
added in 1µl nuclease free water.  
After setting up the ABI Prism 7500 sequence detector and loading the plate the standard 
cycling conditions were as follows: 
 
2 mins  50oC  AmpErase UNG Activation 
10 mins 95oC  AmpliTaq Gold Enzyme Activation 
15 secs 95oC  Denature 
1 min  60oC  Anneal, Extend 
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Following the PCR run, data was downloaded and analyzed using the sequence detector 
software. Data was expressed as Ct values (the cycle number at which logarithmic PCR plots 
cross a calculated threshold line) and used to determine ∆Ct values (∆Ct = Ct of the target 
gene minus Ct of the housekeeping gene). This value can then be compared to other control 
samples by subtracting, for example, the normal sample ∆Ct from the cancer ∆Ct to give the 
∆∆Ct. The fold increase in expression can then be calculated using the formula: 
 
Fold Increase in expression      =     2
-(∆∆Ct) 
 
Data was then graphed using bar graphs of fold increase in expression. Each reaction was 
performed in triplicate and error bars calculated representing the SEM (SEM=SD/√n). 
 
2.6.5  Microfluidic Q-RT-PCRM  
Simultaneous quantitative comparison of multiple gene transcripts was undertaken on the 
custom-designed TaqMan® Low Density Arrays (ABI 7900HT Fast Real-Time PCR 
System). The full list of gene targets is divided into nine functional groups whose expression 
together reflects nuclear receptor signaling capacity. These are 1. Cell surface transporters  2. 
Nuclear receptors 3. Nuclear receptor co-factors 4. Histone modifiers 5. Metabolic enzymes; 
6. Cell death regulators; 7. Transcription factors; 8. Cell cycle regulators; 9. Signal 
transduction components.  
Triplicate RNA samples from both RT4 pNCOR#7 and RT4 pcDNA#6 cells at different 
passage numbers and each treated plus or minus with LCA (10μM, 6 h.), were each measured 
in duplicate on each array. Total RNA was extracted using TriReagent (Sigma) as per section 
2.5.2, and reverse transcribed to cDNA, and quantified using the one-step QuantiTect Probe 
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RT-PCR kit (Qiagen, http://www1.qiagen.com) directly on arrays. Data was normalized to the 
internal control 18S and the pNCOR samples calibrated to the pcDNA samples using the 
∆∆CT method as described above. 
Statistical analysis was performed using TIGR MultiExperiment Viewer 4.0, MeV (freely 
available at www.tm4.org); fold change values, obtained comparing treated and untreated 
pNCOR#7 ∆Cts versus pcDNA#6 ∆Cts, were compared using a one sample t-test. Vectors 
containing gene expression values were tested against the predicted mean of 1 that indicates 
no changes in gene expression with cut-off (p<0.01). 
 
2.7 Protein extraction 
2.7.1 Protease inhibitor cocktail 
Protease inhibitor cocktail (P8340, Sigma) was used for extraction of all cell protein lysate 
production. The inhibitor and final concentration used were AEBSF (104mM), Aprotinin 
(80µM), Leupeptin (2mM), Bestatin (4mM), Pepstatin A (1.5 mM) and E-64 (1.4mM). The 
protease inhibitor cocktail solution was stored at -20
o
C. 
2.7.2 Extraction of cell protein 
Treated cells were grown in T25 cell culture flasks (Greiner) until subconfluent. After 
aspiration of the media, cells were washed in PBS and trypsinised; 10 mls of fresh medium 
was added to halt the reaction. The cells were transferred to a 15 ml Falcon tube (Corning) 
and pelletted (x1500 rpm for 10 mins). The medium was aspirated off and discarded. 100µl of 
RIPA Buffer (1ml NP-40, 0.5g Sodium Deoxycholate, 1ml 10% SDS, 98ml H20 with 30µl 
Protease inhibitors (P8340, Sigma) per 300µl for each use) added to each flask, mixed, and 
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transferred to a 1.5ml eppendorf and incubated at –80 oC for 30mins. RIPA is a cell lysis 
buffer and denatures proteins i.e. unfolds the secondary, tertiary and quartenary structures as 
it contains the ionic detergents sodium dodecylsulphate and sodium deoxycholate. It does so 
by disrupting the non-covalent bonds in proteins as well as imparting a negative charge to 
proteins which is proportional to the mass of the protein. Cell lysis occurs by membrane 
disruption and by freezing. The preparation was allowed to thaw at room temperature, 
vortexed and briefly spun down. A further cycle of freezing at –80 oC was carried out. This 
was followed by centrifugation for 10mins at 12,000rpm to remove cellular debris the 
supernatant was transferred to new labelled eppendorf and stored at -20
o
C prior to 
ascertaining protein concentration. 
2.7.3 Nuclear/Cytosolic Protein Fractionation 
A commercially available kit (BioVision Nuclear/Cytosol Fractionation Kit) was employed to 
extract nuclear and cytosolic protein fractions from wild type bladder cancer cell lines as well 
as RT-4 cells stably transfected with pNCoR1 and pcDNA3 control plasmids. The protein 
fractions were used for Western blot analysis as described below. 
Briefly, bladder cells were pelletted by centrifugation at 600 x g for 5 minutes at 4
o
C. These 
were resuspended in 200 µl of cytosol extraction buffer-A, containing protease inhibitors and 
1mM DTT. 11 µl of ice cold cytosol extraction buffer-B was added and mixed. Nuclei were 
pelletted by centrifugation at 16,000 g for 5 minutes. The supernatant represented the 
cytosolic fraction. The nuclear pellet was resuspended in 100 µl of nuclear extraction buffer 
(containing protease inhibitors and 1mM DTT). This mix was repeatedly vortexed to ensure 
nuclear lysis. The mix was centrifuged at 16,000 g for 10 minutes; the supernatant represents 
the nuclear fraction. 
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2.7.4 Assay to determine protein concentration: Modified Lowry Assay 
The Lowry assay is a calorimetric protein assay based on Copper (II) ions in alkaline solution 
forming complexes with protein. The amount of complex present is directly proportional to 
the amount of protein present. The complexes react with phosphotungstic and 
phosphomolybdic acids in phenol which are reduced to molybdenum/tungsten blue. The 
higher the concentration of protein the deeper the colour of blue obtained; the absorbance can 
be measured by a spectrophotometer at 690 nm (LOWRY et al., 1951). Proteins standards of 
differing concentrations of bovine serum albumin are also assayed to produce a standard 
curve which can then be used to estimate the concentration of protein in the samples. 
Each protein sample to be tested and protein standards of 5.0, 1.0, 0.75, 0.5 and 0.25mg/ml 
were thawed and stored on ice. A 96 well clear, flat bottomed plate was labelled and 5µl of 
each standard or samples were added into allocated wells in triplicate. 25µl of protein 
determination solution A (BIORAD) was then added to each well followed by 200µl of 
protein determination solution B (BIORAD). The plate was then incubated at room 
temperature for 15 minutes before the absorbance at 690nm was read using a 
spectrophotometer. After plotting the standard‟s optical density vs concentration, the 
concentrations of each sample was then interpolated from their optical densities in mg/ml and 
recorded. 
2.8 Western Blotting-Resolution of proteins by SDS-PAGE 
2.8.1  Principle 
Western blotting refers to a semi-quantitative technique to initially separate proteins followed 
by detecting particular proteins by applying specific antibody binding. 
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Proteins are separated by SDS-PAGE which refers to polyacrylamide gel electrophoresis. 
Protein samples are denatured initially by boiling in a solution containing sodium dodecyl 
sulphate and β-mercaptoethanol. The former applies a uniform negative charge to proteins in 
proportion to their molecular weight and thereby disrupts the secondary, tertiary and 
quartenary protein structures so they become rod-like. The latter disrupts disulphide bonds. 
When an electrical current is applied along the polyacrylamide gels containing the protein 
samples, they migrate towards the positive electrode and separate according to their molecular 
weight. 
Detection of particular proteins by antibodies requires the proteins to be transferred to a 
nitrocellulose or PVDF (polyvinylidene difluoride) membrane. The gels are too fragile to 
handle and the protein epitopes are not adequately exposed to allow antibody binding. The 
membranes have good non-specific protein binding characteristics due to both hydrophobic 
and charged interactions. The proteins were transferred via electroblotting i.e. by applying a 
positive electric current across the gel and membrane. The membranes were incubated in a 
solution of fat-free milk powder to allow milk protein to bind to the remaining non-specific 
protein binding sites on the membrane to reduce the occurrence of non-specific antibody 
binding. 
Antibody binding was a two step process. Initially a specific antibody against the protein in 
question was incubated with the membrane. Following this, a secondary antibody which binds 
the Fc or common domain of the primary antibody. The secondary antibody has a conjugated  
horseradish peroxidise enzyme which catalyses a chemiluminescent reaction when exposed to 
ECL reagent (Roche) which is detected on x-ray paper. 
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2.8.2 Western blotting: Method 
Separation of proteins by size was achieved using SDS-PAGE prior to transfer to a PVDF 
membrane and exposure to primary and secondary antibodies. 
Using Protogel reagents (Geneflow) an 8% resolving gel was prepared using 2.67ml protogel 
(30% w/v acrylamide), protogel resolving buffer 2.6ml (1.44M tris-HCl, 0.384% SDS, pH 
8.8), H20 4.62ml, Ammonium persulphate (10%) 100µl and TEMED 10µl and poured into a 
BIORAD gel apparatus and allowed to polymerise at room temperature. Stacking gel was 
prepared using 130µl Protogel (30% w/v acrylamide), 250µl protogel stacking buffer (0.5M 
tris-HCl, 0.4% SDS, pH 6.8), H20 610µl, Ammonium persulphate (10%) 50µl and TEMED 
10µl was then prepared, poured onto the set and allowed to polymerise at room temperature. 
Gel combs were used to allow well formation for loading. 
Protein samples were then thawed on ice and diluted to give 30µg per sample with 10µl of 4x 
SDS loading buffer (3.75ml H20, 1.25ml TRIS HCl pH 6.8, 2.5ml glycerol, 2ml SDS(10%), 
0.5ml mercaptoethanol, 0.5ml Bromophenol Blue, total volume 10mls) to a volume of 40µl. 
Samples were denatured by heating to 95
o
C for 10 mins and loaded, in parallel with a protein 
ladder in a separate well (Prestained Dual Color SDS Page Standards, BIORAD). SDS-PAGE 
running buffer (25mM TRIS, 192mM Glycine, 0.1% SDS, Geneflow) was added to the 
apparatus. Electrophoresis at 200V, 400mA then proceeded for approximately 50 minutes, or 
until the 120kDa Galactosidase marker was approaching the end of the gel. 
Transfer of the separated protein onto a pre-hydrated polyvinylidene difluoride PVDF 
membrane (Immobilon P, Millipore) was undertaken using a BIORAD transfer apparatus and 
transfer buffer (TRIS 25mM, Glycine 192mM, 0.1% SDS and 20% methanol) for 1 hr at 
100V, 400 mA using ice packs and a magnetic stirrer to prevent over heating of the apparatus. 
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Transfer of NCoR1 protein was performed as described above however, at 4
o
C, 10 V for 16 
hours. 
Transfer membranes were preblocked with 10% Blotto (Reconstituted milk powder) for 1hr, 
the membrane was incubated with primary antibody at varying concentrations (see table 
below) in TBST (50ml 1M TRIS HCl pH 7.6, 20g NaCl in 2.5l dH2O). Each membrane was 
then washed in 10ml TBS-T (50ml 1M TRIS HCl pH 7.6, 20g NaCl, 0.1% TWEEN-20 and 
dH20 to 2.5l) for 3x 20 mins prior to exposure to the appropriate secondary antibody (HRP-
conjugated, 1:10000 in TBS, Amersham). Following further washes with 10mls TBS-T for 3x 
20mins membranes were incubated  in 1ml ECL plus (Amersham Biosciences), at room 
temperature for 2 mins prior to exposure to film (Hyperfilm ECL, Amersham pharmacia 
biotech) prior to development and annotation. 
Target Manufacturer Clone / 
Catalogue no 
Dilution Incubation 
time 
VDR 
monoclonal 
Chemicon 
International 
MAB1360 1:500 2.5 hrs, 21
 o
C 
FXR 
monoclonal 
R&D Systems A9033A 1:500 2.5 hrs, 21
 o
C 
NCoR1 
polyclonal 
Abcam ab24552 1:5000 24 hrs, 4
o
C 
Nucleolin 
monoclonal 
Abcam ab13541 1:10,000 20 hrs, 4
o
C 
Β-actin Sigma AC15 1:10,000 1 hr, 21 oC 
 
Table 2.1: Details of various antibodies used for Western blotting. 21
 o
C denotes room temperature. 
2.9 Stable transfection of NCoR1 over-expressing plasmid 
2.9.1 Transformation and maxi-prep: Principle 
Transformation is a process whereby bacteria take up foreign DNA, a plasmid in this instance 
and replicate this plasmid with every round of bacterial cell division. The bacterial cells were 
chemically transformed by chilling the cells on ice in the presence of divalent ions followed 
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by providing a heat shock by immersing the cells in a water bath at 42 
o
C. This allows the 
cells to take up the foreign plasmid. The purpose of transformation in this case is for the 
bacteria to synthesise massive amounts of plasmid as they divide so a significant amount can 
be recovered via the maxiprep to use in transfection. 
 
The maxiprep is a commercial kit which allows chemical recovery of plasmid DNA from 
bacteria which have proliferated in culture having copied the plasmid as they have copied 
their genomic DNA before each cell division. The maxiprep starts by collecting all the 
bacterial cells by centrifugation at 5000 x g. The cellular pellet is treated with an alkali 
solution of detergents to lyse the cell walls. After lysis, the protein and membrane lipid are 
precipitated by adding potassium acetate; this mix is ultracentrifuged to separate the 
precipitate. The plasmid DNA remains in solution which is filtered through and is 
subsequently precipitated by adding isopropanol. This is ultracentrifuged to collect the 
plasmid DNA pellet. This pellet is subsequently purified by binding the plasmid DNA to a 
resin and passing solutions containing ethanol through columns to remove impurities. The 
plasmid is finally eluted by passing through hot water through the columns. 
 
2.9.2 Transformation and maxi-prep: Method 
I transfected a pcDNA3 expression plasmid (figure 6) with a full length NCoR1 insert into 
RT-4 cells. The plasmid was a generous gift from Dr. Johnson Liu (Mount Sinai School of 
Medicine, currently The Feinstein Institute of Medical Research, New York, USA).  
E.Coli cells (α-select chemically competent cells, Bioline BIO-85026) were transformed with 
the plasmid as per the manufacturer‟s instructions. Briefly, 5 µl of plasmid, pcDNA-NCoR1 
as well as control pcDNA3 blank plasmid was added separately to 50 µl of cells in a 15 ml 
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test tube and gently mixed. This was incubated on ice for 3 minutes. The tubes were placed in 
a 42 
o
C waterbath for 45 seconds and then placed on ice for 2 minutes. This solution was then 
diluted by adding 1 ml of LB medium (per litre: 10 g tryptone, 5 g yeast extract, 5 g Na Cl, 1 
ml 1M Na OH). The tubes were shaken for 60 minutes at 200 rpm at 37 
o
C following which 
they were spread on LB agar plates (recipe as per LB medium but with additional 15 g 
agarose) with 100 µg/ml ampicillin and incubated overnight at 37 
o
C.  As a control, 2 µl of 
puc19 plasmid was also used in separate transformations. The next morning, discrete colonies 
of E.Coli cells were picked which had grown on the ampicillin containing plates due to 
resistance afforded by the pcDNA3 plasmid. 300 mls of LB medium in 1 litre sterile conical 
flasks was inoculated with pcDNA3-NCoR1 and mock transformed colonies and cultured 
overnight on a shaker (200 rpm at 37 
o
C). The next morning, plasmid maxipreps were carried 
out as per the manufacturer‟s instructions (Promega Wizard plus maxipreps DNA purification 
system A7270, USA). The culture solution was pelletted by centrifugation at room 
temperature at 5000 g for 10 minutes. The supernatant was discarded and the pellet was 
resuspended in 15 mls of cell resuspension solution (50 mM Tris-HCL (pH 7.5), 10 mM 
EDTA and 100 µg/ml RNase A). The cells were lysed by adding 15 mls of lysis solution (0.2 
M NaOH and 1 % SDS).  This solution was neutralised by adding 15 mls of neutralisation 
solution (1.32 M potassium acetate pH 4.8). The resulting solution was centrifuged at 14,000 
g for 15 minutes at room temperature; the clear supernatant filtered through Whatman paper. 
Plasmid DNA was precipitated by adding ½ volume of room temperature isopropanol and 
centrifuging at 14,000 g at room temperature for 15 minutes. The DNA pellet was 
resuspended in 2 mls of TE buffer (10 mM Tris-HCL pH 7.5, 1mM EDTA).  
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2.9.3 Plasmid DNA purification: Method 
Purification resin (10 mls) was added to the plasmid DNA solution, mixed and run through a 
maxiprep column followed by 25 mls of column wash solution (80 mM potassium acetate, 8.3 
mM Tris-HCL, 40 µM EDTA and 55 % ethanol). The columns were washed through with 5 
mls of 80 % ethanol. The columns were centrifuged at 1300 g for 5 minutes, dried by 
applying a vacuum and the DNA eluted by passing 1.5 mls of preheated (65-70 
o
C) water and 
centrifuging at 130 g for 5 minutes. 
The plasmid DNA concentration was determined by measuring the absorbance at 260 nm 
using spectrometer and using the equation below: 
Concentration of plasmid (µg/µl) = OD x 250 (dilution factor) x 50 
      1000 
 
2.9.4 Stable transfection of plasmid 
5 x 10
5
 RT4 cells per well (6 well plates) were allowed to adhere overnight. Per well, 3 µl of 
Fugene® 6 agent (Roche) was added to 97 µl of Optimem solution (Invitrogen) and after 5 
minutes, 1 µg of plasmid DNA (pcDNA3-NCoR1 or pcDNA3 blank) was added. This was 
left at room temperature for 20 minutes and all of this solution was added per well to 2 mls of 
fresh medium (McCoy‟s 5a with serum). After 48 hours, McCoys 5a medium with selection 
antibiotic, G418 660 µg/ml was added in place of the regular culture medium. This 
concentration of G418 was chosen by previously incubating RT4 cells with a range of 
McCoys 5a medium with varying concentrations of G418 (100-1000 µg/ml in 100 µg/ml 
steps). A concentration of between 600 – 700 µg/ml led to cell death. Further titration led to a 
dose of 660 µg/ml as the threshold for RT-4 cell killing.   
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After 2 weeks of incubation, discrete cell colonies were growing in the G418 containing 
medium. These were isolated by placing sterile steel rings with paraffin wax at the base 
around each colony and by trypsinising and isolating each colony for further subculture, as a 
pure sub-clone. These were maintained in McCoys 5a medium with selection antibiotic G418 
(660 µg/ml) with repeat passages as necessary.  
Figure 2.5: Structure of the empty pcDNA3 plasmid. The insert was the whole sequence of NCoR1; over-
expressing vector obtained from Dr. Johnson Liu (Mount Sinai School of Medicine, currently The 
Feinstein Institute of Medical Research, New York, USA). Image downloaded from website 
http://www.molecularinfo.com/MTM/K/K2/K2-1/pcdna3.pdf. 
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2.10 Affymetrix® gene expression arrays 
The target gene expression in EJ-28 cells was investigated after treatment with LCA, SAHA 
and the combination of the two ligands; total RNA was extracted at 6 hours post treatment. 2 
x 10
6
 cells were plated onto T75 (75 cm
3
 surface area) culture flasks and left overnight (18 
hours) to adhere. The cells were treated with the following concentrations of treatments: LCA 
= 100 µM, SAHA = 0.8 µM and negative control was treated with vehicle i.e. ethanol. At 6 
hours post treatment, total RNA was extracted as described in section 2.5.1. The RNA was 
purified using the Qiagen® RNeasy mini kit as per the manufacturer‟s instructions. Briefly, 
the RNA samples were adjusted to 100 µl volume with RNAse free water. 350 µl of buffer 
RLT is added and mixed well. This is a guanidine isothiocyanate containing denaturing buffer 
which immediately inactivates RNAses. 250 µl of 100 % ethanol is added to this mixture. 
This optimises binding of RNA molecules longer than 200 bases to the silica-gel membrane 
within the mini columns. The mixture is added to the columns and centrifuged for 15 seconds 
at 8000 x g. The flow-through is discarded. We performed the optional on-column DNAse 
digestion step to further eliminate DNA contamination. Following this, 500 µl of RPE buffer 
is added to the column and the centrifugation step is repeated and the flow-through is 
discarded again. This is repeated with centrifugation for 2 minutes to ensure drying of the 
column and also so that ethanol is not carried over into the final RNA eluate. Finally, RNA is 
eluted by passing 30 µl of RNAse free water through the column.  
 
The sample processing for the Affymetrix® has 5 steps before hybridisation of the cRNA to 
the oligonucleotides on the genechip®. The RNA is reverse transcribed to cDNA, this is put 
through a “clean up” process following which the cDNA is converted to biotin-labelled cRNA 
in a process called in vitro transcription (IVT). The cRNA is then put through a further “clean 
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up” process, followed by fragmentation. This fragmented cRNA is hybridised on to the 
genechips®. 
2.10.1 Reverse transcription 
Preparation of Poly-A RNA controls 
The quality of the entire target RNA labelling process is monitored by a set of exogenous 
Bacillus subtilis poly-A RNA molecules added to the target total RNA samples at 
predetermined concentrations. Probes to these bacterial genes are on each of the GeneChip 
arrays; these genes are not found in eukaryotic samples. The poly-A controls are reverse 
transcribed, amplified and labelled together with the target RNA samples and hybridised onto 
the GeneChips. The intensity of hybridisation provides an independent control for the quality 
of pre-hybridisation processing of the target RNA.  
Table 2.2: The following B subtilis genes are present in the poly-A control concentrate: 
B subtilis genes Final Dilution (estimated ratio of copy 
numbers) 
Lys 1:100,000 
Phe 1:50,000 
Thr 1:25,000 
Dap 1:6,667 
(from GeneChip® Expression Analysis Technical Manual-Affymetrix®)     
The starting RNA concentration for these reactions was 5 µg, hence the following serial 
dilutions were used to prepare the poly-A controls from stock concentrate: 
1
st
 dilution 1:20 
2
nd
 dilution 1:50 
3
rd
 dilution 1:10 
2µl of the final dilution was used for each sample. 
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First Strand cDNA synthesis 
5 µg of total RNA is used. The following mix is prepared for each specimen: 
 
2 µl of diluted poly-A control RNA 
1 µl (100 pmol/µl) T7 oligo dT primer 
Made up to 12 µl with DEPC treated water. 
The samples were incubated at 65-70 
o
C for 10 minutes to denature the RNA. The following 
mastermix was added to each sample: 4 µl (x5) first strand buffer, 2 µl DTT, 1 µl (10 mM) 
dNTPs. This mix is incubated for 42 
o
C for 1 hour. 200 IU of Superscript II Reverse 
Transcriptase (Qiagen) is added and the mix incubated at 42 
o
C for a further 1 hour. 
 
Second Strand cDNA synthesis 
At the end of first strand synthesis, RNA/DNA heteroduplex molecules are present. In order 
for the second strand of cDNA to be synthesised, the method first described by Gubler and 
Hoffman (Gubler and Hoffman, 1983) is used. RNAse H enzyme is an RNAse which 
hydrolyses the RNA strand so that short RNA primers are left bound to the cDNA molecule. 
DNA polymerase I then synthesises the second cDNA strand. T4 DNA polymerase is added 
which creates blunt DNA termini.  
The following reaction mix is added to the samples from the last reaction: 91 µl of DEPC 
treated water, 30 µl of (x5) second strand buffer, 3 µl of (10mM) dNTPs, 1µl of E. Coli DNA 
ligase (10 U),  4µl of E. Coli DNA Polymerase I (40 U), 1 µl of E.coli RNAse H (2U). This 
mix is incubated at 16 
o
C for 2 hours; then 2 µl (10 U) of T4 DNA polymerase is added 
followed by incubation at 16 
o
C for 5 minutes. Then 10 µl of 0.5M EDTA is added.   
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Clean-up of Double Stranded cDNA 
This procedure uses spin columns to selectively bind and then elute cDNA akin to the Qiagen 
RNeasy mini kit procedure explained earlier. Briefly, 600 µl of cDNA binding buffer is added 
to the cDNA reaction mix. 500 µl of this mix is added to the cDNA cleanup spin column and 
spun for 1 minute at full speed. This is repeated with the rest of the reaction mix. 750 µl of 
wash buffer is added to the column and spun through. The purified cDNA is eluted by adding 
14 µl of elution buffer and spinning for 1 minute at 10,000 rpm. 
 
Synthesis of cRNA - In vitro Transcription 
This process converts cDNA to cRNA and labels the molecules with biotinylated 
ribonucleotides. The following mix (28 µl) is added to each cDNA sample: 8µl of DEPC 
treated water, 4 µl (10x) IVT labelling buffer, 12 µl of IVT labelling NTP mix and 4 µl of 
IVT labelling enzyme mix containing viral derived RNA polymerases. The samples are 
incubated overnight at 37 
o
C. 
 
cRNA Clean-up 
This process utilises RNA binding columns. The IVT reaction is diluted with 60 µl of RNAse 
free water. 350 µl of cRNA binding buffer is added followed by 250 µl of 100 % ethanol. 
This mix is passed through the cleanup column and spun at 10000 rpm for 15 seconds; the 
flow through is discarded. The columns are washed with 500 µl of wash buffer solution and 
then with 500 µl of 80 % ethanol (centrifuged at 10,000 rpm for 15 seconds). The cRNA is 
then eluted with RNAse free water and the concentration is checked with a nanodrop 
spectrophotometer. 
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cRNA Fragmentation 
The cRNA is fragmented before it can be hybridised to the GeneChips®. 25 µg of cRNA is 
mixed with 10 µl of (x5) fragmentation buffer and made upto 50 µl with DEPC treated water. 
The (x5) fragmentation buffer contains 200 mM Tris-acetate pH 8.1, 500 mM potassium 
acetate and 150 mM magnesium acetate. The reaction mix is incubated at 94 
o
C for 35 
minutes to cause cRNA fragmentation.  
 
Hybridisation to Affymetrix U133 Array 
15 µg of fragmented and labelled cRNA is used to hybridise to the geneChips®. This cRNA 
is mixed with a hybridisation cocktail of control oligonucleotide B2 (3nM) 5 µl, 20 x 
eukaryotic hybridisation controls 15 µl, hybridisation mix 150 µl, 30 µl of DMSO and 
nuclease free water made upto 300 µl. The arrays are equilibrated to room temperature and 
the hybridisation cocktail is applied. The arrays are hybridised in a proprietary oven for 16 
hours followed by staining and scanning as per The GeneChip Expresison Analysis Technical 
Manual (Affymetrix). 
 
2.10.2  Microarray Statistical Analysis 
The Affymetrix gene chip array contains multiple oligonucleotide probes per gene; 
hybridisation of labelled cRNA oligonucleotides from the experimental sample generates a 
signal, the intensity is proportional to the number of cRNA oligonucleotides that have been 
bound and hence the degree of expression of that particular gene. 
 
The first process in microarray data analysis is normalisation. This aims to remove systematic 
errors or biases from the data. In theory, a particular cRNA sample hybridised to two separate 
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microarray chips should generate exactly the same signal density from each probe on the chip. 
However, this does not occur in practice. This is due to random as well as systematic errors or 
biases. Systematic biases may be due to human errors in experiment replication, pippetting 
errors or differences in experiment protocol, if results from microarray experiments conducted 
in different laboratories are being compared. Normalization aims eliminate these biases so 
data generated from separate microarray experiments may be compared. 
 
The Affymetrix Array contains paired sets of probes for each RNA gene. One pair represents 
the perfect Watson-Crick oligonucleotide and the mismatch pair contains the same sequence 
except for a single mismatched base pair. The degree of signal from the mismatch pair is 
representative of non-specific binding of the cRNA sample.  This is subtracted from the signal 
from the perfect pair to give an adjusted result. 
 
The normalisation method used in the present microarray analysis is denoted as quantile 
normalisation. This method ranks all of the probe signals by intensity. It then calculates the 
mean intensity of each rank and replaces the signal intensity at each rank with this mean 
value. The dChip software (freely available on http://biosun1.harvard.edu/complab/dchip/), 
incorporates quantile normalisation.  
 
After normalisation, an expression value is generated for each gene which can then be 
statictically compared between treatments (vehicle only vs LCA alone or SAHA alone or 
LCA + SAHA) using the Student‟s t-test with p<0.01 being statistically significant. 
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Chapter 3 : Expression profiling of nuclear receptors and 
co-repressors in bladder cancer cell lines. 
3.1 Introduction: 
Nuclear receptors have been described as having classical endocrinological actions such as 
the VDR regulating the uptake of calcium from the small intestine. However, NRs are 
expressed in tissues which are not related to their well described classical actions, for example 
VDR is expressed in the prostate (Kivineva et al., 1998) and FXR is expressed in the breast 
(Swales et al., 2006). It is postulated that these NRs may be involved in regulating growth and 
differentiation at these sites, possibly acting as a co-operative network to sense dietary and 
xenobiotic inputs. For example, FXR is known as a bile acid sensor in the hepato-biliary tract. 
However, bile acids have been detected in breast cyst fluid (Javitt et al., 1994) and FXR may 
be involved in sensing these potentially toxic compounds in the breast.  
 Nuclear receptor ligands elicit a spectrum of anti-proliferative responses in cancer cells. 
These responses are not fully explained by either the level of nuclear receptor expression 
alone or the presence of mutations within the NR gene. An example is the VDR and the anti-
proliferative responses to 1α25 (OH)2D3 in prostate cancer cells; Zhuang has demonstrated 
that cellular VDR content does not explain the variety of anti-proliferative responses in a 
panel of prostate cancer cell lines (Zhuang et al., 1997). Also, the VDR is not found to be 
frequently mutated in cancers (Miller et al., 1997). A possible explanation proposed by 
Khanim et al and Banwell et al is the overexpression of the co-repressors SMRT/NCoR2 and 
NCoR1 in prostate and breast cancers changes the NR signalling equilibrium towards 
selective repression of potentially anti-proliferative target genes despite the presence of 
adequate ligand and VDR (Khanim et al., 2004; Banwell et al., 2006). They also describe the 
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frequent overexpression of SMRT/NCoR2 in prostate cancers and NCoR1 in breast cancers as 
measured by Q-RT-PCR compared to matched normal tissue. 
 
The specific hypothesis is that dietary derived NRs are expressed in the bladder cancer cell 
lines and exhibit a spectrum of anti-proliferative responses towards ligands to these NRs. A 
role for co-repressor expression is explored to explain the anti-proliferative responses. 
3.2 Materials and Methods 
 Quantitative real-time PCR. 
 Western blotting. 
 ATP proliferation assay. 
 Stable transcription of NCoR1 over-expressing pcDNA3 plasmid. 
 
 
3.3  Results 
3.3.1 Bladder Cancer Cell lines have a spectrum of anti-proliferative 
responses to nuclear receptor ligands 
The four bladder cancer cell lines were treated with ligands to various nuclear receptors as 
listed below. 
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Ligand Nuclear Receptor 
1α25 (OH)2D3 Vitamin D receptor (VDR) 
Lithocholic acid (LCA) Farnesoid X receptor (FXR) and VDR 
9 cis retinoic acid (9cis RA) Retinoid X receptor α, β, γ (RXR α, β, γ) 
Eicosapentanoiec acid (EPA) Peroxisome proliferator activating receptor α 
(PPAR α) 
5,8,11,14-eicosatetraenoic acid (ETYA) Peroxisome proliferator activating receptor γ 
(PPAR γ) 
Chenodeoxycholic acid (CDA) Farnesoid X receptor (FXR) 
GW3965 Liver X receptor α and β (LXR α and β) 
22 (R) Hydroxy Cholesterol (22-HC) Liver X receptor α and β (LXR α and β) 
Docosahexanoic acid (DHA) Retinoid X receptor α, β, γ (RXR α, β, γ) 
 
Table 3.1: Nuclear receptor ligands and their respective receptors. 
 
Cells were plated out at densities of 2-4 x 10
3
 per well and allowed to adhere overnight. They 
were treated with the stated concentrations of ligand as listed in the graphs below. The cells 
were re-treated at 48 hours and the ATP levels were read at 96 hours as described in section 
2.3.  
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Figure 3.1: Cells were plated at the following densities into 96 well plates; RT-4 2x10
3
 cells per well, HT-
1376 4x10
3 
per well, RT112 and EJ28 3x10
3 
cells per well. These cell densities were pre-optimised to result 
in cells in the exponential phase of growth. The ATP levels were determined as per section 2.3 at 96 hours 
post treatment with an additional dose at 48 hours. The luminescence for the treatment wells was divided 
by that for the negative control to give a survival fraction. Therefore, survival >100 % denotes a pro-
proliferative response and <100 % denotes an anti-proliferative response. The experiments were 
conducted in triplicate and were repeated three times. Error bars denote standard error of the mean. 
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Figure 3.2: Cells were plated at the following densities into 96 well plates; RT-4 2x10
3
 cells per well, HT-
1376 4x10
3 
per well, RT112 and EJ28 3x10
3 
cells per well. The ATP levels were determined as per section 
2.3 at 96 hours post treatment with an additional dose at 48 hours. The luminescence for the treatment 
wells was divided by that for the negative control to give a survival fraction. Therefore, survival >100 % 
denotes a pro-proliferative response and <100 % denotes an anti-proliferative response. The experiments 
were conducted in triplicate and were repeated three times. Error bars denote standard error of the 
mean. 
 
The above dose response graphs illustrate varying responses to treatment with the different 
nuclear receptor ligands and SAHA. ED50 doses, i.e. the estimated dose required to kill half 
the number of cells in comparison to vehicle only control, were calculated as a measure of 
cell sensitivity to the ligands. These are shown in table 3.2. There are two broad patterns 
which emerge from table 3.2. RT-4 cells appear to be the most sensitive i.e. have the lowest 
ED50 for all ligands except 1α,25(OH)2D3. Also, EJ-28 cells appear to be the least sensitive, 
i.e. have the highest ED50 for four ligands (EPA, ETYA, CDA and vorinostat). The dose 
response curve did not cross 50 % for 1α25(OH)2D3, LCA and 9-cis RA, hence, it is not 
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possible to comment on their sensitivity. The exceptions are DHA, GW3965 and 22 H Chol 
where EJ-28 is not the least sensitive cell line.  
 Receptor RT-4 RT-112 HT-1376 EJ-28 
1α,25(OH)2D3 
(nM) 
VDR 90 25 NC NC 
LCA (µM) VDR, FXR 9.3 80 NC NC 
9-cisRA (nM) RXR α,β,γ NC NC NC NC 
DHA (µM) RXR α,β,γ 89 90 110 95 
EPA (µM) PPAR α 105 110 110 130 
ETYA (µM) PPAR γ 3.6 12 20 85 
CDA (µM) FXR 8.9 105 45 862 
GW3965 
(µM) 
LXR α, β 21 85 110 98 
22HChol 
(µM) 
LXR α, β 16 66 110 98 
SAHA 
/Vorinostat 
(µM) 
HDACi 1.2 0.9 1.0 1.3 
 
Table 3.2: The ED50 values of the four bladder cancer cell lines when treated with the NR ligands listed in 
left hand column. ED50 values represent the concentration at which the dose response line crosses 50 %. 
NC-no convergence, describes ligands where dose response curve does not cross 50 %, therefore it is not 
possible to calculate an ED50 value. 
 91 
3.3.2 Bladder Cancer cell lines display a spectrum of nuclear receptor 
and co-repressor expression. 
Relative mRNA expression of a panel of nuclear receptors and co-repressors is shown in 
figure 3-1. These data are expressed relative to RT-4 cells. Unfortunately, a non-malignant 
bladder transitional epithelial cell line is not available for comparison. Hence RT-4 was used 
as a baseline because this cell line is the most sensitive to treatment with nuclear receptor 
ligands and it is the most differentiated cell line (derived from Grade 1 well differentiated 
transitional cell papilloma, ATCC number HTB-2).  
Figure 3-3 reveals a spectrum of expression of nuclear receptors. The most clear pattern in 
terms of suppression of nuclear receptor expression is illustrated for the high grade bladder 
cancer cells, HT 1376 and EJ 28. Between the two of them, they have suppressed expression 
of 8 out of 10 nuclear receptors investigated (FXR, LXRα, PPARγ, PPARδ, VDR, RARα, 
RARβ, RXRα). EJ 28 alone expresses reduced levels of nuclear receptors as compared to the 
well differentiated RT4 cells in 7 out of the 10 nuclear receptors investigated (FXR, LXRα, 
PPARγ, PPARδ, VDR, RARβ, RXRα).  
The pattern for nuclear receptor over-expression is less clear. The moderately differentiated 
RT-112 cell line expresses five nuclear receptors (LXRα,PPARδ,VDR, RARα and RXRα) at 
a higher level. The only co-repressor to be overexpressed is NCoR1 in RT-112 cells (1.59 
fold, p=0.01) and EJ-28 cells (2.56 fold, p=2x10
-5
). 
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Figure 3.3: Relative expression of a panel of nuclear receptors and co-repressors (SMRT/NCoR2, NCOR1 and TRIP15/Alien) with respect to RT-4 cells. 
RNA was extracted from proliferating cells at sub-confluent levels (70 % confluence visually). RNA was reverse transcribed and Taqman qRT-PCR 
performed with primers for stated genes. Results stated relative to RT-4 cells and represent mean fold change from three separate experiments. Error bars 
represent S.E.M. of fold changes. * represents p<0.05 i.e. statistical significance on a 2 tailed student’s t-test.
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3.3.3 VDR and FXR are expressed in bladder cancer cells at the protein 
level. 
Two particular nuclear receptors, VDR and FXR, were investigated at the protein level by 
Western blotting.  
 
 
 
 
 
 
 
 
 
 
 
   
 
             
 
 
 
 
Figure 3.4: Western immunoblot of nuclear and cytoplasmic proteins extracted from the 4 bladder cell 
lines used (commercially available BioVision kit for the nuclear/cytoplasmic protein extraction was used). 
2x10
6
 cells were seeded in T25 cell culture flasks and cells were harvested after they reached mid-
exponential growth (~36 hrs). Monoclonal antibody against VDR clone MAB1360 was obtained from 
Chemicon International. Membranes were re-probed with a polyclonal antibody against nucleolin to 
ensure equal protein loading. Proteins were detected by chemiluminesence. 
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These particular nuclear receptor expression patterns were investigated at protein level 
because the action of LCA, a ligand for both VDR and FXR was further investigated on the 
panel of bladder cancer cell lines in terms of cell cycle FACS analysis, target gene expression 
via Affymentrix genechip microarray and Q-RT-PCR micro-fluidic genecard techniques as 
described in chapter 4. Hence, it is appropriate to confirm protein expression for these 
particular nuclear receptors.  
The blot above illustrates that VDR is not expressed in the cytosolic protein fraction in the 
bladder cancer cell lines. It also broadly follows the same pattern as the real-time PCR 
receptor expression as shown in figure 3-1. Therefore, RT-112 and RT-4 appear to have 
significantly higher VDR expression as compared to HT-1376 and EJ-28 cells. The VDR blot 
has multiple bands in the nuclear protein fraction. This may be due to non-specific antibody 
binding however, this seems unlikely as there are very few bands within the cytosolic 
fraction. The lower nucleolin blot confirms the presence of protein within the nuclear lanes. 
Perhaps the VDR antibody would have been bound within these lanes had there been non-
significant binding, An alternative explanation may be VDR protein with post translational 
modification for some of the bands. There is evidence of VDR binding to nuclear membrane 
proteins; these complexes may be giving rise to the multiple bands (Nangia et al., 1998).  
Figure 3-3 illustrates a Western blot of whole cell protein extract probed for FXR expression. 
This blot does confirm that FXR is expressed at protein level in these bladder cancer cells. 
This Western blot suggests that, when controlled for loading, all 4 cell lines may have similar 
expression of FXR. However, the mRNA expression suggests that expression of FXR in HT-
1376, RT112 and EJ28 is reduced as compared to RT-4. These data suggest that bladder 
cancer cell lines express VDR and FXR mRNA and protein to varying levels. 
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Figure 3.5: Western immunoblot for FXR. 3x10
6
 cells were incubated in T25 flasks overnight and allowed 
to adhere and reach mid-exponential growth. Total cellular protein was extracted by adding RIPA buffer 
with protease inhibitor (Sigma). Western blot as per materials and methods. Monoclonal antibody against 
FXR was obtained from R&D Systems. The membrane was stripped and re-probed for β-actin 
(monoclonal antibody AC-15 Sigma). 
 
3.3.4 Cell Sensitivity is Partly Correlated with Nuclear Receptor to Co-
repressor Ratio 
The co-repressor NCoR1 has significantly raised mRNA expression on RT-112 (1.6 fold) and 
EJ-28 (2.6 fold) cells as illustrated in section 3.3.2. This may lead to a raised ED50 for some 
of the NR ligands due to a shift in the equilibrium of the ligand bound nuclear receptor 
towards the repressor state i.e. bound to co-repressors and histone deacetylase enzymes which 
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would favour a transcriptionally silent state. One would expect the ratio of co-repressor 
expression to nuclear receptor to correlate with the ED50. Therefore, a raised relative level of 
nuclear receptor expression may alleviate the suppressive effect of the raised expression of 
NCoR1. To investigate whether NCoR1 over-expression may be correlated with the 
expression ratio of NCoR1 and each nuclear receptor ED50, these values are given in table 3.2.  
This ratio is significantly correlated with ED50 values for EPA, ETYA and CDA. The 
correlation is difficult to assess for VDR and FXR as these dose response curves did not 
converge towards 50 % inhibition, hence an ED50 value was not generated. The NCoR1 to 
nuclear receptor ratio did not correlate with the ED50 for DHA, GW3965 and 22-HC. Also 
neither the nuclear receptor nor the NCoR1 expressions correlate with the ED50 values for the 
latter ligands (DHA, GW3965 and 22-HC).  
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RT-4 EJ28 Correlation
r2 value p-value
VDR (Vit D) R exp 1 0.04425
NCoR:Recep 1 57.8229 T
ED50 (nM) 90 >100
VDR (LCA) R exp 1 0.04425
NCoR:Recep 1 57.8229
ED50 (mcM) 9.3 >100
RARα R exp 1 1.22702
NCoR:Recep 1 2.0855 T
ED50 (mcM) ND ND
RARβ R exp 1 0.22417
NCoR:Recep 1 11.415
ED50 (mcM) ND ND
RXRα (9cisRA) R exp 1 0.31986
NCoR:Recep 1 8.00023
ED50 (nM) >100 >100
RXRα (DHA) ED50 (mcM) 89 95
PPARα (EPA) R exp 1 0.78752
NCoR:Recep 1 3.24937
ED50 (mcM) 105 130 0.904 0.049
PPARδ R exp 1 0.47843
NCoR:Recep 1 5.34862 T
ED50 (mcM) ND ND
PPARγ (ETYA) R exp 1 0.03475
NCoR:Recep 1 73.6333
ED50 (mcM) 3.6 85 0.977 0.011
FXR (CDA) R exp 1 0.00074
NCoR:Recep 1 3454.8
ED50 (mcM) 8.9 862 0.988 0.006
FXR (LCA) R exp 1 0.00074
NCoR:Recep 1 3454.8
ED50 (mcM) 9.3 >100
LXRα R exp 1 0.61466
NCoR:Recep 1 4.16317
LXRβ R exp 1 2.3268
NCoR:Recep 1 1.09977
(GW3965) ED50 (mcM) 21 98
(22-HC) ED50 (mcM) 16 90
HDAC inh (SAHA) ED50 (mcM) 1.2 1.3
 
Table 3.3: The four bladder cancer cell lines are arranged in their order of reducing differentiation. Total 
mRNA from RT-4 and EJ-28 was extracted, in triplicate, from mid-exponentially proliferating cells, and 
the levels of NCOR1 and the indicated receptors was measured by Q-RT-PCR. From these values the fold 
changes of each target was determined in comparison to RT-4 cells. From these two values a ratio of the 
fold changes in levels of NCOR1 to receptor mRNA is given (NCOR1:Recept), for each receptor. Parallel 
cultures were exposed to dose titration studies of the cognate ligands to generate sigmoidal dose-response 
curves from which the estimated dose required to inhibit proliferation by 50% (ED50) was calculated. The 
correlation between the NCOR1:Receptor ratio and the ED50 was measured and r2 and p values are 
indicated. T denotes those relationships that follow the same trend. 
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3.3.5 NCoR1 stable over-expression. 
3.3.5.1 Confirmation of NCoR1 over-expression 
Stable clones were isolated after transfection of RT-4 cells with either pcDNA3-NCoR1 
plasmid or mock transfected with pcDNA3 empty vector (negative control). To confirm 
NCoR1 over-expression, we performed Q-RT-PCR for NCoR1 mRNA expression for the 
clones and normalised NCoR1 expression in over-expressing clones to the mean of the mock 
transfected clones. 
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Figure 3.6: RNA was extracted from transfected cells in mid-exponential phase, reverse transcribed and 
q-RT-PCR performed for NCoR1 (18S as internal control). The fold changes are expressed as relative to 
the mean δCt of all of the mock transfected clones (pcDNA3 clones #1,5,6,7). The star signifies significant 
over-expression as tested by a one-tailed student’s t-test. 
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Western blotting was performed for NCoR1 protein to confirm overexpression at the protein 
level. 
 
 
 
 
 
 NCoR1  
(250 KDa) 
 
 
 
Nucleolin  
(100 KDa) 
 
 
 
 
Figure 3.7: Western blot for NCoR1 in transfected clones. NCOR#1 and #7 are two clones stably 
expressing the transfected NCoR1. pcDNA#6 and #7 are mock transfected clones. Nuclear and 
cytoplasmic protein preparations were isolated from transfected cells (commercially available BioVision 
kit for the nuclear/cytoplasmic protein extraction was used). A polyclonal NCoR1 primary antibody 
(Abcam ab24552) was used to detect NCoR1. The immunoblot demonstrates a significant high molecular 
weight band in the nuclear fraction of clones NCoR#1 and #7 corresponding to the transfected NCoR1. 
The membrane was reprobed with nucleolin as a loading control. 
 
The blot confirms presence of an appropriate weight band, corresponding to transfected 
NCoR1, in the nuclear fractions of the NCoR1 transfected clones and not the mock 
transfected clones. Expression is higher in NCoR # 7 as compared to NCoR #1 despite the 
latter having higher mRNA expression for NCoR1 as per figure 3.6. 
NCoR #7 NCoR #1 pcDNA#6 pcDNA#7 
Nuc Cyto Nuc Cyto Nuc Cyto Nuc Cyto 
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3.3.5.2 Over-expression of NCoR1 leads to reduced sensitivity to some NR 
ligands. 
NCoR overexpressing clone # 7 and mock transfected pcDNA3 clone cells were treated with 
nuclear receptor ligands at 1, 10 and 100 µM concentrations for ETYA, CDA, LCA and 
SAHA and at 1, 10 and 100 nM for 1,25(OH)2D3 and 9-cis RA. The ligands were incubated 
for 96 hours, with a re-dose at 48 hours as per section 2.3. There was a trend towards 
decreased sensitivity towards ligand with NCoR1 over-expression, best illustrated in figure 
3.8 B, which shows the percentage suppression of cell growth at 10nM (Vit D and 9cisRA) 
and 10 µM (ETYA, CDA, LCA and SAHA). 
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Figure 3.8: Sensitivity to inhibition of proliferation by treatment with the indicated NR ligands comparing 
RT-4 NCoR#7 and RT-4 pcDNA#6; 96 hour incubation with a re-dose at 48 hours; proliferation was 
measured using the ATP bioluminescent proliferation assay as detailed in materials and methods. A – 1 
nM/µM, B – 10 nM/µM, C – 100 nM/µM. Each data point represents the mean value of three separate 
experiments each performed in triplicate wells; * indicates statistical significance at p<0.05 and ** at 
p<0.01 as tested by a one-tailed student’s t-test..  
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Figure 3.8 B clearly shows reduced sensitivity in NCoR#7 cells as compared to mock 
transfected cells when treated with CDA, LCA and SAHA but not for 1,25(OH)2D3, 9 cis RA 
and ETYA. This may suggest that NCoR1 selectively regulates FXR and the responses to 
HDAC inhibition but is not the co-repressor involved in the regulatory protein complexes 
with VDR, RXRs and PPARγ.   
To recap, these experiments demonstrate a spectrum of sensitivity of the panel of bladder 
cancer cell lines towards a panel of NR ligands. The least sensitive cell line, EJ-28 over-
expresses the co-repressor NCoR1 mRNA by 2.6 fold as compared to the most sensitive cell 
line RT-4. EJ-28 cells also over-express NCoR1 at the protein level as demonstrated in our 
publication (Abedin et al., 2009). Forced over-expression of NCoR1 in RT-4 cells resulted in 
reduced sensitivity to treatment with CDA, LCA and SAHA. The cellular model to explain 
these results hinges on nuclear receptors being bound to a repressor complex consisting of a 
multimeric protein complex which includes co-repressors such as NCoR1 as well as histone 
deacetylase enzymes that allosterically maintain a closed chromatin structure and hence 
suppress target gene transcription. Therefore, to test this model cells were treated 
subsequently with ED25 concentrations of NR ligands and SAHA in combination and running 
the proliferation assay to establish anti-proliferative responses. 
 
 
3.3.6 Co-treatment of NR ligands with histone deacetylase inhibitor 
SAHA. 
Treatment of the four cell lines with minimally active ED25 concentrations of the HDACi 
SAHA and ED25 concentrations of nuclear receptor ligands showed a range of additive 
behaviours. RT-4 has no strongly additive combinations whereas, every combination in EJ-28 
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and four out of five combinations in RT-112 cells are strongly additive. This indicates that the 
combination of NR ligand and SAHA lead to a statistically significantly larger inhibition of 
cell growth (p<0.05) than would be expected by the sum of the individual inhibitory effects of 
the NR ligand and SAHA. It is notable that the two cell lines that demonstrate the strongly 
additive inhibitory effect, RT-112 and EJ28 both over-express NCoR1 by 1.6 and 2.6 fold 
respectively. These results revealed that a raised expression of the co-repressor NCoR1 in RT-
112 and EJ-28 cells, may be targeted pharmacologically with a histone deacetylase inhibitor.   
To further investigate this additive effect, the above experiment was repeated with NCoR1 
over-expressing clones. 
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(d).   
Figure 3.9 (a)-(d): Proliferation assays of cell lines treated by either ED25 concentrations of NR ligand, 
SAHA or in combination in a 96 well format. Incubation for 96 hours with a re-dose at 48 hours. Y-axis 
denotes cell proliferation as percentage of negative control. * denotes strongly additive effect in 
combination i.e. the observed anti-proliferative effect is statistically significantly greater than that 
predicted from the sum of the individual effects of the NR ligand and SAHA alone; p<0.05 by the one 
tailed student’s t-test.  
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3.3.7 Co-treatment of NCoR1 over-expressing clones with SAHA 
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Figure 3.10 (a)-(b): Proliferation assays of NCoR1 over-expressing RT-4 clone (NCoR#7) and mock 
transfected clones (pcDNA#7) treated by ED25 concentrations of either NR ligand, SAHA or in 
combination in a 96 well format. Incubation for 96 hours with a re-dose at 48 hours. Y-axis denotes cell 
proliferation as percentage of negative control. * denotes strongly additive effect in combination i.e. the 
observed anti-proliferative effect is statistically significantly greater than that predicted from the sum of 
the individual effects of the NR ligand and SAHA alone. * signifies treatments in the NCoR 
overexpressing clone#7 which exhibit statistically significant (p<0.05 one tailed student’s t-test) reduced 
cell inhibition as compared to the same treatments in the mock transfected control pcDNA#7 clone. 
 
 
The experiment illustrated in figure 3.9 (a) was repeated with the NCoR1 over-expressing 
clone#7 and the mock transfected clone #7. Figure 3.10 shows that the effect of over-
expressing NCoR1 is to make the cells less sensitive to the treatments i.e. the degree of 
inhibition is reduced. For example, the degree of inhibition of the NCoR#7 clone when treated 
with SAHA alone is 14.5 % whereas in the mock transfected clone (pcDNA#7) it is 42.9 % 
i.e. the NCoR#7 over-expressing clone has lost sensitivity to SAHA. This may be expected as 
NCoR1 is a co-repressor, hence forced over-expression has enhanced its repressor role. 
Possibly reflecting this, there is no evidence of a strongly additive interaction between the NR 
ligands and this dose of SAHA.  
 
When the cell inhibition in NCoR#7 clone was compared to the same treatments in the mock 
transfected control pcDNA clone#7 using the one tailed student‟s t-test, the treatments with 
SAHA appeared to lose inhibition and sensitivity in the NCoR over-expressing clone#7 
(shown by * in figure 3.10 (a)). 9cis RA is the only individual treatment which led to a 
statistically significantly less inhibition in the NCoR#7 clone. Otherwise for 1,25(OH)2D3, 
ETYA, CDA and LCA, the individual treatment was not statistically different between the 
two clones however, the combined treatment with SAHA led to a significant loss of 
sensitivity in the NCoR#7 clone. The raised expression of NCoR1 has resulted in SAHA 
being less inhibitory. 
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3.4  Discussion 
These data demonstrate varied responses to treatment with a panel of nuclear receptor ligands 
in four bladder cancer cell lines. This variability can to some extent be explained by the 
relative expression of the relevant nuclear receptors in the different cell lines. Therefore, the 
most sensitive cell line to 1α,25(OH)2D3 is RT-112 with an ED50 of 25 nM as compared to 
RT-4 (ED50 = 90 nM), HT-112 and EJ-28 (ED50  >100 nM). Correspondingly, the VDR 
expression in RT112 is 5.1 fold higher than RT4 and 14.5 fold and 127.5 fold higher than HT-
1376 and EJ-28 cells respectively. In general, EJ28 cells have the lowest relative expression 
of the nuclear receptors tested. This is coupled with increased NCoR1 co-repressor expression 
which, in general, leads to the highest NCoR1: nuclear receptor ratio in EJ-28 cells. These 
cells, in most instances, also have the highest ED50 values, i.e. they are the least sensitive to 
the different ligands. For example, PPARα expression is 1.3 fold lower in EJ-28 cells as 
compared to RT-4 cells. However, this is coupled with an NCoR1 : PPARα ratio of 3.2 for 
EJ-28 which translates into a higher ED50 value (130 µM for EJ28 as compared to 105 µM 
for RT-4).  
I have illustrated expression of the VDR and the FXR in bladder cancer cell lines at the 
protein level (figures 3.2 and 3.3). The expression of VDR in bladder cancer has been 
previously demonstrated via immuno-histochemistry on human bladder tumour tissue 
(Hermann and Andersen, 1997; Sahin et al., 2005). However, no previous references 
demonstrating FXR expression in the urinary bladder are apparent and therefore this is a 
novel finding. Bile acid conjugates have been demonstrated in urine from healthy volunteers. 
Goto et al have demonstrated the presence of acyl galactosides of deoxycholic acid in healthy 
human urine estimated at 20-100 ng/ml concentration (Goto et al., 2005). This bile acid is a 
known ligand for FXR (Makishima et al., 1999; Parks et al., 1999). Deoxycholic acid is 
 109 
known to be a carcinogenic agent, indeed it has long been suggested as a promoter of 
colorectal cancer. Therefore, studies have shown higher levels in the faeces of colon cancer 
patients (Korpela et al., 1988), that it stimulates human colonic mucosal growth (Bartram et 
al., 1993) and stimulates growth of colonic cells in culture (Peiffer et al., 1997). Bile acid 
binding FXR has a number of well described cellular effects including the expression of the 
bile acid export pump (ABCB11) (Ananthanarayanan et al., 2001) and the multidrug 
resistance associated protein 2 (ABCC2) (Kast et al., 2002) and the expression of detoxifying 
enzymes such as CYP3A4 (Gnerre et al., 2004). These membrane pumps export the bile acids 
out of the cell and detoxifying enzymes degrade bile acids to less toxic derivatives. All of the 
above can lead to a model which can explain a possible physiological role for the expression 
of FXR in bladder urothelium. Therefore, FXR can sense potentially damaging bile acid 
conjugates in the urine which leads to expression of export pumps and detoxifying enzymes 
which protect the urothelial cells from the carcinogenic effects of these bile acids. There is 
intriguing evidence that VDR may also be involved in a similar role. Therefore, LCA bound 
to VDR can bind VDR response elements on the CYP3A4 promoter to also stimulate 
expression of this key detoxifying enzyme (Jurutka et al., 2005). These responses lead to 
protection of the bladder epithelial layer as it comes into contact with potentially damaging 
and carcinogenic substances in urine.   
 
In order to support the suggestion that increased NCoR1 expression in RT-112 and EJ-28 
cells may be related to reduced sensitivity to NR ligands, NCoR1 protein was over-expressed 
NCoR1 protein in RT-4 cells. The over-expressing clones demonstrated a significantly 
reduced sensitivity to CDA, LCA and SAHA (figure 3.8 b). This suggests a link between 
NCoR1 and responses to these ligands. Clearly, if the over-expression of NCoR1 in EJ-28 
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cells and responses to these ligands was a chance coincidence then over-expression in RT-4 
would not have altered responsiveness in RT-4 cells. In other words, if NCoR1 was not a 
participant in the multi-meric protein repressor complex then its over-expression would not 
have altered responsiveness to the above ligands.    
Figure 3.8 (a) and (c) demonstrate a dose dependent effect in the loss of sensitivity when 
NCoR1 is over-expressed. Therefore in fig 3.8 (a), clones are treated with 1 µM ETYA, CDA, 
LCA and SAHA; there is significant loss of sensitivity in LCA alone in the NCoR#7 clone. 
SAHA treatment exhibits a p-value of 0.051 i.e. this treatment approaches statistical 
significance. Figure 3.8 (c) exhibits inhibitory effects with 100 µM ETYA, CDA, LCA and 
SAHA treatment; none of these ligands exhibits significant loss of sensitivity. This is likely 
due to excessive cellular toxicity with a high dose of 100 µM; these treatments cause cell 
inhibition of greater than 80 % therefore this insult if likely to be too severe to be rescued by a 
raised expression of NCoR1.    
Combination treatment of the tested nuclear receptor and SAHA (HDAC inhibitor) showed 
contrasting patterns of response (figure 3.9 (a) – (d)). RT-4 and HT-1376 display no strongly 
additive responses i.e. the addition of SAHA does not lead to significantly reduced cell 
numbers as compared to the expected combined response i.e. the sum of the effect of the NR 
ligand and SAHA alone. In RT-112, strongly additive effects are seen with 1,25(OH)2D3, 9 
cis RA, ETYA and LCA. However, in EJ-28 cells, strongly additive effects were seen with all 
of the ligands. This suggests that increased NCoR1 expression in RT-112 and EJ-28 cells (1.6 
and 2.6 fold respectively, p<0.05) may be connected to this strongly additive response. 
However, these experiments were repeated with NCoR1 over-expressing clone #7 and mock 
transfected clone # 7 (figure 3.10) and did not show strongly additive responses apart from 9 
cis RA. There can be two possible explanations for this. NCoR1 mRNA over-expression in 
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EJ-28 cells was 2.6 fold; we did not achieve this level of over-expression with the stably 
transfected clones (NCoR clone #1 was 1.84 fold and NCoR #7 was 1.39 fold, p<0.05). If a 
higher level of NCoR1 over-expression could be achieved then maybe we would have seen 
strongly additive responses. Intriguingly, RT-112 cells over-express NCoR1 by 1.6 fold i.e. 
less than EJ-28 cells and displayed strongly additive responses to 3 out of the 5 tested ligands. 
Also, the NCoR1 over-expressing cells are less sensitive to SAHA, therefore the dose of 
SAHA may be inadequate to elicit a strongly additive response and may need to be increased.  
This may suggest a spectrum of strongly additive response in proportion to the over-
expression of NCoR1. An alternative explanation may be found in the ATP proliferation 
assay. 
    
This assay estimates the number of cells present by measuring the total amount of ATP 
present. Therefore, when there is a reduction in cell numbers in response to treatment with an 
NR ligand +/- SAHA, the proliferation assay does not provide any insight to the mechanism 
leading to reduced cell numbers. A number of mechanisms could be responsible such as 
caspase dependent apoptosis, cell senescence, cell cycle arrest, non-apoptotic programmed 
cell death/paraptosis and autophagic cell death. There is evidence that the initiation of one or 
more of the above pathways is cell context dependent i.e. the response of two particular cell 
types to the same stimulus can lead to different mechanisms of cell death or growth arrest. 
This may occur in different cell lines derived from the same cancer type. An example may be 
the effect on different cells by treatment by the HDAC inhibitor, SAHA. This HDAC 
inhibitor, amongst other mechanisms, can cause the intrinsic pathway of apoptosis which is in 
part regulated by BCL-2 family members. Therefore, over-expression of BCL-2 or BCL-XL 
inhibits SAHA induced apoptosis in prostate cancer cells and inhibition of BCL-2 by the 
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chemical inhibitor HA14-1 increases apoptosis (Xu et al., 2006). The expression of BCL-2 
may control the effect of treatment with SAHA, i.e. whether apoptosis occurs or not.  
In the context of the strongly additive responses seen with co-treatment with NR ligands and 
SAHA in figure 3.9 (d), this response suggests that the combination of NR ligand and SAHA 
induces cellular pathways that do not occur with treatment with the individual agents. For 
example, the combination may induce apoptosis and cell cycle arrest or senescence or any 
other combination of cell death mechanism. Thereby, the combined treatment leads to a 
degree of cell death which is over and above that expected from the sum of the individual 
effects. When considering a separate cell line such as RT-4, this malignant cell line is likely to 
have widespread genomic and epigenetic differences as compared to EJ-28, not just in the 
expression of NCoR1 protein. These differences are likely to impact on the presence of 
functional cell death pathways. For example, the pro-apoptotic proteins BIM or BAX may be 
mutated in RT-4 which would attenuate the ability of this cell line to undergo apoptosis. 
Therefore, this lack of apoptosis may explain why a strongly additive response is not seen in 
RT-4. 
To attempt to resolve this issue the following chapter will present data illustrating the cell-
cycle effects on the four cell lines of treatment with LCA + /- SAHA, demonstrating that the 
cell lines do not have similar effects. This may be supportive of the proposal stated above.  
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Chapter 4 : Gene regulation in response to NR ligands. 
4.1 Introduction 
The previous chapter demonstrated a variety of anti-proliferative responses displayed in four 
bladder cancer cell lines towards a panel of nuclear receptor ligands (figures 3.9 (a)-(d)). 
There are a number of possible mechanisms for the variation in anti-proliferative responses, 
depending upon the contribution of cell-cycle arrest, programmed cell death processes and 
cell senescence. A key consideration to elucidating the mechanism of antiproliferative action 
is identification of the cohort of gene targets activated after treatment with ligand.  
 
There are 17 gene families of cytochrome P450 enzymes in humans (Fukumori et al., 2007). 
These are membrane bound, heme containing mono-oxygenases which play a key 
detoxification role. The first 3 families, CYP1, CYP2 and CYP3 are known to metabolise 
drugs and xenobiotics (Pascussi et al., 2003). CYP3A4 is the most abundant Cyp P450 
enzyme classically expressed in the liver and also expressed in small bowel epithelial cells. It 
plays a role in the metabolism of over 50 % of all drugs and xenobiotics by hydroxylation 
reactions (Wrighton et al., 1996), which convert them into water soluble metabolites for 
excretion via the urine and faeces.   
Nuclear receptors act as sensors to many of these compounds to regulate the expression of 
CYP3A4. The Pregnane X receptor (PXR) is expressed in the liver and small intestine and is 
activated by endogenous compounds such as bile acids and exogenous substances such as the 
antibiotic rifampicin. Similar to VDR and FXR, PXR forms heterodimers with the retinoid x 
receptor (RXR) and upon activation, binds to response elements in the promoters of target 
genes. CYP3A4 is a key target gene; the PXR-RXR heterodimer binds via ER6, DR3 and 
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DR4 repeat sequences in the promoter. Xie W et al have robustly proven that the nuclear 
receptor PXR (and its homologue SXR) is a xeno-sensor and is a regulator of CYP3A4 
expression (and of its rat homologue Cyp3A23 and mouse homologue Cyp3a11) in response 
to appropriate inducers (Xie et al., 2000). They engineered PXR null mice and demonstrated 
lack of induction of Cyp3A enzymes by dexamethasone (Dex) and pregnenalone-16α-
carbonitrile (PCN) which are rodent specific Cyp3A inducers. Only the Cyp3A enzyme was 
affected; induction of other CYPs such as Cyp 1A2 was intact in response to its inducer 3-
methylcholanthrene. Dexamethasone, acting via the glucocorticoid receptor (GR), was also 
able to induce GR target gene hepatic tyrosine amino transferase. Hence, only Dex‟s action 
via the PXR was ablated. 
 
4.2 Methods 
 Propidium iodide cell staining and flow-cytometry for cell cycle analysis. 
 Quantitative Real-time PCR (Q-RT-PCR) 
 Q-RT-PCRm microfluidic arrays 
 Affymetrix™ U133 plus 2 gene chip microarrays. 
 
4.3 Results 
4.3.1 Cell cycle effects of lithocholic acid +/- SAHA 
To assess mechanistic details, one of the ligands, lithocholic acid (LCA), either alone or in 
combination with SAHA was chosen for cell cycle analysis (fig 4.1). 
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Figure 4.1: Cell cycle analysis using FACS (fluorescent activated cell sorting). 2x10
6
 cells were seeded in T25 flasks and allowed to adhere overnight. They were treated with 
LCA alone (ED50 dose; RT-4 20 µM, HT-1376 and EJ-28 100 µM, RT-112 50 µM) or in combination with SAHA (0.8 µM) and incubated for 96 hours with a re-dose at 48 
hours. Total cells (both adherent and detached) were trypsinised, pelleted and washed in PBS. They were resuspended in FACS buffer (1% sodium citrate, 0.1% Triton X-
100, 0.1 mM Na Cl and 10 µg/ml PI) and stained with PI. Cell cycle distribution was determined via flow cytometry analysis. Mean of triplicate independent experiments 
shown. Error bars show standard error. Statistical significance assessed with students t-test, * p<0.05 compared to negative control. 
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In EJ-28 cells, there is clear evidence of a G1/S cell cycle arrest with LCA treatment (mean 
percentage of cells in G1: 57.87 % +/- 4.55 for negative control as compared to 82.66 % +/- 
4.06 for LCA treatment (p=0.03); mean percentage of cells in S phase is 28.22 % +/- 3.53 for 
negative control and 9.91 % +/- 5.01 for LCA treatment p=0.054). There is some evidence 
suggesting a G1/S phase cell-cycle arrest upon treatment with LCA + SAHA (mean 
percentage of cells in G1: negative control 57.87 % +/- 4.55, LCA+SAHA treatment 79.37 % 
+/- 1.61, p=0.51; mean percentage of cells in S phase: negative control 28.22 % +/- 3.53 as 
compared to LCA+SAHA treatment 7.49 % +/- 2.16, p=0.027) i.e. the reduction in cell 
number in S-phase is statistically significant even if the increase in cells in G1 phase upon 
treatment with LCA + SAHA is just short of reaching statistical significance.  There is no 
evidence of a cell-cycle arrest in the other cell lines. 
 
To investigate the cell cycle arrest in EJ28 cells, a Q-RT-PCR approach was used to 
investigate the expression of putative target genes that may underlie the anti-proliferative 
responses seen with LCA +/- SAHA treatment; p21
(waf1/cip1)
 and CYP3A4 were chosen.  
 
P21
 (Cip1/Waf1)
 is a cyclin dependent kinase inhibitor which is a key anti-proliferative target of 
dietary derived nuclear receptors. Freedman LP et al first demonstrated the expression of 
p21
(waf1/cip1)
  in response to 1α,25(OH)2D3, as well as the presence of a VDR response element 
within the p21
 (Cip1/Waf1) 
promoter (Liu et al., 1996).  Saramaki et al demonstrated  in 2006, 
using chromatin immuno-presipitation, the presence of VDR response elements as well as 
1α,25(OH)2D3 binding within the p21
Cip1/Waf1
 promoter (Saramaki et al., 2006). There is 
evidence that lithocholic acid in combination with all trans retinoic acid can induce 
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oesophageal cells to express p21
 (Cip1/Waf1)
 (Chang et al., 2007), hence there is circumstantial 
evidence suggesting that p21
 Cip1/Waf1
 is a relevant potential target gene under these conditions.  
 
4.3.2 Induction of CDKN1A (p21(Waf1/Cip1)) post treatment with LCA+/- 
SAHA 
Four bladder cancer cell lines were treated with LCA +/- SAHA at the same concentrations as 
used in figure 3.9, and mRNA was extracted at 6 hours post treatment. CDKN1A mRNA 
levels were measured using Q-RT-PCR. All four cell lines show significant induction of 
CDKN1A in at least the SAHA treatment. This is expected as CDKN1A  is an established 
SAHA target gene (Gui et al., 2004).  
 
RT-4 cells displayed the highest significant CDKN1A induction with all treatments [3.4 +/-
0.32 fold for SAHA, 2.28 +/- 0.31 fold for LCA and 4.62 +/- 0.30 fold for the combination 
treatment of LCA and SAHA]. Interestingly, in EJ-28 cells, SAHA induced nearly twice as 
much CDKN1A mRNA compared to control (1.91 +/- 0.16 fold) and the combination of LCA 
+ SAHA induced 2.30 +/- 0.16 fold increased CDKN1A mRNA. These are statistically 
significant results. However, LCA treatment alone displayed no significant change in 
CDKN1A levels. This induction of CDKN1A mRNA reflects the G1 cell cycle arrest 
demonstrated in EJ-28 cells (figure 4.1). However, in figure 4.1, there is no statistically 
significant evidence of cell cycle arrest in RT-4 cells despite the larger induction of CDKN1A 
in these cells. Most likely, this reflects the difference in the time points (6 hours for CDKN1A  
and 96 hours for the cell cycle analysis). 
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Figure 4.2: Induction of CDKN1A(p21
Waf1/Cip1
) after LCA+/- SAHA at 6 hours. Cells were treated with 
LCA (RT-4 20 µM, HT1376 and EJ-28 100 µM, RT-112 50 µM) +/- SAHA (0.8 µM) and total RNA 
isolated at 6 hours post treatment. After reverse transcription, Q-RT-PCR was conducted using CDKN1A 
primers and probes. Results from three independent experiments performed in triplicate are represented. 
Statistical significance was assessed by the students t-test (2-tail); *=p<0.05 compared to negative 
(untreated) control. 
 
 
 
4.3.3 Induction of CYP3A4 after treatment with LCA +/- SAHA  
The induction of CYP3A4 following treatment with LCA +/- SAHA was also investigated 
under the conditions above; illustrated in figure 4.3 below. In RT-4 cells, there was 
statistically significant induction of CYP3A4 mRNA in all three treatments [SAHA alone 
2.47 +/- 0.64 fold; LCA alone 3.36 +/- 0.81 fold; LCA + SAHA 2.65 +/- 0.37 fold]. There 
was no evidence of additive induction with the combination treatment of LCA + SAHA. Both 
HT-1376 and RT-112 cells exhibited significant induction of CYP3A4 when treated with 
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LCA alone [1.80 +/- 0.35 fold and 2.01 +/- 0.50 fold respectively], but this was not altered 
significantly by LCA and SAHA treatments. 
   
With EJ-28 cells, SAHA and LCA alone did not significantly induce CYP3A4 [1.37+/- 0.32 
and 1.58 +/- 0.53 fold respectively], However, the combined treatment demonstrated 
significant induction by 3.42 +/- 1.02 fold (figure 4.3). 
 
It is interesting that LCA induces CYP3A4 in all of the cell lines apart from EJ-28 (figure 
4.3), which overexpresses NCoR1 by the highest amount (2.56 fold +/- 0.21 as compared to 
RT-112 cells which overexpress NCoR1 by 1.59 fold +/- 0.11). As previously demonstrated, 
FXR does induce CYP3A4 expression, therefore it is not surprising that LCA should increase 
CYP3A4 mRNA expression in RT-4, HT-1376 and RT-112. Perhaps increased NCoR1 
expression in EJ28 cells, dampens the transactivation function of ligand bound FXR at 
response elements in the CYP3A4 promoter so transcription does not occur. The simultaneous 
addition of the HDAC inhibitor, SAHA may inhibit the bound histone deacetylases and either 
release or attenuate the inhibitory effect of NCoR1. 
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Figure 4.3: CYP3A4 induction after LCA +/- SAHA treatment at 6 hours. Cells were treated with LCA 
(RT-4= 20 µM, HT1376 and EJ-28= 100 µM, RT-112= 50 µM) +/- SAHA (0.8 µM) and total RNA isolated 
at 6 hours post treatment. After reverse transcription, Q-RT-PCR was conducted using CYP3A4 primers 
and probes. Results from three independent experiments performed in triplicate are represented. 
Statistical significance was assessed by the students t-test (2-tail); *=p<0.05 compared to negative 
(untreated) control. 
 
There is some evidence that FXR acts as a regulator of CYP3A4 expression. Gnerre et al 
incubated Hep G2 liver cells with CDA or GW4064 (Gnerre et al., 2004). The former is a 
natural and the latter is a synthetic FXR ligand. Using Q-RT-PCR, they demonstrated a 
statistically significant increase in mouse Cyp3A4 expression after 24 hour incubation with 10 
µM of GW4064. Gene reporter studies identified a highly FXR responsive fragment and 
further evidence from wild type, FXR
-/-
 and PXR 
-/-
 mice treated with intra-peritoneal 
injections of GW4064 add support to the concept that FXR is an activator of Cyp3A4 
expression.  
There is evidence to suggest that VDR is also a regulator of CYP3A4 expression. Human 
primary hepatocytes treated with 1α 25 (OH)2 D3 express CYP3A4 mRNA as detected by RT-
PCR and Q-RT-PCR (15 fold) (Drocourt et al., 2002). Gel mobility shift assays have 
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demonstrated a band shift when VDR was incubated with the DR3 and ER6 response 
elements from the CYP3A4 distal enhancer and promoter regions respectively. Finally, when 
HepG2 hepatocyte cells were co-transfected with CYP3A4 promoter-reporter plasmids 
containing the DR3 or ER6 sequences as well as VDR, and treated with 1 nM 1α 25 (OH)2 
D3, reporter gene activity was increased 12 and 40 fold respectively compared to control 
(Drocourt et al., 2002). Mice fed oral LCA demonstrated increased Cyp3A4 protein 
expression in the intestine (Matsubara et al., 2008). These authors have also demonstrated 
increased Cyp3A4 reporter activity in mice livers upon feeding with LCA provided the mice 
had adenovirally over-expressed VDR in their livers.  
 
4.3.4 Target gene expression in NCoR1 transfectants 
4.3.4.1 Expression of CDKN1A and CYP3A4 in NCoR1 transfectants 
To investigate the possible role of NCoR1 expression on the expression of target genes, 
CDKN1A and CYP3A4, we treated NCoR stably overexpressing clones #1 and #7 and mock 
transfected control clones pcDNA#3 and #7 with 10 µM LCA and extracted mRNA at 4, 6, 8 
and 24 hours. Subsequently, CDKN1A and CYP3A4 expression was measured using Q-RT-
PCR.  
Figure 4.4 illustrates the different CDKN1A expression patterns. Both pcDNA#6 and #7 have 
expression curves which lie above those of the NCoR overexpressing clones, which might be 
expected in view of elevated co-repressor expression. Indeed, CDKN1A expression in NCoR 
clone #1 is down regulated throughout the period of the time course experiment by as much as 
0.63 fold +/- 0.027 at 8 hours. The fold change in CDKN1A expression in NCoR#1 and 
pcDNA#7 at 4 and 8 hours is statistically significantly different as detailed in Fig 4‟s legend.  
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Figure 4.4: Time course experiment of expression of CDKN1A as measured by taqman Q-RT-PCR. Stably 
transfected cells (pNCoR overexpressing clones #1 and #7 and mock transfected pcDNA clones #6 and #7) 
were treated with LCA 10 µM and total RNA isolated at 4,6,8 and 24 hours post treatment. After reverse 
transcription, Q-RT-PCR was conducted using CDKN1A (p21
(Cip1/Waf1)
) primers and probes. Results from 
three independent experiments performed in triplicate are represented. There is a statistically significant 
difference (2 tailed t-test) in relative expression of CDKN1A in NCoR#1 and pcDNA#7 at 4 and 8 hrs (at 4 
hrs mean fold change for pcDNA#7 = 1.04 and NCoR#1 = 0.69 p= 0.04; at 8 hrs mean fold change for 
pcDNA#7 = 0.97 and NCoR#1 = 0.63 p<0.05). 
 
 
Figure 4.5 illustrates the expression of CYP3A4 in NCoR over-expressing and mock 
transfected clones in response to 10 µM LCA. In contrast to figure 4.4, NCoR clone #1 
exhibits an early peak in CYP3A4 expression of 2.09 fold. Expression then falls to 0.86 fold 
at 8 hours and gradually rises to 1.76 fold at 24 hours. In comparison, NCoR clone #7 does 
not exhibit any peaks in expression at all, which gradually rises from baseline to 1.65 fold at 
24 hours. Both pcDNA mock clones #6 and #7 have remarkably consistent patterns of 
CYP3A4 expression. However, unlike Figure 4.4, where pNCoR#1 has a clearly repressed 
pattern of CDKN1A as compared to pcDNA#6 and #7, in figure 4.5 CYP3A4 mRNA 
* 
* 
* 
* 
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expression is not clearly repressed across the different time points as compared to the mock 
control counterparts. 
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Figure 4.5: Time course experiment of CYP3A4 expression as measured by taqman qRT-PCR. Stably 
transfected cells (pNCoR overexpressing clones #1 and #7 and mock transfected pcDNA clones #6 and #7) 
were treated with LCA 10 µM and total RNA isolated at 4,6,8 and 24 hours post treatment. After reverse 
transcription, Q-RT-PCR was conducted using Cyp3A4 primers and probes. Results from three 
independent experiments performed in triplicate are represented. There is no statistically significant 
difference amongst the four cell lines. 
 
 
 
 
4.3.4.2  NCoR1 overexpressing clones express different cohort of genes as 
compared to controls. 
In order to extend the limited gene expression studies above, Applied Biosystems® 
microfluidic genecards (Q-RT-PCRm) were used containing the primers and probes for 94 
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genes. These were selected by virtue of current experimental evidence suggesting their 
presence amongst the target genes of common nuclear receptors. These genes were divided 
into 9 functional groups; (1) Cell surface transporters, (2) Nuclear Receptors, (3) Nuclear 
receptor co-factors, (4) Metabolic enzymes, (5) Cell death regulators, (6) Transcription 
factors, (7) Histone modifiers, (8) Cell cycle regulators, (9) Signal transduction factors (eg. 
IGFBPs, MAPKs).  
NCoR1 over-expressing clone#7 and mock transfected pcDNA clone #6 (RT-4 cells), were 
treated with 10 µM LCA and mRNA harvested by the standard Tri-reagent method at 6 hours 
incubation. 3.5 µg of RNA was assayed on the genecards, in triplicate.  
 
Table 4.1: Fold changes in expression of genes, as measured by Taqman genecard. 
GENE TARGET 
BASAL FOLD 
CHANGE IN  
RT-4 pNCOR#7 
REGULATED - COMMON REGULATED - UNIQUE 
RT-4 pcDNA#6  RT-4 pNCOR#7 RT-4 pcDNA#6 RT-4 pNCOR#7 
Cell surface transporters      
ABCA1  0.3    1.7 
ABCB8  1.4 1.4   
ABCC3 0.8    1.5 
Nuclear receptors      
DAX1 0.3     
PPAR  0.3     
LXR  0.6   1.5  
PPAR (64) 0.7     
THRB 0.7 1.5 1.6   
LXR  0.8    1.4 
RXR     1.4  
ER      1.4  
ER  2.5    1.6 
GR 1.5    1.7 
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RAR  0.6    1.6 
VDR     1.7 
FXR(65)    1.9  
Nuclear receptor  
co-factors 
     
PPARGC1A 0.2     
NCOR2(25) 0.5   1.4  
SIN3A 0.6   1.5  
NCOA3 0.6     
NCOA4 0.7    1.5 
CRSP2 0.7    1.3 
NCOA1  1.4 1.4   
NCOA2  1.5 1.6   
SIN3A  1.5 1.5   
TRIP15/Alien    1.3  
CRSP6    1.6  
CARM1 0.5   1.5  
PPARBP    1.7  
Metabolic enzymes      
CYP24A1(13, 66) 0.07     
SULT2A1(18, 67) 0.1   1.3  
ALOX5(68) 0.5 1.4 1.3   
CYP27B1(69) 0.7   1.6  
PTGS2(70) 1.3    1.8 
ACADM(71)    2.1  
AKR1C1;AKR1C2- 1.7  1.5 1.6  
AKR1C3     1.5 
Cell death regulators      
BAX 0.6     
CASP4 0.8   1.5  
Transcription factors      
MYB 0.4     
ID1 0.6     
CEBPA 2.4   1.5  
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GATA3 0.8   1.5  
YY1    1.4  
Histone modifiers      
HDAC6 0.4     
CARM1 0.5   1.6  
HDAC4 0.5 1.5 1.7   
HDAC3 0.6    1.3 
HDAC1     1.4 
SUV39H1     1.5 
SIRT2    2.1  
PADI4     2.2 
AOF2    1.5  
HDAC2    1.9  
HDAC7A    1.5  
HDAC6 0.4   1.5  
HDAC10    1.6  
Cell cycle regulators      
CDKN1A(21, 72) 0.5   1.2  
CDC2(73) 0.7     
CDKN1B(74, 75) 0.7   1.4  
RBBP4 0.6     
CCND1 0.8     
TP53 1.5     
G0S2(76) 4.3     
CCNE1  1.6 1.4   
CDK5  1.5 1.4   
CCNB1    1.5  
Signal transduction      
TGIF 0.5     
IKBKB 0.6 1.8 2.0   
EGFR  1.7 1.8   
CDH1(77)  1.8 1.6   
MAPKAPK2(14)     1.5 
IGFBP3(78, 79)    1.4  
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IGFBP5(78, 79)    1.3  
MAPKAPK5 1.3   1.4  
IKBKG 1.4     
 
Total mRNA from the cells RT-4 pCDNA #6 and RT-4 pNCOR #7 was extracted from each 
clone, in triplicate, prior to Q-RT-PCRM analyses in duplicate wells per gene target, as 
indicated in the Materials and Methods. The full list of gene targets analysed is given in the 
Appendix 1; only those targets that have significantly different expression in RT-4 pNCOR 
#7 compared to RT-4 pcDNA#6 are listed above (Adj. p value < 0.01). Known gene targets of 
individual nuclear receptors are indicated.  
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4.3.4.3 Lithocholic acid induces a coordinated xenobiotic resistance 
response in bladder cancer cells. 
Lithocholic acid is toxic to human cells; which have evolved complex protective mechanisms 
to protect against damage from exposure to this secondary bile acid. This is best characterised 
in hepatocytes (reviewed in (Elias and Mills, 2007)). LCA induces hepatocytes to hydroxylate 
this bile acid via Cyp3A4 or alternatively sulphate via the enzyme SULT2A1; these reactions 
lead to LCA detoxification and clearance. Coupled with detoxification, LCA is actively 
excreted out of hepatocytes and intestinal cells via MRP2 and MDR1, members of the ATP 
binding cassette transporter family of trans-membrane efflux pumps (ABC transporters). 
These are key components of a coordinated defence strategy against the xenobiotic LCA. 
 
Lithocholic acid treatment in RT-4 cells stably over-expressing NCoR1 or mock transfected 
control plasmid induces a protective response towards this xenobiotic typified by upregulation 
of trans-membrane efflux pumps, detoxifying enzymes and cell-cycle arrest proteins (table 
4.1). 
MRP3, also known as ABCC3 is a member of the ABC transporter efflux pumps. These 
proteins span the cell membrane and export a wide variety of substances, including 
xenobiotics and bile acids out of the cell in an energy dependent manner. Lithocholic acid 
induces the RT-4 pNCoR#7 cells to upregulate ABCC3 expression by 1.5 fold.   Teng et al 
demonstrated the increased expression of ABCC3 by two fold in the hepatoma cell line 
HuH7, by RT-PCR, when treated with 50 µM LCA for 24 hours (Teng et al., 2003). It is 
interesting that the induction of ABCC3 is only seen in the NCoR overexpressing clone, i.e. 
NCoR1 has a dose dependent effect to change the expression of ABCC3/MRP3. There may 
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be a negative regulator of MRP3 expression; raised NCoR1 levels may antagonise this 
regulator which in turn may release its inhibition on MRP3 expression. 
ABCB8 is also an ATP binding cassette transporter membrane protein which is upregulated 
by 1.4 fold in both the mock transfected and RT-4 pNCoR#7 cells. There is no change in the 
basal expression of ABCB8 in RT-4 pNCoR#7 when compared to the mock transfected clone.  
ABCA1 is a third ATP binding cassette transporter which is downregulated at basal 
conditions in the RT-4 pNCoR#7 (by 0.3 fold) and when this clone of cells is treated with 
lithocholic acid, its expression is stimulated by 1.7 fold.  
The ATP binding cassette transporters are described as being central players in the 
phenomenon of multixenobiotic resistance (MXR). This was initially described in the context 
of aquatic organisms such as mussels and sea urchins which are constantly exposed to toxins 
in polluted water and appear to express these trans-membrane transporters in their gills which 
actively pump a broad spectrum of toxins and xenobiotics out of cells (Smital et al., 2004). In 
the context of human liver cells, the FXR ligand and bile acid Chenodeoxycholic acid has 
been shown to upregulate expression of the ATP binding cassette transporters ABCB1, 
ABCC1 and ABCC2 at the mRNA level in the HepG2 cell line and primary hepatocytes and 
at protein level in HepG2 and Caco-2 cells (Martin et al., 2008). 
 
On a second front, treatment of RT-4 transfected cells with LCA led to regulated expression 
of the detoxifying enzyme of the sulphotransferase family SULT2A1 (Elias and Mills, 2007; 
Falany, 1997). The latter is downregulated at basal level in the RT-4 pNCoR1#7 by 0.1 fold, 
however upon treatment with LCA, the mock transfected RT-4 pcDNA#6 upregulates 
SULT2A1 by 1.3 fold.  SULT2A1 acts to sulphate conjugate hormones, drugs, bile acids and 
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xenobiotics, to convert them from hydrophobic to water soluble conjugates in an attempt to 
metabolise and excrete them via urine and faeces.   
 
A third aspect of the coordinated response to exposure to LCA is expression of genes 
associated with cell cycle arrest. Therefore, the cyclin dependent kinase inhibitor 
CDKN1B/p27
kip1
 is induced by treatment with LCA (1.4 fold) and the basal expression in RT-
4 pNCoR#7 is suppressed by 0.7 fold. A similar pattern is seen with CDKN1A ( p21
waf1/cip1
). 
In RT-4 pcDNA#1 the expression is marginally raised by 1.2 fold and the basal expression is 
suppressed by 0.5 fold in the RT-4 pNCoR#7. Hence, LCA induces expression of targets 
associated with a G1/S phase cell-cycle arrest. Overexpression of the co-repressor NCoR1 
suppresses the anti-proliferative response elicited in the RT-4 cells by treatment with 
lithocholic acid (figure 3.8 B). 
 
In the context of the cellular response to exposure to a xenobiotic, the RT-4 pcDNA#6 appear 
to stop dividing by inducing a cell-cycle arrest and then express genes encoding proteins that 
either pump toxic compounds out of the cell (e.g. members of the ATP binding cassette 
transporter family) or genes that encode proteins which metabolise xenobiotics and facilitate 
their excretion in urine (e.g. sulphotransferase enzymes). 
 
4.3.4.4 Over-expression of NCoR1 in RT-4 cells leads to repression of NR 
target genes 
 Table 4.1 and Figure 4.6 illustrate the basal changes in gene expression in RT-4 NCoR#7 
cells, i.e. the effects of NCoR1 overexpression. Apart from 9 genes (ERβ, GR, PTGS2, 
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AKRC1/AKRC2, CEBPA, TP53, G0S2, MAPKAPK5 and IKBKG) which are up-regulated, 
37 genes are down-regulated. This is not surprising as NCoR1 acts as corepressor and hence, 
overexpression would be expected to dampen down target gene expression. However, the 
expected overall effect of the basal gene expression changes in RT-4 NCoR#7 would be to 
reduce sensitivity to a wide range of NRs by reducing their expression (DAX1, PPARα and γ, 
LXR α and β, THR β and RAR α) and to obtain a more pro-proliferative phenotype by 
suppressing expression if the pro-apoptotic protein BAX and the cell cycle inhibitors 
CDKN1A and CDKN1B. However, it is of interest that despite down-regulation of PPARγ in 
RT-4 NCoR#7 cells, treatment with ETYA does not lead to a statistically significant 
difference in proliferation between control RT-4 pcDNA and NCoR over-expressing cells as 
shown in Figure 3.8.     
 
Multiple target genes are expressed or suppressed in response to treatment with LCA. 
Individual genes products may have interactions with each other which will affect the overall 
behaviour of the cells in question. In order to have a better understanding of the inter-related 
effects of the different target gene expression patterns, network diagrams were constructed 
from the Q-RT-PCRm data (and the Affymetrix™ genechip data as illustrated later) by 
utilising commercially available GeneGo™ network analysis software. This utilises 
previously published experimental data to generate networks between target genes 
demonstrated by the Q-RT-PCRm and gene array data. 
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Figure 4.6: Network diagram of basal gene changes in pNCoR overexpressing clone #7 as compared to 
control mock transfected pcDNA clone #6. Stably transfected cells (pNCoR clone #7 and mock transfected 
pcDNA clone #6) were treated with LCA 10 µM and total RNA isolated at 6 hours post treatment. After 
reverse transcription of 3.5 µg of total RNA per sample, Q-RT-PCRm was conducted using the one-step 
QuantiTect Probe RT-PCR kit (Qiagen, http://www1.qiagen.com) directly on the custom-designed 
TaqMan® Low Density Arrays. Results from three independent experiments performed in duplicate are 
represented. Data was normalized to the internal control 18S and the pNCOR#7 samples calibrated to the 
pcDNA#6 samples using the δδCT method. The network diagram was generated using the GeneGo™ 
network analysis tools which use algorithms to build an interconnected network of interactions based on 
previously published experimental data. Green connectors indicated up-regulated targets. Red connectors 
indicate down-regulated gene targets. Gene targets with Red and Blue tags are up- and down-regulated in 
the network respectively. Network diagram generated by Dr. Moray Campbell. 
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Figure 4.7: Network diagram of gene changes in control mock transfected pcDNA clone #6 on treatment 
with Lithocholic acid. Stably transfected cells (mock transfected pcDNA clone #6) were treated with LCA 
10 µM and total RNA isolated at 6 hours post treatment. After reverse transcription of 3.5 µg of total 
RNA per sample, Q-RT-PCRm was conducted using the one-step QuantiTect Probe RT-PCR kit (Qiagen, 
http://www1.qiagen.com) directly on the custom-designed TaqMan® Low Density Arrays. Results from 
three independent experiments performed in duplicate are represented. Data was normalized to the 
internal control 18S and the treated samples calibrated to the untreated negative control samples using 
the δδCT method. The network diagram was generated using the GeneGo™ network analysis tools which 
use algorithms to build an interconnected network of interactions based on previously published 
experimental data. Green connectors indicated up-regulated targets. Red connectors indicate down-
regulated gene targets. Gene targets with Red and Blue tags are up- and down-regulated in the network 
respectively. Network diagram generated by Dr. Moray Campbell. 
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Figure 4.8: Network diagram of gene changes on treating pNCoR overexpressing clone #7 with 
Lithocholic acid. Stably transfected cells (pNCoR clone #7) were treated with LCA 10 µM and total RNA 
isolated at 6 hours post treatment. After reverse transcription of 3.5 µg of total RNA per sample, Q-RT-
PCRm was conducted using the one-step QuantiTect Probe RT-PCR kit (Qiagen, http://www1.qiagen.com) 
directly on the custom-designed TaqMan® Low Density Arrays. Results from three independent 
experiments performed in duplicate are represented. Data was normalized to the internal control 18S and 
the treated samples calibrated to the untreated negative control samples using the δδCT method. The 
network diagram was generated using the GeneGo™ network analysis tools which use algorithms to build 
an interconnected network of interactions based on previously published experimental data. Green 
connectors indicated up-regulated targets. Red connectors indicate down-regulated gene targets. Gene 
targets with Red and Blue tags are up- and down-regulated in the network respectively. Network diagram 
generated by Dr. Moray Campbell. 
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4.3.4.5  Hepatocyte Nuclear Factor 4 α (HNF4α) is the key regulator of the 
xenobiotic response. 
Figure 4.7 illustrates the central position of the nuclear receptor HNF4α (Hepatocyte Nuclear 
Factor 4 α) in the network of gene transcriptional responses to treatment of pcDNA clone #6 
with lithocholic acid. In contrast, figure 4.8 which shows gene expression changes in RT-4 
NCoR#7 upon treatment with 10 µM LCA, does not indicate HNF4α as a central regulator, 
suggesting a connection between overexpression of NCoR1 and suppression of HNF4α 
regulated genes. 
HNF4α is known to have a key role in regulating xenobiotic protective cellular responses. 
Tirona et al investigated the role of HNF4α in the context of the Pregnane-X-receptor (PXR) 
and induction of CYP3A4, the key cytochrome P450 xenobiotic enzyme, in hepatocytes 
(Tirona et al., 2003). They used a luciferase based promoter construct of the CYP3A4 
proximal promoter along with the distal xenobiotic response enhancer module (XREM). The 
latter has been demonstrated to be responsible for PXR mediated Cyp3A4 induction in 
response to the antibiotic and PXR activator Rifampicin (Goodwin et al., 1999). This 
construct was used to transfect the liver cell line HepG2 which was co-transfected with a 
plasmid containing PXR as well as a variety of other nuclear receptors (FXR, LXR, VDR and 
HNF4α). This experiment was designed to assess the role of these latter nuclear receptors to 
potentiate PXR dependent CYP3A4 reporter plasmid activation. Only co-transfection of 
HNF4α led to augmented luciferase activity when the cells were treated with Rifampicin, 
suggesting a cooperative role for HNF4α in PXR dependent CYP3A4 activation.       
Finally, Tirona et al generated mice with organ specific hepatic knockout of HNF4α. RT-PCR 
was used to measure Cyp3A4 mRNA from livers from such mice embryos; no Cyp3A4 
mRNA was measured as compared to normal, control litter mates (Tirona et al., 2003). Adult 
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mice with hepatic HNF4α disruption using the Cre-Lox system have also been generated. 
These livers had approximately 50% less basal expression of CYP3A4. On treatment with 
PCN, the induction of Cyp3A4 is higher in wild type mice as compared to HNF4α knock out 
clones; there was no difference in PXR expression. 
This paper provides evidence for HNF4α in augmenting the expression of the xenobiotic 
metabolising enzyme Cyp3A4 in response to signalling via the nuclear receptor PXR. HNF4α 
appears to bind a particular sequence in the enhancer module of the Cyp3A4 gene and appears 
to regulate the xenobiotic response in due to treatment with the PXR ligand PCN. In the 
context of the target gene network effects (fig 4.6 and 4.7), Tirona‟s paper provides evidence 
for two nuclear receptors, PXR and HNF4α to switch on the xenobiotic response enzyme 
Cyp3A4 in a cooperative fashion (Tirona et al., 2003). It is therefore possible that HNF4α 
may be playing a similar role when pNCoR1 or mock transfected RT-4 cells were treated with 
LCA.           
 
4.3.5  Target gene expression of EJ-28 cells when treated with 
Lithocholic acid and a histone deacetylase inhibitor SAHA and assessed 
with Affymetrix™ U133 array. 
Strongly additive anti-proliferative effects were demonstrated by treating EJ-28 cells with the 
nuclear receptor ligands ETYA, CDA or LCA in combination with the histone deacetylase 
inhibitor SAHA in figure 3.9(d). Also, as in figure 4.1, treating EJ-28 cells with LCA leads to 
a cell cycle arrest and when in combination with SAHA, the rise in proportion of cells in 
phase G1 approaches statistical significance (p=0.51); i.e. there is a suggestion of a cell-cycle 
arrest upon treating with the combination of LCA and SAHA. In order to investigate the 
genome wide expression of target genes associated with these effects, EJ-28 cells were treated 
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with 100 µmol of LCA +/- 0.8 µmol SAHA and hybridised the mRNA onto Affymetrix® 
U133 genechips. The cells were treated for 6 hours before extracting RNA with a view to 
studying the changes in gene expression directly regulated by the treatments.   
4.3.5.1 Treatment of EJ-28 cells with LCA and SAHA produces a defined 
transcriptional response. 
Figure 4.9 illustrates a network diagram of genes expressed uniquely when EJ-28 cells were 
treated with LCA and SAHA (as compared to gene expression changes when EJ-28 cells 
treated singly with LCA or SAHA). Remarkably, only a small cohort of 83 genes are uniquely 
regulated out of a total of 33,000 gene sequences represented on the Affymetrix® U133 
genechip. The genes thus regulated can be broadly divided into three groups based on their 
predominant cellular function:  
1. Genes that drive cell proliferation and progress through the cell cycle   
2. Genes involved with transcription and post transcriptional mRNA processing. 
3. Genes involved with repair of damaged cellular components. 
 
Illustrative examples are detailed below: 
Pro-proliferative genes 
HB-EGF (Heparin binding EGF-like ↑ Growth Factor 
Growth factor)  
 
N-RAS (neuroblastoma RAS viral  
oncogene homolog) ↓ G-protein, proto-oncogene 
 
elf-5 (E74-like factor 5) ↓ ets domain transcription  
  factor; involved in cell  
  division and organ  
  development eg. Lung  
  development. 
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CDCA8 (cell division cycle ↓ component of chromosomal  
associated 8)  passenger complex; required 
  for stability of bipolar mitotic  
  spindle. 
 
CDC5L (cell division cycle 5 like) ↓ cell cycle regulator important 
  For G2/M phase progression. 
 
 
Transcription/post-transcriptional mRNA processing 
   
SUPT16H (suppressor of Ty 16 homolog) ↓ subunit of the protein FACT; 
  this interacts with histones  
  H2A/H2B to cause  
  nuceolosome disassembly 
  prior to transcription.  
 
PRPF4 (pre-mRNA processing ↓ associates with spliceosomes 
factor 4 homologue)   involved with removal of 
  introns from pre-mRNA. 
 
 
Cellular repair: 
 
PIMT (protein l-isoaspartyl  ↑ enzyme involved in repair 
methyltransferase)  of age damaged cellular  
  proteins. 
 
 
This data suggests a cellular response to treatment with the bile acid and FXR ligand LCA in 
combination with the histone deacetylase inhibitor SAHA, punctuated with inhibition of cell 
division, expression of transcriptional/post-transcriptional processing genes and expression of 
cellular reparative enzymes. This response has similarities to the previously demonstrated 
xenobiotic response in mock transfected RT-4 cells (section 4.3.4.3). Therefore, the cells 
appear to stop dividing when they are exposed to LCA in combination with SAHA, by 
reducing expression of the oncogene N-RAS and CDCA8 and CDC5L, both genes being 
important for cell division. The cells also express PIMT, an enzyme involved in repairing 
protein damage that may have been sustained during exposure to the xenobiotic LCA. This is 
analogous to the expression of SULT2A1 in the mock transfected RT-4 cells (figure 4.7) i.e. 
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this represents an enzyme-based cellular protection mechanism against the damaging effects 
of LCA.  
The expression profile generally illustrates suppression of cellular proliferation however, 
contrasts with figure 4.1 which demonstrates a G1/S phase cell cycle arrest on treating EJ-28 
cells with LCA and SAHA. The data above shows reduced expression of the protein CDC5L 
which is required for G2/M phase expression.  
 
 
 140 
 
Figure 4.9: Heat map of the raw data from Affymetrix® U133 expression chip analysis. Cells 
were treated with LCA alone (100 µM), SAHA alone (0.8 µM) or LCA and SAHA in 
combination and total RNA extracted at 6 hours. This RNA was further purified using the 
RNeasy mini-kit using a RNAse free DNAses according to the manufacturers protocol 
(http://www1.qiagen.com).  The RNA is reverse transcribed to double stranded cDNA which is 
then converted to biotin labelled cRNA as detailed in chapter 2. The cRNA is purified and 
fragmented before hybridisation to the Affymetrix U133 genechip arrays®. The results were 
analysed using the dChip software (http://biosun1.harvard.edu/complab/dchip/). Three 
independent experiments in triplicate were performed, in accordance with MIAME 
recommendations. Hybridisation was performed by Ms. Sim Sahota, research technician at 
Cancer Studies, Birmingham. Bioinformatic analysis performed by Dr. Sebastiano Battaglia. 
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Figure 4.10: Network diagram of genes uniquely regulated by treatment with LCA + SAHA. EJ-
28 cells, in the mid-exponential phase, were treated with 100 µM of LCA and 0.8 µM of SAHA 
and total RNA extracted at 6 hours. This RNA was further purified using the RNeasy mini-kit 
using a RNAse free DNAses according to the manufacturers protocol (http://www1.qiagen.com).  
The RNA is reverse transcribed to double stranded cDNA which is then converted to biotin 
labelled cRNA as detailed in chapter 2. The cRNA was purified and fragmented before 
hybridisation to the Affymetrix U133 genechip arrays®. The results were analysed using the 
dChip software (http://biosun1.harvard.edu/complab/dchip/). Three independent experiments in 
triplicate were performed. The network diagram was generated using the GeneGo™ network 
analysis tools which use algorithms to build an interconnected network of interactions based on 
previously published experimental data. Green connectors indicated up-regulated targets. Gene 
targets with Red and Blue tags are up- and down-regulated in the network. Downregulation of 
BCDIN3 and upregulation of ZNF277 was validated by demonstrating these changes in 
expression in EJ-28 cells treated with LCA following si-RNA silencing of NCoR1 expression 
(Abedin et al., 2009). This suggests that NCoR1 downregulation has a similar effect to treatment 
with the HDACi SAHA. Network diagram by Dr Moray Campbell.  
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4.4 Discussion 
The cellular and gene transcriptional effects of treating bladder cancer cells with the 
xenobiotic lithocholic acid have been demonstrated under different cellular environments. A 
remarkably consistent theme emerges in terms of cellular response to exposure to the 
xenobiotic LCA, namely inhibition of the cell cycle and expression of a panel of genes whose 
common purpose is to limit the toxic effects of the xenobiotic to the cell. The latter set of 
genes include members of the ATP binding cassette superfamily of trans-membrane efflux 
pumps which act to pump out xenobiotics from the cell, enzymes that degrade and metabolise 
the xenobiotics by hydroxylation (CYP3A4) or sulphonation (SULT2A1); and finally genes 
that repair damage to cellular structure such as PIMT, which repairs cellular proteins.    
 
4.4.1   LCA and the Cell Cycle 
Increased expression of the cyclin dependent kinase inhibitor CDKN1A was demonstrated, in 
figure 4.2, in RT-4 and EJ-28 cells upon treatment with lithocholic acid with and without the 
HDAC inhibitor SAHA. There is evidence of bile acids inducing a G1/S cell cycle arrest in 
the prostate cancer cell line PC-3 (Choi et al., 2003). Choi et al have demonstrated a G1/S 
phase cell cycle arrest upon treatment with 100 µM of derivatives of CDA and 
ursodeoxycholic acid as determined by FACS analysis. This was associated with increased 
association of phosphorylated Rb (retinoblastoma protein) with E2F-1 protein as detected by 
immunoprecipitation with E2F-1 antibody and detected by Western blotting with anti-Rb 
antibody. Therefore, the sequestration of the E2F-1 transcription factor will prevent the cell 
from G1/S phase progression. This G1/S cell cycle arrest was further augmented by increased 
expression of CDKN1A (p21
Cip1/Waf1
) upon treatment with 100 µM of bile acid derivatives as 
 143 
demonstrated by Western blotting. Transient transfection of wild type p21
(Cip1/Waf1) 
coupled 
with luciferase followed by demonstration of increased luminescence upon treatment with the 
bile acid derivatives (5.2 and 7.3 fold) provides suggestive evidence of bile acid derivatives 
leading to p21
Cip1/Waf1 
expression. The authors demonstrate association of p21
Cip1/Waf1 
with 
both Cdk-2 (cyclin dependent kinase-2) and PCNA (proliferating cell nuclear antigen) by 
immunoprecipitation of protein complexes with Cdk-2 and PCNA antibodies respectively 
following bile acid derivative treatment, and detection of bound p21
Cip1/Waf1 
using a p21 
antibody via Western blotting.  
These experiments provide supportive evidence for the finding of a G1/S phase cell cycle 
arrest in EJ-28 cells upon treatment with lithocholic acid. However, it is unclear as to why a 
G1/S arrest is not demonstrated in RT-4 cells (figure 4.1) in view of increased expression of 
CDKN1A
 
in this cell line on treatment with LCA +/- SAHA. This may be due to the effect of 
timing of the FACS analysis in relation to the dosing of LCA and SAHA.  
 
It is striking that treatment with SAHA in figure 4.2 leads to a significant induction of 
CDKN1A in all of the four cell lines. CDKN1A is an established SAHA target gene; Richon 
et al reported treating the T24 bladder cancer cell line with SAHA which led to induction of 
p21
Cip1/Waf1 
mRNA and protein. They went on to perform chromatin immunoprecipitation of 
T24 bladder cell line following SAHA treatment using an antibody against acetylated histones 
and followed with PCR of precipitated DNA with primers for the p21
Cip1/Waf1 
promoter and 
demonstrated enriching of the p21
Cip1/Waf1 
promoter with acetylated histones. Clearly, this 
suggests that the SAHA‟s HDACi activity is targeting the p21Cip1/Waf1 promoter leading to 
mRNA induction (Richon et al., 2000). 
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4.4.2 LCA and Expression of Metabolic Enzymes 
 Cyp3A4 is the most abundantly expressed member of the cytochrome P450 family of 
xenobiotic metabolising enzymes; hence its expression in relation to LCA treatment of the 
four tested cell lines was investigated. Figure 4.3 illustrates significant Cyp3A4 induction in 
RT-4, HT-1376 and RT-112 cells after LCA treatment (RT-4 20 µM, HT1376 and RT-112 50 
µM). Fukimori et al have demonstrated similar findings in LS180 human intestinal cells, 
albeit with higher fold increases in Cyp3A4 mRNA as measured by Q-RT-PCR. They treated 
LS180 cells with 10, 30 and 100 µM LCA for 6 hours and obtained 4, 16 and 20 fold 
induction of Cyp3A4 mRNA respectively. As discussed later in this chapter, the intestine, 
along with the liver play a key role in protecting the body from the toxic effects of LCA, in 
part by induction of metabolic enzymes such as Cyp3A4. Therefore, LS180 intestinal cells 
may have a higher capacity to express Cyp3A4 in view of their tissue of origin as compared 
to bladder cancer cells (Fukumori et al., 2007).    
 
The Q-RT-PCRm genecard experiments were designed to reveal the gene expression 
signatures on LCA treatment of RT-4 cells stably transfected to over-express NCoR1 or 
mock-transfected [as illustrated in figures 4.6 – 4.8] have revealed a key omission (table 4.1). 
I have previously demonstrated CYP3A4 mRNA induction in RT-4 cells upon treatment with 
SAHA (0.8 µM), LCA (20 µM) and the combination of LCA+SAHA for 6 hours (figure 4.3), 
however, treatment of RT-4 p NCoR#7 transfected and mock pcDNA#6 clones with LCA (10 
µM) for 6 hours did not lead to CYP3A4 induction as measured by microfluidic Q-RT-PCRm 
gene cards (table 4.1). The mock transfected clones would conventionally be expected to 
behave as the wild type RT-4 cells. The lack of Cyp3A4 induction may be due to the lower 
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concentration of LCA used in the Q-RT-PCRm experiment as compared to figure 4.3 (10µM 
as compared to 20 µM).  
The Q-RT-PCRm genecard  transcriptional profile of pNCoR#7 and pcDNA#6 clones has 
demonstrated differential expression of the metabolic enzyme SULT2A1 and ALOX5. Both 
these enzymes show reduced expression in the basal state in pNCoR#7 clone as compared to 
the control pcDNA#6 (0.1 and 0.5 fold respectively). SULT2A1 is a member of the 
sulfotransferase family and catalyses the addition of sulphate groups by conjugation to steroid 
hormones, drugs, xenobiotics and bile acids. This increases the solubility of bile acids and 
thereby facilitates excretion via faeces or urine (Elias and Mills, 2007). ALOX-5 (or 
arachidonate 5 lipoxygenase) catalyses the production of leukotrienes (important 
inflammatory mediators) from arachidonic acid. Rodriguez-Ortigosa studied the relationship 
between ALOX-5, leukotrienes and bile salt excretion in isolated, perfused rat livers 
(Rodriguez-Ortigosa et al., 1995). In this model system, they demonstrated increased 
expression of ALOX-5 mRNA in the rat livers when they were perfused with the bile acid 
taurocholate. This was associated with increased de novo production of leukotrienes within 
the liver and was followed by increased bile acid excretion within bile. Therefore, by some as 
yet undetermined mechanism, there appears to be a possible role for leukotriene production 
via ALOX-5 in increasing bile acid excretion from hepatocytes. There may be a similar 
mechanism within the bladder cancer cell model as a means of protection from the increased 
exposure to LCA. 
Over-expression of NCoR1 in the pNCoR#7 clones suppresses the basal expression of both 
SULT2A1 and ALOX-5 as noted above, however, treatment with LCA causes a modest 
induction of these enzymes in the pcDNA#6 control clone by 1.3 and 1.4 fold respectively. 
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SULT2A1 is not induced when pNCoR#7 cells are treated with LCA suggesting a role for 
transcriptional suppression by NCoR1.     
 
4.4.3 LCA and Expression of ABC Transporters 
 The ATP binding cassette family of transporters represents a large protein family expressed 
in both eukaryotes and prokaryotes, which act as trans-membrane pumps which transport 
specific molecules across intra and extracellular membranes in an energy dependent fashion. 
These proteins have two trans-membrane domains composed of α helices with between 6-11 
trans-membrane spanning regions. These proteins have one or two ATP binding domains on 
the cytosolic surface which release energy from ATP hydrolysis which drives the protein 
conformational change enabling the trans-membrane transfer. These proteins have been 
implicated in a wide range of biological processes such as multi-drug resistance in cancer and 
in bacterial cells, physiological processes such as transport across the gut or the blood-brain 
barrier and transport across intracellular organelles such as peroxisomes.  
The membrane transporters MRP3 (multi-drug resistance protein 3) and ABCA 1 are 
downregulated in the pNCoR#7 cells (0.8 and 0.3 fold respectively) in the basal state, 
suggesting a repressive effect of NCoR1 over-expression. Upon treatment with LCA, these 
are not induced in the pcDNA#6 control cells. However, the transporter ABCB8 is 
upregulated by 1.4 fold. When pNCoR#7 cells are treated with LCA, both MRP3 and ABCA1 
demonstrate increased mRNA expression of 1.5 and 1.7 fold respectively.  
 
ABC transporters play a key role in the known mechanisms of limiting intracellular levels of 
LCA by actively transporting the bile acid out of cells and this is the likely role of the ABC 
transporters induced in pcDNA#6 and pNCoR#7 clones upon treatment with LCA.  
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MRP 3 gene promoter has been shown to be transcriptionally induced by VDR and RXR in 
response to treatment with 1 25(OH)2D3 and LCA. McCarthy et al cloned a 5 Kb regulatory 
region of the mouse MRP-3 promoter into a luciferase expression plasmid and co-transfected 
this into Hep G2 hepatoma cells with an RXR expression vector and a variety of relevant bile 
acid sensing nuclear receptors such as CAR, FXR, PPAR α, PXR and VDR. These cells were 
treated with the relevant NR ligands; significant reporter activation was seen with VDR co-
transfection when treated with 1 25(OH)2D3 (6-7 fold with 1 nM) or LCA (4.5 fold with 10 
µM) (McCarthy et al., 2005). 
 
There is little evidence to show a transcriptional link between the ABCA1 gene and LCA 
apart from Sporstøl‟s study which appears to demonstrate reduced ABCA1 mRNA expression 
(39 % with 5 µM and 85 % with 25 µM LCA) and protein expression as assessed by Western 
blotting, in Hep G2 cells in response to LCA treatment (Sporstol et al., 2005). The authors 
performed an ABCA1 gene reporter experiment by transient transfection into HepG2 cells; 
there was a reduced promoter activity by 43 % with 25 µM of LCA. With co-transfection with 
PXR and RXR expression vectors, this suppression of promoter activity with 25 µM of LCA 
increased to 80 %. This result appears to contradict with the apparent induction of ABCA1 
mRNA in pNCoR#7 cells. It is possible that the raised NCoR1 level may inhibit possible 
PXR signalling which Sporstøl et al appear to suggest is inhibitory towards ABCA1 
expression (Sporstol et al., 2005). 
4.4.4    A Coordinated Xenobiotic Protective Response in the Bladder 
The bladder transitional cell urothelium is exposed to xenobiotics in urine. Significant 
quantities of bile acids are found in human urine in the presence of bile duct obstruction or 
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cholestasis. However, Goto et al have demonstrated galactoside conjugates of the bile acids 
cholic and deoxycholic acid in urine from healthy subjects (Goto et al., 2005). The 
carcinogenic potential of these bile acid derivatives are unclear however, protection of the 
urothelium from potentially toxic bile acid derivatives may provide the selective advantage 
for development and maintainance of a coordinated protective response to these xenobiotics. 
Therefore, the urothelial cell first stops cell division and initiates a cell cycle arrest when 
exposed to these chemicals. DNA replication and cell division are a particularly vulnerable 
time for cells to endure geno-toxic injury. Cell-cycle arrest allows the cell to clear the 
xenobiotic effectively or alternatively undergo apoptosis if it is unable to do so to avoid 
proliferation of urothelial cells with genetic mutations. A well established example of such a 
coordinated protective response exists in the liver. 
 
4.4.5  The Hepatocellular Protective Response to Xenobiotics 
The liver has a strategic position at the cross-roads of the alimentary tract and the systemic 
circulation. Therefore, all substances, including xenobiotics absorbed from the small bowel 
are transported to the liver via the hepatic portal vein. The mechanism of LCA handling 
provides an example of a coordinated protective response employed by hepatocytes to handle 
this potentially toxic xenobiotic. Indeed, this mechanism is only present in humans and 
chimpanzees which can handle LCA; New Zealand white rabbits fed a 0.5 % dietary 
concentration of LCA have a 14 day mortality of 50 % as they lack the ability to sulphate 
LCA which is a key detoxifying step (Elias and Mills, 2007).  
Levels of lithocholic acid are sensed in hepatocytes by VDR and FXR and probably other 
nuclear receptors such as PXR. The two most important target detoxifying genes are Cyp3A4 
and SULT2A1. Cyp3A4 hydroxylates LCA and increases aqueous solubility and hence 
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increases excretion in urine. SULT2A1, via sulphonation of LCA, increases solubility in bile 
and water and hence excretion via faeces. Sulphonation of LCA also reduces reuptake of LCA 
in the colon via the entero-hepatic circulation. These detoxifying steps are coordinated with 
active pumping of LCA and its conjugates out of the cell, via the ABC transporters MDR1 
and MRP2 and is also linked with regulation of bile acid synthesis. FXR binds bile acids 
(CDA, LCA and Cholic acid) and represses transcription of the enzyme cholesterol 7 α 
hydroxylase which is the rate limiting enzyme in bile acid synthesis (Elias and Mills, 2007). 
Hence this is an important example in which the separate actions of bile acid sensing, 
detoxifying enzymes, transmembrane pumps and bile acid synthesis enzymes are regulated in 
concert to achieve the overall aim of hepato-cellular protection from a toxic compound. 
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Chapter 5 : Discussion 
5.1 Summary 
5.1.1  Expression of nuclear receptors in non-classical tissue sites 
Figure 3.3 demonstrates the expression of a panel of nuclear receptors and co-repressors at the 
mRNA level in the four bladder cancer cell lines (RT-4, RT-112, HT1376 and EJ-28). These 
nuclear receptors have defined classical physiological roles in other organ systems rather than 
the urinary bladder. For example, VDR is expressed in the small bowel, the kidney and skin 
in relation to its classical role in regulating calcium reabsorption from the gastro-intestinal 
tract and maintaining serum calcium levels. However, this nuclear receptor has been 
demonstrated in diverse tissues such as the breast (Friedrich et al., 1998), the prostate 
(Kivineva et al., 1998b; Krill et al., 2001) and the bladder (Hermann and Andersen, 1997; 
Sahin et al., 2005) and has demonstrable anti-proliferative roles by upregulating genes such as 
p21
(Waf1/Cip1) 
(Saramaki et al., 2009; Saramaki et al., 2006a).  
 
5.1.2  Bladder cancer cell lines display a spectrum of anti-proliferative 
responses towards a panel of nuclear receptor ligands 
Table 3.2 demonstrates the ED50 values for a panel of nine nuclear receptor ligands towards 
the four bladder cancer cell lines RT-4, RT-112, HT-1376 and EJ-28. Eight ligands display a 
range of ED50 values; 9 cis-RA does not demonstrate a dose-response curve which crosses 50 
%, hence an ED50 cannot be determined. EJ-28 cells are least sensitive five of the remaining 
eight ligands (1α,25(OH)2D3, LCA, EPA, ETYA, CDCA). This particular cell line also has 
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the highest expression of the co-repressor NCoR1 (fig 3.3) which may be responsible for the 
reduced sensitivity towards these NR ligands.   
 
5.1.3  Forced over-expression of NCoR1 leads to reduced sensitivity 
towards CDA, LCA and SAHA 
In order to test the hypothesis that overexpression of NCoR1 in EJ28 cells may be responsible 
for the reduced sensitivity to some NR ligands, NCoR1 was stably over-expressed in RT-4 
cells which is the most sensitive amongst the four cell lines (table 3.2). When the NCoR1 
over-expressing clone#7 and mock transfected control clone were treated with 10 µM for 96 
hours with a re-dose at 48 hours, there was a statistically significant reduction in the anti-
proliferative response to CDA, LCA and SAHA (figure 3.8B). There was no difference in 
anti-proliferative response between the two clones when treated with 1α,25(OH)2D3, 9cis RA 
or ETYA. This may be due to the presence of another co-repressor in the NR complex 
associated with these ligands.  
 
5.1.4  Co-treatment with HDAC inhibitor SAHA leads to a cooperative 
anti-proliferative response in cells which over-express NCoR1 
I hypothesised that co-treatment of the bladder cancer cell lines with a histone deacetylase 
inhibitor, SAHA would target the co-repressor complex as HDACs co-locate with co-
repressors and lead to a closed chromatin structure via deacetylation. Figure 3.9 (a)-(d) 
illustrate cell proliferation as % of control when the four cell lines were treated with ED25 
doses of a panel of NR ligands. Interestingly, RT-112 and EJ-28, both cells which over-
express NCoR1, demonstrate a strongly additive anti-proliferative effect when co-treated with 
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NR (except CDA in RT-112 cells) and SAHA. This may be due to increased HDAC 
association with the NRs secondary to raised NCoR1 expression, which may make these two 
cell lines (RT-112 and EJ28) more susceptible to cell death by the NR ligands in combination 
with SAHA. 
 
5.1.5  LCA induces a G1/S phase cell cycle arrest in EJ-28 cells 
In order to assess the mechanism of the anti-proliferative response to one of the NRs (LCA) 
+/- SAHA, cell cycle FACS analysis was performed as illustrated in fig 4.1. This 
demonstrates a clear G1/S phase cell cycle arrest when EJ-28 cells are treated with LCA. 
When EJ-28 are treated with LCA and SAHA in combination, there is a trend towards 
statistical significant accumulation of cells in G1 phase and reduction of cells in S phase, i.e. 
G1/S arrest. However, there is no statistical evidence of cell cycle arrest in any of the other 
three cell lines with LCA +/- SAHA. 
 
5.1.6 Induction of CDKN1A (p21(Waf1/Cip1)) and CYP3A4 upon treatment 
with LCA +/- SAHA   
As described above, treatment with NR ligands, with or without SAHA, produces a spectrum 
of anti-proliferative responses. In order to investigate whether these are associated with 
expression of particular anti-proliferative genes, I initially measured the expression of 
CDKN1A which is a 1α,25(OH)2D3 target gene (Saramaki et al., 2009) and has also been 
shown to be upregulated in response to derivatives of bile acids such as CDA and 
ursodeoxycholic acid (Choi et al., 2003a). 
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Figure 4.2 illustrates expression of CDKN1A as assessed by Q-RT-PCR. SAHA induces a 
statistically significant rise in CDKN1A mRNA in all four cell lines; this is not surprising as 
it is a known SAHA target gene (Gui et al., 2004). In RT-4 cells, both LCA as well as LCA + 
SAHA induce a significant CDKN1A mRNA induction however, in EJ-28 cells, only the 
combined treatment of LCA + SAHA leads to CDKN1A expression.  
 
CYP3A4 is the most abundant of the cytochrome p450 enzymes and is involved in 
detoxification of bile acids as well as xenobiotics and drugs. Hence, I investigated its 
expression in the bladder cancer cells in response to the secondary bile acid LCA. Figure 4.3 
illustrates the induction of CYP3A4 mRNA using Q-RT-PCR. LCA treatment leads to a 
statistically significant induction in CYP3A4 mRNA in RT-4, HT-1376 and RT-112 cells but 
not EJ-28. LCA has been previously demonstrated to induce CYP3A4 induction in intestinal 
and liver cells (Fukumori et al., 2007; Matsubara et al., 2008) as well as in mice (Matsubara et 
al., 2008). The lack of induction in EJ-28 cells may be due to the over-expression of NCoR1 
which may lead to a closed chromatin conformation around the CYP3A4 promoter. 
Interestingly, co-treatment with LCA + SAHA in EJ-28 cells does lead to significant 
CYP3A4 mRNA induction; SAHA may be antagonising the elevated NCoR1‟s co-repressor 
effect.      
 
5.1.7 LCA induces a xenobiotic protective response in RT-4 cells 
RT-4 cells stably transfected to overexpress NCoR1 (pNCoR#7) as well as mock transfected 
RT-4 cells (pcDNA#6) were treated with LCA (10µM) for 6 hours and changes in mRNA 
expression were investigated via Q-RT-PCR microfluidic arrays (figures 4.7 and 4.8). There 
are three groups of genes which display changes in expression with LCA: the ATP-binding 
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cassette transporter family of trans-membrane efflux pumps, detoxifying enzymes and cell-
cycle arrest proteins. pNCoR#7 cells induce expression of ABCC3, ABCB8 and ABCA1 
upon exposure to LCA; pcDNA#6 also expresses ABCB8 on LCA treatment. 
 
SULT2A1 is a detoxifying enzyme belonging to the sulphotransferase family and plays a key 
role in detoxifying xenobiotics in the liver. In pNCoR#7 cells, this enzyme is down-regulated 
under basal conditions as compared to pcDNA#6, no doubt due to the enhanced repressor 
effect of NCoR1 overexpression. When pcDNA#6 cells are treated with LCA, SULT2A1 
expression is increased which is probably in an effort to detoxify this bile acid. 
 
The cell cycle arrest proteins CDKN1B/p27
kip1 
and CDKN1A / p21
waf1/cip1 
are both suppressed 
in their basal expression in pNCoR#7 clones and upon treatment with LCA, their expression 
is increased in the pcDNA#6 clone by 1.4 and 1.2 fold respectively. 
 
In the context of the cellular response to exposure to a xenobiotic, the RT-4 pcDNA#6 appear 
to stop dividing by inducing a cell-cycle arrest and then express genes encoding proteins that 
either pump toxic compounds out of the cell (e.g. members of the ATP binding cassette 
transporter family) or genes that encode proteins which metabolise xenobiotics and facilitate 
their excretion in urine (e.g. sulphotransferase enzymes). 
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5.2 Future Studies 
5.2.1  Measurement of VDR, FXR and NCoR1 expression in human 
samples 
Chapter 3 describes expression of a panel of nuclear receptors and co-repressors at the mRNA 
level (figure 3.3) and the expression of VDR (figure 3.4) and FXR (fig 3.5) at the protein 
level in the panel of four bladder cancer cell lines. These immortalised cell lines are a model 
system for bladder cancer. It is possible that the culture conditions of these cells may alter the 
spectrum of genes expressed by the cell lines as compared to the original bladder tumours that 
they were derived from; hence it is imperative that expression of the nuclear receptors and co-
repressors are verified in a representative cohort of primary bladder cancer tissue. It would 
also be possible to assess expression in bladder biopsy samples from patients undergoing 
surgery for benign prostatic disease such as benign prostatic hyperplasia. This can act as an 
age matched normal control tissue as there are no established non-malignant bladder epithelial 
cell lines.      
 
5.2.2  Chromatin Immunoprecipitation 
I have demonstrated induction of CDKN1A
 
in all four cell lines (RT-4, RT-112, HT137 and 
EJ-28) upon treatment with SAHA alone, in RT-4 cells upon treatment with LCA alone and in 
RT-4 and EJ-28 cells upon treatment with LCA and SAHA combined (figure 4.2). I have 
surmised that LCA is binding either VDR or FXR and is binding to its relevant response 
elements in the CDKN1A (p21
(Cip1/Waf1)
) promoter. The traditional approaches to demonstrate 
binding of a nuclear receptor to a target gene promoter involved gene reporter assays or 
alternatively using recombinant NR DNA binding domains to enrich for DNA sequences from 
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libraries of random sequences. However, these approaches are hampered by numerous 
problems. Firstly, NR binding to a promoter sequence occurs outside the context of chromatin 
therefore, in vivo binding sites may differ from in vitro sites as chromatin compaction and 
relaxation may hide or reveal particular NR binding sites in vivo. Also, in the in vitro 
conditions, protein conformations of the NR DNA binding domains may be different from the 
vivo native conformation which may lead to differing NR/DNA binding (Massie and Mills, 
2008). 
These limitations are overcome via chromatin immunoprecipitation which involves treatment 
of cells with the particular NR ligand followed by treatment with formaldehyde which 
chemically cross-links DNA-protein interactions by forming covalent bonds between the 
exocyclic amino groups and the endocyclic imino groups of DNA bases and the α-amino 
groups of amino acids as well as the nitrogen side chains of lysines, arginines and histidines 
(Kuo and Allis, 1999). This cross-linking „fixes‟ any NR-DNA interaction for further 
analysis. The chromatin extract is sonicated to break-up the cross-linked DNA/protein into 
small DNA fragments with attached proteins. This allows the DNA to be handled more easily 
during the incubation with specific antibody to the protein in question (VDR or FXR in our 
current example). The antibody incubation step immuno-precipitates DNA sequences bound 
to the protein in question. The antibody-protein/DNA complexes are eluted and the cross-
likages are reversed by incubation in a NaCl solution incubated at 65
o
C (Kuo and Allis, 
1999). This DNA can then be analysed in a variety of ways. Conventional PCR or Q-RT-PCR 
may be performed provided primer sequences are used for candidate binding regions, for 
example in the p21
(Cip1/Waf1) 
promoter region. The immune-precipitated DNA would always be 
compared to the background genomic DNA to assess the degree of enrichment by immune-
precipitation. 
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The above approach necessitates investigating transcription factor binding against a particular 
target gene sequence which can be amplified by a PCR reaction. Alternative strategies for an 
unbiased approach to identifying target binding sequences involve the ChIP on chip approach 
and ChIP sequencing (Zecchini and Mills, 2009). 
 
ChIP on chip describes amplifying and fluorescent labelling the DNA fragements isolated 
from a round on chromatin immunoprecipitation and hybridising to a DNA microarray. Total 
genomic DNA is also hybridised to the microarray after labelling with a different fluorescent 
probe and acts as a control. Therefore, the fluorescent signals from the ChIP DNA fragments 
which correspond to the transcription factor binding sites would generate a significantly 
higher signal as compared to the total genomic DNA control (Zecchini and Mills, 2009). This 
technique allows for genome wide screening for nuclear receptor binding sites and allows for 
generation of network diagrams similar to figures 4.6-4.9 which provide a genome wide view 
of the disparate effects of binding of a particular nuclear receptor to its target sequences.  
ChIP sequencing involves processing of DNA fragments generated from ChIP via a high 
throughput parallel whole genome sequencing platform such as Solexa, Roche/454 and ABI 
SOLiD. After a round of ChIP, the DNA fragments generated are purified and adapters are 
tagged to the ends of the DNA fragments. Adapters are short sequences of DNA which can be 
used to bind the DNA fragments to the sequencing platform. The tagged fragments are 
amplified and simultaneously sequenced. The analysis software will then align the different 
DNA fragments to the known genomic sequence and identify the identity of the fragments. 
This method of post ChIP analysis has the advantage of not being limited by the spacing 
between probes, which occurs in ChIP on chip analysis (Zecchini and Mills, 2009). 
 
 158 
Journal publications related to this thesis 
1. “Elevated NCOR1 disrupts a network of dietary-sensing nuclear receptors 
in bladder cancer cells.” Abedin SA, Thorne J, Battaglia S, Maguire O, 
Hornung L, Doherty AP, Mills IG, Campbell MJ. Carcinogenesis 2009 
Mar;30(3):449-56. Epub 2009 Jan 6. 
 
2. “Epigenetic corruption of VDR signalling in malignancy.” Abedin SA, 
Banwell CM, Colston KW, Carlberg C, Campbell MJ.  AntiCancer Research. 
July 2006. 26:2557-2566.  
 
3. “Vitamin D and Cancer”. Campbell MJ and Abedin SA. Expert Reviews 
in Endocrinology and Metabolism. 2006;1(2):219-231.  
 
 
 
Published Abstracts 
1. “Targeting Farnesoid X receptor in bladder cancer cells.” Abedin SA, 
Thorne J, Battaglia S, Doherty AP, Wallace DM, Campbell MJ. BJU Int. June 
2008;101 (Supplement 5):43. 
 
2. “Targeting novel nuclear receptors with histone deacetylase inhibitor 
combination therapy in bladder cancer.” Abedin SA, Veerakumarasivam A, 
Kelly J, Neal DE, Mills I, Campbell MJ. Eur Urol Suppl 2006;5(2):36. 
 
3. “Epigenetic corruption of dietary sensing on bladder cancer cells.” Abedin SA, 
Veerakumarasivam A, Wallard M, Mills IG, Neal DE, Kelly J, Campbell MJ.  
Proceedings of the AACR 2005 Apr;46:820. 
 
 
 
 159 
Conference Proceedings 
1. “Targeting Farnesoid X receptor in bladder cancer cells.” Abedin SA, 
Thorne J, Battaglia S, Doherty AP, Wallace DM, Campbell MJ.  Annual 
Scientific Meeting of the British Association of Urological Surgeons. 
Manchester. U.K. June 2008. 
 
2. “Targeting novel nuclear receptors with histone deacetylase inhibitor 
combination therapy in bladder cancer.” Abedin SA, Veerakumarasivam A, 
Kelly J, Neal D, Mills I, Campbell M. Annual Congress of the European 
Association of Urology. Paris, France. April 2006. 
 
 
3. “Epigenetic corruption of dietary signals in bladder cancer.” Abedin SA, 
Kelly J, Neal DE, Mills IG, Campbell MJ. National Cancer Research Institute. 
Annual Meeting. ICC, Birmingham, UK. Oct 2005. 
 
4. “Epigenetic corruption of dietary sensing capacity in bladder cancer 
cells.” Abedin SA, Veerakumarasivam A, Wallard M, Mills IG, Neal DE, Kelly 
J, Campbell MJ. American Association of Cancer Research. Annual Meeting. 
Anaheim, California, USA 2005. 
 
5. “Epigenetic disruption in epithelial cancers of nuclear receptor mediated 
dietary sensing.” Campbell MJ, Abedin SA, Gommersall LM, Banwell CM, 
Mills IG, Peehl DM, Colston KW, Turner BT. The Alan Wolffe EMBO 
Conference on Chromatin and Epigenetics. Heidelberg, Germany 2005. 
 
6. “Environmental sensing capacity by VDR and related nuclear receptors.” 
Abedin SA, Veerakumarasivam A, Mills IG, Neal DE, Kelly JD, Campbell MJ. 
2
nd
 Symposium on Vitamin D Analogs in Cancer Prevention and Therapy. 
Lübeck, Germany. May 2005. 
 
7. “Co-repressor complexes as targets for epigenetic therapy.” Gommersall 
LM, Coulter HSO Abedin SA, Peehl DM, Doherty AP, James ND Campbell 
MJ.  British Prostate Group/British Association of Urologic Surgeons Joint 
Meeting 2004 
 160 
Appendix 1 
List of genes on Q-RT-PCRm genecard 
Gene Symbol Alternative names 
Common 
name LocusLink Gene Name 
Cell surface 
transporters       
ABCA1 
ABC-1, ABC1, CERP, FLJ14958, 
HDLDT1,  ABCA1 ATP-binding cassette, sub-family A (ABC1), member 1,Gene hCG1789838 Celera Annotation 
ABCB8 MABC1; M-ABC1; EST328128 ABCB8 ATP-binding cassette, sub-family B (MDR/TAP), member 8,Gene hCG18685 Celera Annotation 
ABCC3 MLP2; MRP3; ABC31; ABCC3 ATP-binding cassette, sub-family C (CFTR/MRP), member 3,Gene hCG29634 Celera Annotation 
ABCG2 
MRX; MXR; ABCP; BCRP; BMDP; 
MXR1;  ABCG2 ATP-binding cassette, sub-family G (WHITE), member 2,Gene hCG37696 Celera Annotation 
Nuclear 
receptors       
AR NR3C4, AIS, DHTR, HUMARA, TFM AR 
androgen receptor (dihydrotestosterone receptor; testicular feminization; Kennedy disease),Gene hCG15093 
Celera Annotation 
ESR1   ER   estrogen receptor 1,Gene hCG1811630 Celera Annotation 
ESR2 
NR3A2,Erb; ESRB; ESTRB;; ER -
BETA;  ER  estrogen receptor 2 (ER beta),Gene hCG21449 Celera Annotation 
NR0B1 NROB1, AHC; AHX; AHCH; DAX1; DAX1 nuclear receptor subfamily 0, group B, member 1,Gene hCG15520 Celera Annotation 
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DAX-1;  
NR1H2   LXR  nuclear receptor subfamily 1, group H, member 2,Gene hCG22944 Celera Annotation 
NR1H3   LXR  nuclear receptor subfamily 1, group H, member 3,Gene hCG25179 Celera Annotation 
NR1H4 BAR; FXR; HRR1; HRR-1; RIP14 FXR nuclear receptor subfamily 1, group H, member 4,Gene hCG20893 Celera Annotation 
NR1I2 
BXR; PAR; PRR; PXR; SAR; SXR; 
ONR1;  PXR nuclear receptor subfamily 1, group I, member 2,Gene hCG21777 Celera Annotation 
NR1I3 
CAR; CAR1; MB67; CAR-SV1; CAR-
SV4;  CAR nuclear receptor subfamily 1, group I, member 3,Gene hCG1766510 Celera Annotation 
NR3C1 GR GR nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor),Gene hCG37601 Celera Annotation 
PPARA   PPAR  Peroxisome proliferative activated receptor, alpha,Gene hCG41801 Celera Annotation 
PPARD 
FAAR; NUC1; NUCI; NR1C2; PPAR-
beta PPAR  Peroxisome proliferative activated receptor, delta,Gene hCG17666 Celera Annotation 
PPARG 
NR1C3; PPARG1; PPARG2; 
HUMPPARG PPAR  Peroxisome proliferative activated receptor, gamma,Gene hCG26772 Celera Annotation 
RARA RAR; NR1B1 RAR  retinoic acid receptor, alpha,Gene hCG2007196 Celera Annotation 
RARB, HAP; RRB2; NR1B2 RAR  retinoic acid receptor, beta,Gene hCG26863 Celera Annotation 
RARG   RAR  retinoic acid receptor, gamma,Gene hCG31521 Celera Annotation 
RXRA   RXR  retinoid X receptor, alpha,Gene hCG18150 Celera Annotation 
RXRB NR2B2; DAUDI6; RCoR-1; H-2RIIBP RXR  retinoid X receptor, beta,Gene hCG2042227 Celera Annotation 
THRB 
THR1;NR1A2; THRB1; THRB2; 
ERBA-BETA THRB 
thyroid hormone receptor, beta (erythroblastic leukemia viral (v-erb-a) oncogene homolog 2, avian),Gene 
hCG15525 Celera Annotation 
VDR NR1I1 VDR vitamin D (1,25- dihydroxyvitamin D3) receptor,Gene hCG27705 Celera Annotation 
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Nuclear 
receptor  
co-factors       
COPS2 CSN2; SGN2; ALIEN; TRIP15 
ALIEN/TRIP
15 COP9 constitutive photomorphogenic homolog subunit 2 (Arabidopsis),Gene hCG41786 Celera Annotation 
CREBBP CBP CBP CREB binding protein (Rubinstein-Taybi syndrome),Gene hCG16633 Celera Annotation 
CRSP2 
EXLM1; MED14; DRIP150; 
TRAP170; 
DRIP150/ 
TRAP170 cofactor required for Sp1 transcriptional activation, subunit 2, 150kDa,Gene hCG18523 Celera Annotation 
CRSP6 
MED17; CRSP77; DRIP80; 
TRAP80;  
TRAP80/DR
IP80 cofactor required for Sp1 transcriptional activation, subunit 6, 77kDa,Gene hCG20933 Celera Annotation 
NCOA1 SRC1; NCoA-1; RIP160; F-SRC-1;  
NCoA1/RIP
160 nuclear receptor coactivator 1,Gene hCG21379 Celera Annotation 
NCOA2 TIF2; GRIP1; NCoA-2; NCo-A2 nuclear receptor coactivator 2,Gene hCG18449 Celera Annotation 
NCOA3 AIB1; RAC3; SRC3; pCIP;CAGH16;  NCOA3 nuclear receptor coactivator 3,Gene hCG44065 Celera Annotation 
NCOA4 RFG; ELE1; PTC3; ARA70;  NCoA4 nuclear receptor coactivator 4,Gene hCG1982904 Celera Annotation 
NCOR2 SMRT; SMRTE; TRAC1; TNRC14;  
SMRT/NCO
R2 nuclear receptor co-repressor 2,Gene hCG25303 Celera Annotation 
PPARBP 
PBP; MED1;RB18A; CRSP200; 
DRIP205; DRIP230;; TRAP220;  
DRIP/ 
TRAP220 PPAR binding protein,Gene hCG1818520 Celera Annotation 
PPARGC1A 
LEM6; PGC1; PGC1A; PGC-
1(alpha) PPARGC1 Peroxisome proliferative activated receptor, gamma, coactivator 1, alpha,Gene hCG1811770 Celera Annotation 
SIN3A 
FLJ90319; KIAA0700; 
DKFZP434K2235 SIN3A/KIAA SIN3 homolog A, transcription regulator (yeast),Gene hCG2005450 Celera Annotation 
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Metabolic 
enzymes       
ACADM MCAD; ACAD1; MCADH ACADM acyl-Coenzyme A dehydrogenase, C-4 to C-12 straight chain,Gene hCG22915 Celera Annotation 
AKR1C1/2 
C9; DD1; DDH; DDH1; H-37; MBAB; 
HAKRC; MGC8954; 2-ALPHA-HSD; 
20-ALPHA-HSD; DD; DD2; BABP;  AKR1C1/2 
aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1; 20-alpha (3-alpha)-hydroxysteroid 
dehydrogenase),aldo-keto reductase family 1, member C2 (dihydrodiol dehydrogenase 2; bile acid binding protein; 
3-alpha hydroxysteroid dehydrogenase, type III),Gene hCG1773822 Celera Annotation 
AKR1C3 
DD3; HAKRB; HAKRe; HA1753; 
HSD17B5; hluPGFS; KIAA0119 AKR1C3 
aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type II),Gene hCG19343 Celera 
Annotation 
ALOX5   ALOX5 arachidonate 5-lipoxygenase,Gene hCG18416 Celera Annotation 
APOA1 MGC117399 APOA1 apolipoprotein A-I,Gene hCG41332 Celera Annotation 
CYP24A1 P450-CC24 Cyp24 Cytochrome P450, family 24, subfamily A, polypeptide 1,Gene hCG37130 Celera Annotation 
CYP27B1   Cyp27 Cytochrome P450, family 27, subfamily B, polypeptide 1,Gene hCG2014568 Celera Annotation 
CYP3A4 
HLP; CP34; CYP3A; NF-25; 
P450C3;  Cyp3A4 Cytochrome P450, family 3, subfamily A, polypeptide 4,Gene hCG17094 Celera Annotation 
PTGS1 
COX1; COX3; PHS1; PCOX1; 
PGHS1;  COX-1 
prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase),Gene hCG31046 
Celera Annotation 
PTGS2 COX-2; PHS-2; PGG/HS; PGHS-2 COX-2 
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase),Gene hCG39885 
Celera Annotation 
SULT2A1   SULT2A 
sulfotransferase family, cytosolic, 2A, dehydroepiandrosterone (DHEA)-preferring, member 1,Gene hCG201431 
Celera Annotation 
        
Cell death        
 164 
regulators 
BAX Bax zeta BAX BCL2-associated X protein,Gene hCG1811614 Celera Annotation 
CASP4 
TX; ICH-2; Mih1/TX; ICEREL-II; 
ICE(rel)II CASP4 caspase 4, apoptosis-related cysteine peptidase,Gene hCG40121 Celera Annotation 
        
Transcription 
factors       
CEBPA CEBP; C/EBP-alpha C/EBPa CCAAT/enhancer binding protein (C/EBP), alpha,Gene hCG20142 Celera Annotation 
GATA3 HDR GATA3 GATA binding protein 3,Gene hCG23634 Celera Annotation 
ID1 ID ID1 inhibitor of DNA binding 1, dominant negative helix-loop-helix protein 
MYB   MYB v-myb myeloblastosis viral oncogene homolog (avian),Gene hCG32380 Celera Annotation 
SNAI1 SNA; SNAH; SLUGH2; SNAI1 snail homolog 1 (Drosophila),Gene hCG37886 Celera Annotation 
YY1 
DELTA; NF-E1; UCRBP; YIN-
YANG-1 YY1 YY1 transcription factor,Gene hCG25023 Celera Annotation 
        
Histone 
modifiers       
AOF2 LSD1; BHC110; KIAA0601 LSD1/KIAA amine oxidase (flavin containing) domain 2,Gene hCG38847 Celera Annotation 
CARM1 PRMT4 CARM coactivator-associated arginine methyltransferase 1,Gene hCG29972 Celera Annotation 
HDAC1   HDAC1 histone deacetylase 1,Gene hCG41610 Celera Annotation 
HDAC2 RPD3; YAF1 HDAC2 histone deacetylase 2,Gene hCG21384 Celera Annotation 
HDAC3   HDAC3 histone deacetylase 3,Gene hCG42506 Celera Annotation 
HDAC4 HD4; HDACA; HA6116; HDAC-A;  HDAC4 histone deacetylase 4,Gene hCG22188 Celera Annotation 
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HDAC5   HDAC5 histone deacetylase 5,Gene hCG1991411 Celera Annotation 
HDAC6   HDAC6 histone deacetylase 6,Gene hCG19817 Celera Annotation 
HDAC7A HGNC HDAC7 histone deacetylase 7A,Gene hCG27711 Celera Annotation 
HDAC10 HDAC10 HDAC10 histone deacetylase 10,Gene hCG31857 Celera Annotation 
PADI4 PAD; PDI4; PDI5; PADI5 PADI4 peptidyl arginine deiminase, type IV,Gene hCG25125 Celera Annotation 
SET7 SET7; SET9; SET7/9; FLJ21193;  SET7/KIAA SET domain-containing protein 7,Gene hCG37951 Celera Annotation 
SIRT2   SIRT2 
sirtuin (silent mating type information regulation 2 homolog) 2 (S. cerevisiae),Gene hCG1997264 Celera 
Annotation 
SIRT6   SIRT6 
sirtuin (silent mating type information regulation 2 homolog) 6 (S. cerevisiae),Gene hCG2004101 Celera 
Annotation 
SUV39H1   SUV39A Suppressor of variegation 3-9 homolog 1 (Drosophila),Gene hCG19814 Celera Annotation 
        
Cell cycle 
regulators       
CCNB1   Cyclin B1 cyclin B1,Gene hCG27173 Celera Annotation 
CCND1 BCL1; PRAD1; U21B31; D11S287E Cyclin D1 cyclin D1 (PRAD1: parathyroid adenomatosis 1),Gene hCG2016647 Celera Annotation 
CCNE1   Cyclin E1 cyclin E1,Gene hCG20435 Celera Annotation 
CDC2   CDC2 Cell division cycle 2, G1 to S and G2 to M,Gene hCG40242 Celera Annotation 
CDH1 
UVO; CDHE; ECAD; LCAM; Arc-1; 
CD324 Arc-1/CDH1 cadherin 1, type 1, E-cadherin (epithelial),Gene hCG28201 Celera Annotation 
CDK5   CDK5 cyclin-dependent kinase 5,Gene hCG18690 Celera Annotation 
CDKN1A P21; CIP1; WAF1; CDKN1; MDA-6;  P21
(waf1/cip1)
   cyclin-dependent kinase inhibitor 1A (p21, Cip1),Gene hCG15367 Celera Annotation 
CDKN1B KIP1; CDKN4; P27KIP1 
P27
(kip1)
   
cyclin-dependent kinase inhibitor 1B (p27, Kip1),Gene hCG27692 Celera Annotation 
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CDKN2A p16 P16
(ink4a)
 cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4),Gene hCG28309 Celera Annotation 
G0S2   G0S2 G0/G1switch 2,Gene hCG1641564 Celera Annotation 
GADD45A   GADD45  growth arrest and DNA-damage-inducible, alpha,Gene hCG21703 Celera Annotation 
TP53   P53 tumor protein p53 (Li-Fraumeni syndrome),Gene hCG42016 Celera Annotation 
RBBP4 NURF55; RBAP48 RBBP4 retinoblastoma binding protein 4,Gene hCG2032433 Celera Annotation 
        
Signal 
transduction       
EGFR ERBB; mENA; ERBB1 EGFR 
epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian),Gene 
hCG1811404 Celera Annotation 
IGFBP1 
AFBP; IBP1; PP12; IGF-BP25; 
hIGFBP-1 IGFBP1 insulin-like growth factor binding protein 1,Gene hCG2003734 Celera Annotation 
IGFBP3   IGFBP3 insulin-like growth factor binding protein 3,Gene hCG1735376 Celera Annotation 
IGFBP5 IBP5 IGFBP5 insulin-like growth factor binding protein 5,Gene hCG16384 Celera Annotation 
IKBKB   IKKB inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta,Gene hCG17395 Celera Annotation 
IKBKG   IKKG inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma,Gene hCG2003089 Celera Annotation 
MAPK4 ERK3; Erk4; PRKM4; p63MAPK MAPK4 mitogen-activated protein kinase 4,Gene hCG23688 Celera Annotation 
MAPKAPK2   MAPKAP2 mitogen-activated protein kinase-activated protein kinase 2,Gene hCG22205 Celera Annotation 
MAPKAPK5   MAPKAPK5 mitogen-activated protein kinase-activated protein kinase 5,Gene hCG40141 Celera Annotation 
TGFB2   TGFB2 transforming growth factor, beta 2,Gene hCG24906 Celera Annotation 
TGIF HPE4 TGIF TGFB-induced factor (TALE family homeobox),Gene hCG1994498 Celera Annotation 
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Appendix 2 
List of genes uniquely regulated by LCA + SAHA on Affymetrix 
U133 genechip array after 6 hours treatment. 
Probe Set 
Fold 
Change 
 
Probe Set 
Fold 
Change 
 
Probe Set 
Fold 
Change 
ADNP -1.63 
 
EIF5 -1.47 
 
PROCR 1.6 
ARF6 -1.77 
 
EIF5 -1.57 
 
PRPF4 -1.6 
ARL4C -1.52 
 
FAM131A 2.12 
 
PTBP1 -1.66 
BCLAF1 -2.12 
 
FLJ12529 -1.58 
 
PWP1 -1.36 
BICD2 1.66 
 
FSCN1 2.07 
 
RAD21 -1.7 
BRD2 -1.55 
 
FUS -1.62 
 
RBM22 -1.54 
BRD2 -1.56 
 
FUS -1.85 
 
RBM22 -1.58 
C14orf32 -1.42 
 
GABARAPL2 1.35 
 
RELA -1.38 
C14orf4 -1.46 
 
HBEGF 1.48 
 
RIN2 -1.78 
C1orf43 -1.46 
 
HN1L -1.39 
 
RPL37A -1.65 
C1orf52 1.57 
 
HSPA1A /// 
HSPA1B 1.62 
 
RTF1 1.7 
C6orf211 2.15 
 
IL18 1.82 
 
SAP30 1.85 
C9orf5 1.43 
 
IRF2BP2 -1.45 
 
SC4MOL 1.59 
CASC3 -1.66 
 
LOC440983 -1.9 
 
SHOC2 1.48 
CBL 1.8 
 
MCM2 -1.52 
 
SMARCD1 -1.74 
CDC5L -1.68 
 
MCM7 -1.39 
 
SNX9 -1.49 
CDCA8 -1.45 
 
MEPCE -3.54 
 
SNX9 -1.56 
COIL -1.94 
 
MLF1 1.63 
 
STXBP1 1.96 
CPOX 1.93 
 
MPDU1 -1.7 
 
SUPT16H -1.85 
CTF8 -1.58 
 
MRPS10 -1.5 
 
TBPL1 1.89 
DHX15 -1.39 
 
MRPS10 -1.61 
 
TGIF1 -1.47 
DKFZP686M0199 -1.37 
 
MRTO4 -1.52 
 
TM2D2 1.59 
DNAJB11 1.43 
 
MSL-1 -1.98 
 
TMEM189 1.98 
DUSP5 1.68 
 
NOL11 -1.35 
 
TMEM41B 1.57 
EID2 1.65 
 
NRAS -1.52 
 
TSR1 -1.43 
EIF1 -1.46 
 
NUP43 1.42 
 
TUFT1 2.25 
EIF1 -1.47 
 
PCMT1 1.37 
 
UBLCP1 1.8 
EIF1 -1.53 
 
POGK -2.02 
 
VAT1 1.42 
EIF3A -1.43 
 
PPP2R1A -1.43 
 
WSB2 -1.57 
   
PRKAR1A -1.65 
 
ZFR -1.39 
      
ZNF207 -1.49 
      
ZNF277 2.33 
      
ZNF313 1.64 
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